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ABSTRACT
Animal noses have evolved the ability to rapidly detect a seemingly infinite array
of odors at minute concentrations. The basis of this sensitivity are the olfactory (smell)
receptors - a large, highly related class of sensory G-protein coupled receptors that
function together combinatorially to allow discrimination between a wide range of
volatile and soluble molecules. However, the structural and functional mechanisms of
these amazing receptors are not currently known.
In order to begin to investigate the molecular mechanism(s) of olfaction, I have
developed a mammalian expression system for the large-scale production and purification
of functional olfactory receptor (OR) proteins in milligram quantities. Expressed OR
genes were fabricated from scratch using PCR-based gene synthesis, which facilitated
codon optimization and attachment of different affinity tags for purification. Established
methods for the production and purification of rhodopsin were adapted to olfactory
receptors through extensive optimization (including a full-spectrum screening of over 45
detergents). Key to the efficient extraction and solubilization of olfactory receptors tested
is the use of novel zwitter-ionic fos-choline detergents.
Following initial experiments on the inducible expression of a human olfactory
receptor (hOR17-4) in adherent HEK293S cell cultures, the system was successfully
scaled up using a suspension bioreactor. Large-scale culture allowed the purification of
>10 milligrams of hOR17-4 monomer at >90%, which was suitable for subsequent X-ray
crystallization screening trials. The purified protein was also characterized using several
spectroscopic methods and shown to possess the correct secondary structure and several
predicted post-translational modifications. To assay the functionality of purified (non-
membrane-bound) hOR17-4, we successfully developed an in vitro assay method using
surface plasmon resonance (SPR) to demonstrate that the receptor retains functional
selectivity in binding specific odorant ligands in a concentration-dependent manner.
The application of these techniques to other olfactory receptors already shows
promise and could lead to a generalized method for obtaining large quantities of any
olfactory receptor in a rapid and simple manner. Such methods could prove extremely
useful in elucidating the structural and functional mechanism(s) of olfactory receptors
and in their integration into OR-based biosensor devices.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
1.1 Olfactory Receptors
Introduction
The mammalian nose has evolved the ability to rapidly detect small airborne
molecules at minute concentrations. Furthermore, the range of odorants (smellable
molecules) detected is chemically diverse and seemingly infinite. This is due to the fact
that the olfactory (smell) receptors recognize only parts of the scent molecule, and thus
one odorant can in turn activate many different types of receptor [1]. The combinatorial
signal generated is then interpreted by the brain and identified. Likewise, since every
receptor only recognizes key molecular groups, multiple odorants will activate the same
receptor [2]. This gives the mammalian nose the striking ability to detect new chemicals
never encountered in evolution.
The detection range of the human nose is on the order of parts per million (ppm)
down to parts per billion (ppb). As an analogy, detecting one part per billion is the
equivalent of finding one particular penny in 10 million dollars worth of pennies! The
sensitivity of the mammalian nose is exemplified in the canine and mouse, where many
compounds can be detected down to below the parts per trillion (ppt) threshold [3]. By
conparison, most current artificial noses can only detect in the ppm range. Additionally,
other mammalian species possess even greater olfactory capability. For example, it is
estimated that the grizzly bear has a sense of smell seven times more sensitive than a
bloodhound's.
Olfactory Receptor (OR) Background
Figure 1.1 - Cartoon representation of an olfactory receptor showing the seven
transmembrane domains and loop regions. Reprinted from [5] (figure 3) with kind
permission from Springer Science+Business Media, @2003.
Olfactory receptors (or odorant receptors) are a large, highly related class of 0-
Protein Coupled Receptors (GPCRs) that function together to allow discrimination
between a wide range of volatile molecules [4]. All GPCRs are integral membrane
proteins with seven transmembrane domains arranged in a barrel-like conformation (see
figure 1.1). In olfactory receptors, it is thought that this configuration forms a funnel-
shaped pocket for odorant binding [5].
The olfactory receptor gene family constitutes the largest single class of genes in
the vertebrate genome (2-3% in the human) [6]. Current estimates put the number of
human olfactory receptor genes at 636, with only 339 being functional and the rest being
non-functional pseudogenes [1, 7-9]. This is considerably less than the mouse OR gene
family of nearly 1300 (913 functional) [10, 11] or the canine OR gene family of roughly
1200 (-1000 functional) [12].
The olfactory receptor gene family has been broken into two classes, Class I and
Class II. Class II receptors constitute the bulk of mammalian olfactory genes and have
affinity for small, volatile hydrophobic compounds. The Class I "fish-like" receptors
show genetic similarity to many amphibious ORs and have affinity for small water-
soluble compounds. Olfactory receptors are additionally subdivided into a number of
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Figure 1.2 - Diagram of olfactory receptor downstream signaling in olfactory
neurons. Reprinted from [15] with permission from Elsevier, @ 1998.
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Vigure 1.3 - Neuronal wiring of olfactory system. Signals from neurons that express
the same receptor later converge, thus the brain can tell which receptors were activated
by analyzing a spatial pattern of activity. Reprinted from [19] with permission of Oxford
University Press, @2002.
subfamilies (172 total for humans) [8, 13].
All ORs (with key exceptions) are expressed solely on the cilia of olfactory
neurons within the nasal cavity [14]. Odorant binding and recognition leads to activation
and release of the olfactory G-protein Golf, which triggers cyclic-AMP production, ion-
channel-mediated Ca - release, and finally the firing of an action potential into the
olfactory bulb to be interpreted by the brain (see Figure 1.2) [15-17]. Through an
unknown mechanism of allelic inactivation, every olfactory neuron chooses a single OR
gene to express [18]. Signals from neurons that express the same olfactory receptor later
converge downstream at neural foci called glomeruli [19, 20]. As the same odorant will
stimulate multiple ORs (and to various strengths), the brain receives a spatial map of
receptor activity through these glomeruli (see Figure 1.3) [21]. Odorants are thought to
be recognized by matching a specific spatial pattern (a combinatorial code) [1, 22].
................. .  ................. .. ..........
Despite the genetic and signaling knowledge of the OR family, very little is known
regarding how these receptors function and what determines their odorant specificity
[23]. Currently, ligand specificities have only been determined in 26 mammalian ORs
and a handful of ORs from other non-mammalian species (for a summary, see [8, 11]).
The method of measuring odorant specificity currently relies on several techniques for
measuring downstream OR activation in cells:
a) calcium-influx imaging assays of single olfactory neurons
b) calcium-release assays in heterologous expression systems (such as
HEK293 cells)
b) voltage clamping
c) cAMP-responsive element (CRE)-driven luciferase reporters
d) detection of cAMP via radiolabeling
There have been a host of previous studies that have expressed and studied
olfactory receptors in native and heterologous systems (see Table 1). However, to date
there has not been a case where olfactory receptors have been overexpressed and shown
to be functionally purified. While purification attempts have been made in bacterial and
insect systems, these organisms lack mammalian post-translational machinery and thus
purified receptors may be missing critical modifications. It is known that most, if not all,
GPCRs are glycosylated, and indeed the olfactory receptors have conserved N-linked
glycosylation sites (Asn-X-Ser/Thr) at their N-terminus [24-26]. Several studies have
indicated that loss of glycosylation can lead to improper folding and targeting, resulting
in decreased function and compromised structure [25, 27, 28]. Loss of either N-terminal
glycosylation site (Asn-2 or Asn-15) of rhodopsin is sufficient to cause loss of signal
transduction despite no apparent change in localization or folding [29, 30]. This indicates
that purification of olfactory receptors from mammalian expression systems might be
crucial for functional expression and purification.
Table 1 - Summary of previous OR expression methods
Expression System: Functionality: Purification: Reference(sh
1acteria (E. Coli) Not measured 6x-His [31-33]
Insect (Sf9) Measured by No [34]
radiolabeled cAMP
Insect (Sf9) Not measured 6x-His / [35-37]
FLAG
Xenopus Oocyte Voltage clamp No [38-41]
Olfactory Epithelium Measured by [Ca2+] No [1, 42-46]
influx
Mammalian (COS- 1) Measured by [Ca2+] No [41, 47]
influx
Mammalian (HeLa) Measured by [Ca2+] No [48]
influx
Mammalian Measured by [Ca2+] No [2, 39, 41, 43, 47,
(HEK293) influx 49-52]
Mammalian Measured by CRE- No [53]
(HEK293) responsive luciferase
There have been numerous reports in the literature citing difficulties in expressing
functional olfactory receptors in heterologous systems [54]. This problem stems from
improper membrane targeting and resulting cytoplasmic localization of the majority of
ORs [27, 55-57]. A recent study by Saito et. al. [53] discovered several genes exclusively
expressed in olfactory neurons that dramatically increased OR expression levels and
membrane targeting when co-transfected with olfactory receptors into heterologous
mammalian expression systems. These were genes were dubbed RTPs (Receptor
Targeting Proteins).
.2 Detergent Solubilization
When purifying and studying integral membrane proteins, it is essential to select
optimal detergents and surfactants that efficiently solubilize receptors from cell
membrane and also maintain protein stability and allow high concentrations of receptor
without protein aggregation and precipitation [59]. When detergents are used at
concentrations above their critical micelle concentration (CMC), they form micelles
which can disrupt cellular lipid bilayers and extract membrane proteins (Figure 1.4A) In
this thesis we performed a full spectrum detergent screen that included representatives
from the non-ionic, zwitter-ionic, polar, and ionic detergent classes (Figure 1.4B).
1.3 Inducible Cell Lines
Initial OR expression trials in HEK293S cells using transient transfections had
several disadvantages for large-scale protein purification: i) the transfection alone caused
significant cellular toxicity; ii) a significant fraction of the cells remain untransfected and
do not produce OR; iii) the cost of transfection reagents required for milligram-scale
production would be prohibitive. One solution is to generate cell lines which have a
stable copy of the OR gene integrated into the genome, maintained by drug selection.
However, this would result in constant production of the OR protein, which we know to
have toxic effects. Additionally, harvesting cells with constitutive production would yield
OR protein at various stages of degradation by the cell, leading to inhomogeneity and
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Figure 1.4 - Detergent Solubilization. (A) Depiction of detergent extraction membratie
pioteins from native lipid bilayers. Detergent is introduced at a concentration above its
CMC so that detergent micelles break up the cell membrane (left). Solubilized membrane
proteins will have their hydrophobic portions coated with detergent monomers, such that
integral membrane proteins (such as ORs) will have a "belt" of solubilizing detergent
surrounding their transmembrane area (right). Reprinted from [59] with permission fronm
Elsevier, @2003. (B) Molecular structure of several representatives of different detergent
classes. FCl4 was later found to be the optimal detergent for solubilizing hOR17-4.
ER- Anzergent 3-14
II~k~f ~CH3 0
............. ..........
ZWITT
IONIC f
A
pcDNA6/TR
Expression repressed
B
pcDNA4/To
v
V V v+ tetracycline (v)
v
C
Expression
3 derepressed
-_j TATA TetO2 - TtO2
Figure 1.5 - Diagram of the T-REx tetracycline-inducible system. (A) The
pcDNA6/TR plasmid (blasticidin resistance) expresses the tetR protein, which forms
homodimers. (B) The gene of interest is inserted into the pcDNA4/To plasmid (zeocin
resistance) and expression is repressed by tetR homodimers binding to TetO sites present
in the CMV promoter. (C) Upon addition, tetracycline binds to tetR homodimers. (D) The
resulting conformational change of tetracycline-bound tetR homodimers causes them to
release from the TetO2 sites, which causes derepression and expression of the gene of
interest from upstream CMV promoter.
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functionally compromised receptor. Therefore we used the tetracycline-inducible T-REx
system [60] from Invitrogen (see Figure 1.5) to construct cell lines in which production
of OR could be initiated on demand. Thus the cells can be grown to the desired
concentration and, when desired, production of fresh OR triggered by the addition of
tetracycline (a so called "tet ON" system). Such a system is advantageous as it is cheap
(no further transfection required) and efficient (100% of the cells will express OR).
1.4 Bioreactor Culture
Although a confluent 150 mm tissue culture plate can contain 50-70 million
HEK293S cells, the low levels of expression seen for most membrane proteins result in a
yield of tens of micrograms of GPCR per plate, and even less following subsequent
purification. Therefore, in order to obtain milligram levels of a GPCR using mammalian
cell culture, hundreds of tissue culture plates would be required, and such experiments
would be both extremely time consuming and expensive to perform. One solution is the
use of liquid bioreactors to culture mammalian cells in suspension. For instance the
suspension-adapted HEK293 cell line (HEK293S) can achieve cell densities in excess of
5 million cells per milliliter in suspension culture [61], and thus one liter of bioreactor
medium can contain the cellular equivalent of 100 tissue culture plates.
A bioreactor is essentially a self-regulating sterile fluid chamber (see Figure 1.6).
In my research I used the Celligen Plus stirred-tank bioreactor (New Brunswick
Scientific). A 4-gas mixture (Air, N2, 02, C0 2 ) is bubbled through the media and the
mixture automatically adjusted to regulate the pH and dissolved oxygen content. A
Figure 1.6 - Bioreactor operation. (A) The Celligen Plus liquid bioreactor during a
suspension culture run. (B) Close-up of reactor vessel showing sensors, impeller, and gas
sparge. (C) Bottle equipped with a sterile siphon system to aseptically add liquid to the
reactor vessel. (D) Cell suspension harvested after a successful bioreactor run.
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circulating external water jacket maintains culture temperature (37"C). The cells are kept
cells in suspension by an impeller blade that rotates throughout the run and breaks up
chumps. The reactor housing has four inlet ports for the sterile addition or of solutions or
cell suspensions to the reactor, as well as one total drain line in order to evacuate the
vessel. For general operation and set-up of the bioreactor, please see [62].
1.5 Circular Dichroism Spectroscopy
Circular dichroism (CD) spectroscopy can be used to characterize molecules ini
solution based on their differential absorption of circularly polarized light [63, 64]. In
contrast to linearly polarized light, where the electric field vector component only
oscillated in one plane, in circularly polarized light this electric field vector has constant
magnitude and rotates in a circle about the direction of propagation. Thus as the light
moves through space, the electric field vector forms a helix, which can either be left-
handed (left circularly polarized) or right-handed (right circularly polarized). For an
excellent depiction of circularly polarized light, see [65]. As this light is "handed" (or
chiral), it will preferentially be absorbed by chiral molecules. To obtain a CD spectrum,
equal amounts of left- and right-handed circularly polarized light are applied to a solution
containing chiral molecules, and the differential absorption is measured with respect to
wavelength.
Chiral biomolecules such as nucleic acids, peptides, and proteins can be analyzed
in one of several methods [66]. To obtain secondary structure, the far-ultraviolet (190-
250 nm) region of the spectrum can be used to estimate the fraction of alpha-helix, beta-
sheet, and random coil present in a protein [67], as all these structures have characteristic
spectra (Figure 1.7). This technique has been successfully applied not only to soluble
proteins but detergent-solubilized membrane proteins as well [68, 69]. As olfactory
receptors possess seven alpha-helical transmembrane domains, their far-UV CD spectra
should be dominated by the 208 nm and 222 nm peaks. To obtain information on tertiary
structure, the near-UV (250-300 nm) range can be analyzed, although this requires a
much higher protein concentration as the absorption signals are quite weak compared to
secondary structures. Signals in the near-UV range are due to highly structured aromatic
amino acids and disulfide bonds as well as their surrounding environment [70]. One
disadvantage to near-UV CD is that, unlike far-UV, spectra cannot be quantified and
assigned to any particular structure. Thus, it is only useful if one compares related
spectra, such as mutations or denatured versions of the same protein.
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2 - Antiparallel p
6e + 4 - 3 - Extended
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5 4e + 4 - 5 - Collagen (denatured)
E
0Em 2e + 4 -
Oe+
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Figure 1.7 - Far-UV circular dichroism spectra characteristic of the major protein
secondary structures. Secondary structures shown are alpha-helix (1), beta-sheet (2),
random coil (3), coiled coil (4), and fully denatured (5). Reprinted from [67] with
permission from Macmillan Publishers Ltd, C2006.
L6 Surface Plasmon Resonance
Surface plasmon resonance (SPR) is a proven method to analyze molecular
interactions in real time. For a review of SPR principles and analysis, please see [71, 72].
A major advantage of the system is that it is label-free, meaning none of the analytes
need to be modified with such additions as fluorophores. The assay relies on the
phenomena that under total reflection conditions, polarized light bouncing off a glass-
liquid interface will produce an electrical field in the liquid (called an evanescent field).
If the glass-liquid interface is coated with a thin layer of gold, the evanescent field will
interact with gold electrons and produce a surface plasmon (a charge density wave). At a
critical angle (called the SPR angle), energy transfer between the plasmon and evanescent
field occurs, causing an intensity minimum in the reflected light. The SPR angle varies
with the index of refraction of the liquid near the gold surface (within about 200 nm) due
to this energy coupling, and thus changes in mass bound or near the surface will cause
changes in the SPR angle [73]. Flowing molecules past the detector and constantly
measuring the shifts in SPR angle as a function of time gives an SPR data readout, called
a sensorgram.
When studying receptor-ligand interactions, the receptor can be immobilized onto
the SPR chip surface using any of several methods such as via covalent amine-coupling
to a gold-linked dextran matrix. A mobile ligand is then injected and run along the flow
cell, whereupon binding to receptor causes a change in the local index of refraction and a
resulting shift in the SPR angle (Figure 1.8A) [74]. The resulting sensorgram displays
several phases (Figure 1.8B): i) an association phase dependent on kinetics (ko11), ii) a
steady-state which depends on the dissociation constant (Kd), and, after the ligand is no
longer applied, iii) a dissociation phase depending on kinetics (koff). By analyzing
sensorgrams from multiple concentrations of ligand it is possible to estimate these rate
constants [75]. The technique has already been applied to several GPCRs including a2-
adrenergic receptor [76], neurotensin receptor [77], and the CCR5 and CXCR4
chemokine receptors [78]. While the ligands for these receptors are large polypeptides,
Other studies have been able to detect the mass increase associated with the binding of
molecules as small as 200 Daltons [79]. As most odorants are in this range, the use of the
latest SPR machines like the Biacore'" T100 (sensitive to less than 0.1 pg/mm2) has a
high potential to measure odorant-OR binding events in such an assay.
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Figure 1.8 - Overview of surface plasmon resonance (SPR). (A) Diagram of an SPR
biosensor surface. Binding interactions of the soluble ligand with immobilized protein is
detected via a change in the SPR angle. (B) Resulting sensorgram readout of the
experiment in part A. Sample injection results in association and steady state phases. A
dissociation phase results when ligand is no longer injected. Reprinted from [74] with
permission from Elsevier, 02007.
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CHAPTER 2
FABRICATION OF CUSTOM
OLFACTORY RECEPTOR GENES
1.1 Overview of PCR-based gene synthesis
The initial stage of the project will be the construction of selected olfactory
receptor gene constructs and insertion into specific expression plasmids. For this I chose
the method of polymerase construction and amplification (PCA). This utilized a PCR-
based method of gene synthesis [1] that involves parsing the gene sequence into a set of
small overlapping oligonucleotides. During an initial assembly PCR, these oligos
function as both primer and template, while the DNA polymerase successively builds
longer and longer fragments with each round of PCR. A second amplification PCR then
enriches for the full-length gene. For a detailed illustration of the mechanism of PCl-
based gene synthesis, please see Figure 2.1.
To assist in parsing the sequence into oligos, I used the online program
DNAWorks (http://helixweb.nih.gov/dnaworks) developed by Hoover and Lubkowski
[2]. The amino acid sequence of each olfactory receptor was obtained from GenBank and
directly inputted into the software. To adapt the gene for use in specific expression
systems and to facilitate purification and detection, the following sequence modifications
were made using the DNAWorks software:
a. Codon optimization for expression system of interest
b. Addition of N-terminal and C-terminal tags (along with glycine linkers and
signal cleavage sequences) for purification and detection
c. Addition of ribosome binding sites (Kozak / Shine-Delgarno sequences) at 5'
end of gene
d. Addition of flanking restriction sites for cloning into expression vector
A number of N-terminal and C-terminal sequence tags were tested, including
FLAG and 6x-His (see Appendix A.2). Initially, we focused on the purification tag
utilized by the Khorana lab for rhodopsin, namely the nine C-terminal amino acid
sequence (TETSQVAPA) for which a specific antibody has been generated (rholD4).
This tag has already facilitated early-stage immunoaffinity purifications of other several
other membrane proteins [3, 4].
There have been numerous reports in the literature citing difficulties in expressing
functional olfactory receptors in heterologous systems. The main problem seems to be
improper membrane targeting and resulting cytosolic localization of the majority of ORs
[5-8]. Several studies have been able to alleviate this problem by the addition of putative
membrane import signals to the N-terminus of the olfactory receptor [9, 10]. However,
more recent studies [11, 12] have managed to express functional olfactory receptors in
HJEK293 cells without the use of such signal tags. We decided to also investigate whether
these putative import sequences could improve expression in the olfactory receptors
studied.
Figure 2.1 - Overview of PCR-based Gene Assembly
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2.2 Selection of OR Genes for Construction
To select genes for study, we took the subset of ORs with known ligand
specificity and selected a small group that represented the diversity of olfactory receptors
(both genetically and in the class of odorants they respond to) and that also showed
strong homology across the well-studied mammalian OR families (canine, mouse,
htuman). The following list of candidate OR genes contains members of both Class I and
Class II, and respond to a range of aliphatic and aromatic chemicals (see Figure 2.2).
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Figure 2.2 - Olfactory receptor phylogenetic tree: Receptors boxed in green have had
synthetic genes constructed using PCA. The receptor boxed in red, hOR17-4, was the
candidate receptor chosen for subsequent expression and large-scale purification. The
grayed top quadrant of the tree consists of Class I (fish-like) receptors. Reprinted with
permission from [13], ©2004, National Academy of Sciences, U.S.A.
Human hOR17-4 receptor (also known as OR1D2)
This is the second human olfactory receptor for which ligand specificity has been
studied. This receptor is unique in that it is expressed in sperm and appears to govern the
sperm's ability to "home in" on the egg. It has been shown to respond to bourgeonal [14-
16], and other lily-like aromatic aldehydes such as lilial and floralozone (Figure 2.3).
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Figure 2.3 - Partial odorant ligand spectrum for hOR17-4. The hOR17-4 receptor
was transiently expressed on HEK293 cells and odorant responses measured by calcium
imaging. Active compounds, such as bourgeonal, were aromatic with an aldehyde group(usually two carbons away from the aromatic ring) and a carbohydrate group in the para
position. Undecanal was found to be a receptor antagonist. From [16], reprinted with
permission from AAAS, C2003.
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Mouse IG7 receptor (also known as mOR276-1)
This receptor shows a high response to limonene [9], a well-studied aromatic
alkene (hydrocarbon) from citrus fruits that is highly used in industry. The mouse
receptor is 88% identical to its human ortholog, hOR2V 1.
Mouse S51 receptor (also known as mOR40-1)
This receptor is a member of the "fish-like" Class I olfactory receptor family. It
has been shown to respond to a range of aliphatic carboxylic acids and alcohols [17]. The
mouse receptor is 85% identical to its human ortholog, hOR56A5.
Mouse 17 receptor (also known as mOR103-15)
This Class I receptor has been highly studied in both rat and mouse, and shows
90% identity with its human ortholog, hOR6A2. It is highly responsive to aliphatic
aldehydes, such as octanal and heptanal [9, 18].
Mouse M71 receptor (also known as mOR71-2)
This receptor shows specificity for acetophenone [19], an aromatic ketone.
Acetophenone is highly used in the perfuming and flavoring industries for such odors as
strawberry and jasmine. The mouse receptor shows 85% identity to its human ortholog
hOR8A1.
Mouse OR73 receptor (also known as mOR-EG and mOR174-9)
This receptor shows specificity for eugenol [20], an aromatic alcohol / ester.
Eugenol has a spiced clove and cinnamon odor and is widely used in industry. The mouse
receptor is 82% identical to its human ortholog hOR5D 18.
Mouse IC6 receptor (also known as mOR118-1)
This receptor shows specificity for the (-) stereoisomer of citronellal [9], a
letion-scented monoterpenoid, which is often used as an insect repellant. The mouse
receptor is 81% identical to its human ortholog hOR6E1P.
Mouse OR23 (also known as mOR267-13)
This is the mouse homolog to human olfactory receptor 17-4, in that it is
expressed in mouse sperm and mediates chemoattraction. It has been shown to respond to
the bourgeonal-like odorant lyral [21]. It is 39% identical to hOR17-4 and 87% identical
to hOR1OJ5.
Nematode ODR-10 receptor
A well studied olfactory receptor in the worm (C. elegans) which has been shown
to have high specificity for diacetyl [22-24], an aliphatic ketone. This receptor is shows
little homology to mammalian receptors.
2.3 Fabrication of the hOR17-4-rho synthetic gene
Methods
To adapt the genes for use in mammalian cell expression and purification, the
following sequence modifications were made using the DNAWorks software:
i. Human codon optimization (for HEK293S cells)
ii. Addition of C-terminal rholD4 epitope tag "TETSQVAPA" (preceded
by a two glycine linker) to facilitate purification
iii. Addition of NotI restriction site at the 3' end of gene
iv. Addition of EcoRI restriction site and Kozak sequence (eukaryotic
ribosome binding site) at the 5' end of gene
The designed oligos (Table 2) were purchased from IDT (Coralville, IA) with a
maximum length of 45 bp. The assembly PCR was run for a variable number of cycles
using a mixture of all oligos at a concentration of 25 nM each. The amplification PCR
was run for 30 cycles using 1 [tL of the assembly PCR (in a total reaction volume of 50
[tL) and each end oligo at a concentration of 300 nM each. PCR reactions were then
analyzed by gel electrophoresis and stained with ethidium bromide. Full-length product
was excised, extracted, and then digested with the pertinent restriction enzymes. The
genes were then ligated into the pcDNA4/To expression plasmid (Invitrogen), sequenced,
and a correct clones grown up using a MaxiPrep kit (Qiagen, Valencia, CA).
Perimer Sequence # bp
Si: CCTGAATTCGCCGCCACCATGGACGGAGGCAA 32
52: CCAAAGCGAGGGCAGCGAGTTTCTGCTGCTGG 32
S3: GCATGTCCGAGAGCCCCGAGCAACAGCAGATCCT 34
S4: CTTTTGGATGTTTCTGAGCATGTATCTGGTCACCGTGGTCG 41
$5: GAAATGTCCTGATTATCCTCGCTATTAGCTCCGACAGCAGACTC 44
S6: CATACCCCCGTCTACTTCTTTCTGGCTAACCTCTCCTTTACAGA 44
S7: CCTGTTTTTCGTCACAAACACCATTCCCAAAATGCTCGTCAA 42
S8: CCTCCAAAGCCACAACAAAGCTATTAGCTATGCCGGCTG 39
$9: CCTCACACAACTCTATTTTCTCGTGAGCCTGGTGGCCC 38
SlO: TGGATAATCTGATTCTCGCCGTCATGGCTTACGATCGGTAC 41
S11: GTGGCTATTTGTTGCCCTCTCCACTATACAACAGCTATGAGCC 43
S12: CTAAACTGTGCATCCTGCTCCTGTCCCTGTGCTGGG 36
813: TGCTCTCCGTGCTGTATGGACTCATTCACACACTGCTCA 39
Si4: TGACAAGAGTGACCTTTTGTGGCTCCAGAAAGATCCACTACATTT 45
515: TCTGCGAAATGTACGTCCTCCTCCGGATGGCCTGTAG 37
S16: CAACATTCAGATTAACCATACCGTGCTGATTGCTACCGGATGCTT 45
S17: TATTTTCCTCATCCCCTTCGGATTCGTGATCATCAGCTACGTC 43
$18: CTCATTATCAGAGCCATTCTCCGGATCCCTTCCGTCAGCAAAA 43
S19: AATATAAGGCTTTCAGCACCTGTGCCAGCCATCTGGGAG 39
S20: CCGTCAGCCTGTTTTATGGAACACTGTGTATGGTCTATCTCAAAC 45
S21: CTCTCCACACCTACAGCGTCAAGGACTCCGTCGCTA 36
S22: CAGTGATGTATGCCGTCGTCACCCCCATGATGAACCC 37
S23: CTTCATCTACTCCCTCAGAAACAAAGATATGCATGGCGCTCTC 43
S24: GGAAGACTCCTGGACAAACACTTTAAAAGACTGACCGGAGG 41
S25: CACAGAGACATCCCAAGTCGCTCCTGCTTAAGCGGC 36
AS 1: CTTCTCGCGGCCGCTTAAGCAGGAG 25
A52: CGACTTGGGATGTCTCTGTGCCTCCGGTCAGTCTTTTAAAG 41
AS3: TGTTTGTCCAGGAGTCTTCCGAGAGCGCCATGCATATC 38
AS4: TTTGTTTCTGAGGGAGTAGATGAAGGGGTTCATCATGGGGGTG 43
AS5: ACGACGGCATACATCACTGTAGCGACGGAGTCCTTGA 37
AS6: CGCTGTAGGTGTGGAGAGGTTTGAGATAGACCATACACAGTGT 43
AS7: TCCATAAAACAGGCTGACGGCTCCCAGATGGCTGGC 36
ASB: ACAGGTGCTGAAAGCCTTATATTTTTTGCTGACGGAAGGGATC 43
A59: CGGAGAATGGCTCTGATAATGAGGACGTAGCTGATGATCACGAA 44
AS10: TCCGAAGGGGATGAGGAAAATAAAGCATCCGGTAGCAATCAG 42
AS11: CACGGTATGGTTAATCTGAATGTTGCTACAGGCCATCCGGAG 42
AS12: GAGGACGTACATTTCGCAGAAAATGTAGTGGATCTTTCTGGAGC 44
AS13: CACAAAAGGTCACTCTTGTCATGAGCAGTGTGTGAATGAGTC 42
AS14: CATACAGCACGGAGAGCACCCAGCACAGGGACAG 34
AS15: GAGCAGGATGCACAGTTTAGGGCTCATAGCTGTTGTATAGTGG 43
AS16: AGAGGGCAACAAATAGCCACGTACCGATCGTAAGCCATGA 40
AS17: CGGCGAGAATCAGATTATCCAGGGCCACCAGGCTC 35
A§18: ACGAGAAAATAGAGTTGTGTGAGGCAGCCGGCATAGCTAATAG 43
AS19: CTTTGTTGTGGCTTTGGAGGTTGACGAGCATTTTGGGAATG 41
AS20: GTGTTTGTGACGAAAAACAGGTCTGTAAAGGAGAGGTTAGCCA 43
AS21: GAAAGAAGTAGACGGGGGTATGGAGTCTGCTGTCGGAGC 39
A522: TAATAGCGAGGATAATCAGGACATTTCCGACCACGGTGACCA 42
AS23: GATACATGCTCAGAAACATCCAAAAGAGGATCTGCTGTTGCTCG 44
AS24: GGGCTCTCGGACATGCCCAGCAGCAGAAACTCG 33
AS25: CTGCCCTCGCTTTGGTTGCCTCCGTCCATGG 31
Table 2 - Primers used for the PCR-based synthesis of the engineered hOR17-4-rho
gene. A total of 50 oligonucleotides were used to construct the synthetic gene (25 sense
strand oligos, labeled S 1-25) and 25 anti-sense strand oligos, labeled AS 1-25).
Results
Default protocols for PCR-based gene assembly suggest 20-30 cycles in the
assembly reaction to be sufficient for the synthesis of genes up to and beyond 1 kb [2].
However, all of our initial trials using these parameters proved unsuccessful. We
hypothesized that, due to possible inefficiencies in oligo gene assembly, more cycles
might be necessary to fully elongate the oligo templates. Indeed, we then discovered that
the critical parameter governing the success of our PCR-based gene assemblies to be the
number of PCR cycles in the initial assembly reaction. As can be seen in Figure 2.4, the
1st PCR (assembly) 2nd PCR (amplification)
#cycles in
1 st PCR rxn:- god
Figure 2.4 - Fabrication of custom hOR17-4-rho gene. Increasing cycles in 1st PCR
generate longer assembly products and ultimately enable amplification of full-length OR
gene in 2nd PCR. Lane 1 is DNA standards - the bands (from the bottom) are 250, 500,
750, and 1000 bp.
11 .... .. .... .... . ...... ..... . .. ........ .......... - A: ' - - - n - - ...... . . .  .... . ... .  .... .  .... ....
largest species visible in the assembly reaction "smear" increased with number of cycles,
and full-length product (~1 kb) was not achieved in the amplification reaction (2nd PCR)
until 45 assembly cycles.
Subsequent to construction of our first olfactory receptor, hOR17-4-rho, eight
additional olfactory receptors (see Appendix C) were synthesized, most on the first
attempt, using our modified procedure. Additionally, we have adapted the system to
include generalized tag "modules" which can be swapped into existing oligo gene sets
using a custom linker oligo. Three additional tagged versions (R-hOR17-4, HF-hOR17-4,
and HF-hOR17-4), incorporating N-terminal "membrane import sequences" or His and
FLAG tags, have been generated to date. This demonstrates that our adapted protocol can
be generally applied to our project for the rapid fabrication of synthetic olfactory receptor
gene constructs.
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CHAPTER 3
PRODUCTION OF HOR17-4 IN
ADHERENT CELL CULTURES
NOTE: This chapter is a review and expansion ofpreviously published result:
Cook BL, Ernberg KE, Chung H, Zhang S. Study of a synthetic human olfactory
receptor 17-4: expression and purification from an inducible mammalian cell line.
PLoS ONE. 2008 Aug 6,3(8):e2920.
3,1 Abstract
In order to begin to study the structural and functional mechanisms of olfactory
receptors, methods for milligram-scale purification are required. Here we demonstrate the
production and expression of a synthetically engineered human olfactory receptor
hOR17-4 gene in a stable tetracycline-inducible mammalian cell line (HEK293S). The
OR gene was fabricated from scratch using PCR-based gene-assembly, which facilitated
codon optimization and attachment of a 9-residue bovine rhodopsin affinity tag for
detection and purification. Induction of adherent cultures with tetracycline together with
sodium butyrate led to hOR17-4 expression levels of -30 ptg per 150 mm tissue culture
plate. Fos-choline-based detergents proved highly capable of extracting the receptors, and
fos-choline-14 (N-tetradecylphosphocholine) was selected for optimal solubilization and
subsequent purification. Analysis by SDS-PAGE revealed both monomeric and dimeric
receptor forms, as well as higher MW oligomeric species. A two-step purification method
of immunoaffinity and size exclusion chromatography was optimized which enabled 0.13
milligrams of hOR17-4 monomer to be obtained at >90% purity. This high purity of
hOR17-4 is not only suitable for secondary structural and functional analyses but also for
subsequent crystallization trials. Thus, this system demonstrates the feasibility of
purifying milligram quantities of the GPCR membrane protein hOR17-4.
3.2 Introduction
Membrane proteins are of vital importance to life, as evidenced by the fact that
~-30% of the genes in almost all sequenced genomes code for membrane proteins [1-3].
However, our understanding of the structures and functions of membrane proteins has
lagged behind the known soluble proteins. As of June 2008, there are only 160 unique
membrane protein structures known [http://blanco.biomol.uci.edu/MembraneProteiris
xial.html], which constitutes less than 1% of all known protein structures. The major
bottleneck in obtaining membrane protein structures is the notorious difficulty involved
in expressing and purifying the large quantities of membrane protein sample required for
X-ray crystallography. In order to accelerate membrane protein structural and function
studies, new and simple methods for membrane protein production must be developed.
Olfactory receptors (or odorant receptors) are an extremely large class of G-
Protein Coupled Receptors (GPCRs) that function together combinatorially to allow
discrimination between a wide range of volatile molecules [4,5]. All GPCRs are integral
membrane proteins with seven transmembrane domains arranged in a barrel-like
conformation. In olfactory receptors, it is believed that this configuration forms a funnel-
shaped pocket for odorant recognition [6]. The olfactory receptor (OR) gene family
constitutes the largest single class of genes in the vertebrate genome (2-3% in the
human). Current estimates put the number of human olfactory receptor genes at 636, with
only 339 being functional and the rest being non-functional pseudogenes [7]. This is
considerably less than the mouse OR gene family of 1209 (913 functional) [8] or the
canine OR gene family of roughly 1200 (-1000 functional) [9]. Despite the fact that they
represent the largest class of known membrane proteins, no detailed structure exists for
any olfactory receptor and the functional mechanisms of these amazing receptors remains
unknown. The crucial first step to enable such pivotal studies is to engineer systems with
the capacity to generate and purify milligram quantities of an olfactory receptor.
Mammalian olfactory receptors are expressed on the cilia of olfactory neurons
within the nasal cavity. Odorant binding and recognition leads to activation and release of
the olfactory G-protein Golf, which triggers cyclic-AMP production, ion-channel-
mediated Ca2+ influx, and finally the firing of an action potential into the olfactory bulb
to be interpreted by the brain [10]. Through an unknown mechanism of allelic
inactivation, every olfactory neuron chooses a single OR gene to express. Signals from
neurons that express the same olfactory receptor later converge downstream at neural foci
called glomeruli [11]. As the same odorant will stimulate multiple ORs (and to various
strengths), the brain receives a spatial map of receptor activity through these glomeruli
[12]. Odorants are thought to be recognized by matching a specific spatial pattern (a
combinatorial code) [5].
The human olfactory receptor 17-4 (hOR17-4, alternately known as ORlD2) is of
particular interest since, in addition to olfactory neurons, it is also expressed on the
midpiece of human spermatozoa [13]. Sperm expressing hOR17-4 were found to migrate
towards known hOR17-4-responsive odorants such as bourgeonal. Thus the receptor
serves a dual role in that it recognizes odorants in the nose as well as plays a potential
role in sperm chemotaxis and fertilization. As structural studies of hOR17-4 would not
only provide information crucial to understanding the molecular mechanism(s) of
olfaction but also have application to human reproduction, we selected this receptor as
our prototype OR for expression and purification trials.
The GPCR family represents one of the most important known receptor classes as
evidenced by the fact that half of all pharmaceutical drugs target GPCRs [14]. Despite
their crucial role in mediating such diverse physiological processes as sight, smell, and
the response to hormones and neurotransmitters, extremely little is known about these
receptors at the structural level. A major breakthrough in 2007 was the determination of
only the second GPCR crystal structure - that of a highly engineered human beta2-
adrenergic receptor expressed in Sf9 insect cells where intracellular loop 3 was replaced
with either antibody or T4 lysozyme to facilitate crystallization [15, 16]. Rhodopsin is
perhaps the only GPCR that can be easily extracted from tissue, and this may explain
why it was the first GPCR to have a detailed structure determined [17-19]. However,
recent advances in the Khorana laboratory have led to the development of specific
mammalian HEK293 cell lines for heterologous expression as well as methods for
purification that yield milligram quantities of functional rhodopsin which is suitable for
functional analysis and structural study [20-22]. We recently used same rholD4-tag
system for a one-step affinity purification of the human tetraspanin membrane protein
CD81 [23]. Here we show that this system can be also adapted to facilitate the production
and purification of another GPCR, the human olfactory receptor 17-4.
In order to carry out biochemical and structural analyses of olfactory receptors as
well as engineer olfactory receptor-based biosensor devices, large quantities of receptors
are required. Here we here report inducible expression, large-scale production of human
olfactory receptor hORi7-4. We bioengineered the synthetic hOR17-4 gene into 50
oligonucleotide fragments, self-assembled them through high cycle PCR and inserted the
assembled gene into an inducible human embryonic kidney cell line (HEK293S). We
then induced its production using a combination of tetracycline and sodium butyrate.
After systematic detergent screening, the zwitter-ionic detergent fos-choline-14 (FC14)
was found to be most effective for solubilization and was subsequently used throughout
the entire solubilization and purification. To our knowledge this is the first time an
olfactory receptor has been purified from a mammalian cell line.
3.3 Results
Description of synthetic hOR17-4-rho gene
To fabricate synthetic gene constructs we utilized a PCR-based method of gene
synthesis [24] that involves parsing the DNA sequence into a set of small overlapping
oligonucleotides. During an initial assembly PCR, these oligos function as both primet
and template, while the DNA polymerase successively builds longer and longer
fragments with each round of PCR. A second amplification PCR then enriches for the
full-length gene. This process has more recently become known as PCA, or polymerase
construction and amplification. To assist in parsing the sequence into oligos, we used the
online program DNAWorks (http://helixweb.nih.gov/dnaworks) developed by Hoover
and Lubkowski [25].
The 312 amino acid sequence of wild-type human olfactory receptor hOR17-4
was obtained from GenBank and directly inputted into the software in protein mode. To
adapt the resulting gene for use in our specific expression system and to facilitate
purification and detection, the reverse-translated DNA sequence was human codon-
optimized and appended with a C-terminal rholD4 epitope tag (TETSQVAPA) [20-22].
The synthetic DNA corresponding to the hOR17-4 gene consisted of 1004 bp, encoding a
receptor protein of 323 amino acids (Figure 3.1). Other than the addition of the rholD4
tag and linker, the hOR17-4 protein sequence is wild-type and completely full length.
Noteworthy in the synthesis procedure was the requirement for a high number of PCR
cycles (45) during the assembly PCR, presumably due to inefficiencies resulting from
non-productive oligonucleotide mispairings.
EcoRI Kozak Start
CCTGAATTCG
CTGGGCATGT
TATCTGGTCA
CTCCATACCC
ACAAACACCA
GCCGGCTGCC
CTCGCCGTCA
GCTATGAGCC
TATGGACTCA
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GAAG
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Figure 3.1 - Codon-optimized hOR17-4 sequence. The DNA (A) and corresponding
amino acid (B) sequence of synthetic hOR17-4 olfactory receptor gene. The DNA
sequence was human codon-optimized and a mammalian Kozak ribosome binding site
introduced upstream of the translation start site. Translation start and stop sites as well as
restriction cloning sites are indicated. The engineered construct also contains a C-
terminal tag (underlined) consisting of a glycine linker followed by a nonapeptide epitope
for the monoclonal rho ID4 antibody.
Induction of hOR17-4 expression in stable HEK293S cell lines
To minimize the toxic effects of receptor overexpression, stable hOR17-4-
inducible HEK293S cell lines were created using the Invitrogen T-REx tetracycline
regulation system (Materials and Methods). This allowed large-scale cell culture batches
to be grown and then, when desired, concerted production of fresh olfactory receptor to
be induced in nearly 100% of the cells. Results for the induction of hOR17-4 expression
in two of the subcloned HEK293 lines are shown in Figure 3.2A. Western
immunoblotting using a monoclonal antibody against the rholD4 tag revealed major
immunoreactive bands at approximately 32 kD and 60 kD, which correspond in size to
monomeric and dimeric forms of the hOR17-4 receptor. This size pattern has been
reported previously for several solubilized olfactory receptors expressed in Sf9 and
mammalian cells [26-28]. Larger molecular weight complexes were also present,
presumably due to aggregation and precipitation of the receptor. As sample boiling only
increases the precipitation, it is possible that increased temperatures (above 4*C) caused
by the electrophoresis could be causing the receptor to partially aggregate. Thus these
high MW species could be a side effect of the SDS-PAGE electrophoresis and not
originally present in the solubilized receptor fractions.
The histone deacetlyase inhibitor sodium butyrate has been demonstrated to
synergistically enhance expression when used with tetracycline-regulated systems [21].
Induction of hOR17-4 in HEK293S cells using tetracycline in conjunction with sodium
butyrate increased expression by approximately 4-5 fold over tetracycline alone at all
time points tested (Figure 3.2B). There was no detectable expression of hOR17-4 in the
Clone 1 Clone 5 b
- + -+ 15000.
0 24 htours
12500 4 h
2e 0 72 hours
im S 10000
7500-
5000
2500
0-
Tetracydlin Tetracyclin Tetracyclin Tetracyclin
(1 ug/mL) (2 ug/mL) (1 ug/mL) + (2 ug/mL) +
NaBu (5mM) NaBu (5mM)
lfgure 3.2 - Induction of hOR17-4 in stable HEK293S cell lines. (A) Stable inducible
cell lines were generated in HEK293S cells using the T-REx system (Invitrogen)
expressing hOR17-4 tagged with the rholD4 tag (TETSQVAPA) at the C-terminus. The
pooled cells were then subcloned, expanded, and then tested for induction in media
supplemented with (+) or without (-) 1 pg/ml tetracycline for 48 hours. Levels of hOR17-
4 were probed via SDS-PAGE western blotting using the rho 1D4 antibody. Clones 1 and
5 showed the highest levels of induction while maintaining undetectable background
levels in the absence of tetracycline. Clone 5 was selected for all subsequent experiments.
(B) Addition of sodium butyrate enhances induced expression of hOR17-4. Inducible
HEK293 was subjected to a dosage time course using the indicated concentrations of
tetracycline and sodium butyrate. Samples were harvested, subjected to dot blot analysis
(western blot against rholD4), and the results quantified by spot densitometry
Tetracycline in conjunction with sodium butyrate increased expression by approximately
4-5 fold over tetracycline alone at all time points tested. Tetracycline was necessary to
cause induction, as no expression was detected if sodium butyrate was used alone.
Additionally, increasing tetracycline concentration to 2 jig/ml had no significant effect on
induction levels.
absence of tetracycline or with sodium butyrate alone. Significant cell toxicity and death
was observed in treatments combining tetracycline and sodium butyrate (5 mM) at the 48
and 72 hours time points. Treatment with sodium butyrate or tetracycline alone did not
show this toxicity, indicating it to be a result of the high level expression induced by the
drugs in conjunction.
. .......... ....................  - .::.::
To characterize this effect the samples were subjected SDS-PAGE analysis
(Figure 3.3A). The gel showed two monomer band sizes, approximately 30 kD and 32
kD, suggesting distinct monomer forms (and corresponding dimer forms). It is possible
these size discrepancies are due to differences in glycosylation of the receptor. Sodium
butyrate addition for 24 hours showed a very large increase in expression over
tetracycline alone, with the monomer band running at approximately 32 kD. Sodium
butyrate addition for longer periods further increased total expression, however this
caused the appearance of the additional monomer form running at 30 kD. The 48-hour
time point contained roughly equal parts of both forms while the 72 hour time point
consisted predominantly of the 30 kD form. To attempt to avoid the aforementioned
toxicity we next performed a time course using a range of sodium butyrate concentrations
(Figure 3.3B). We discovered that high levels of expression appeared to correlate with
the appearance of the 30 kD form (and correspondingly smaller dimer form) and the
observed cytotoxicity noted previously.
For subsequent purification experiments, we selected a treatment consisting of
sodium butyrate (1 mM) with tetracycline (1 ptg/ml) for 48 hours for attempts to purify
primarily the 32 kD form. However, to further compare and characterize both forms,
increasing the sodium butyrate concentration to 5 mM could be used, as relatively equal
amounts of both monomer forms would be present.
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Figure 3.3 - High-level induction correlates with a band shift of hOR17-4. (A) Time
point samples (from Figure 2) were normalized to total protein content and subjected to
SDS-PAGE western blotting against rho1D4. All lanes were treated with 1 pg/ml
tetracycline with (+) or without (-) sodium butyrate (5 mM) for the time indicated. (B)
hOR17-4-inducible HEK293S cells were subjected to a dosage time course using the
indicated concentrations of sodium butyrate. All samples were co-treated with 1 pg/ml
tetracycline. Samples were normalized to total protein content and subjected to SDS-
PAGE western blotting against rho lD4.
Purification of heterologously expressed hOR17-4
We incorporated a C-terminal rholD4-tag utilized by the Khorana lab for
rhodopsin purification and detection [20-22], namely the nine C-terminal amino acid
sequence (TETSQVAPA) against which a specific monoclonal antibody has been
72 hrs
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generated (rholD4). This tag has already facilitated early-stage immunoaffinity
purifications of several GPCR membrane proteins [29-32]. For the initial immunoaffinity
purification, we used CNBr-activated Sepharose 4B beads linked to the mouse
monoclonal rholD4 antibody to capture detergent solubilized receptors [21].
We first performed a small-scale purification from six 150 mm culture plates of hOR17-
4-inducible HEK293S cells. The plates were treated as to have equal amounts of the 30
kD and 32 kD bands upon harvesting (tetracycline plus 5 mM sodium butyrate, 48 hours).
Following a thorough wash procedure to remove non-specific impurities, the bound
receptors were eluted by the addition of an excess of epitope peptide (TETSQVAPA).
Fractions were subjected to SDS-PAGE followed by either western immunoblotting
(Figure 3.4A) or total protein staining using highly sensitive SYPRO-Ruby (Figure
3AB). The receptor was completely captured by the bead matrix, as no hOR17-4 was
detected in the flow through by western blot. The bound OR eluted primarily in the first
and second elution fractions. Total yield of hOR17-4 was approximately 30 pig per 150
mm plate. Mass spectrometry analysis on samples isolated from SDS-PAGE gel bands
confirmed the identity of putative monomer and dimer protein bands as hOR174
receptor (see Materials and Methods).
To expand the system to potential milligram scale, fifty 150 mm culture plates of
hOR17-4-inducible HEK293S cells were used. The plates were treated tetracycline plus 5
mM sodium butyrate, 48 hours). The total yield of hOR17-4 following immunoaffinity
purification was 1.5 milligrams. To further purify the receptor and to remove the elution
peptide, the hOR17-4 was subjected to size exclusion chromatography (SEC) using a gel
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Figure 3.4 - Immunoaffinity purification of hOR17-4. Six 150 mm tissue culture plates
of were grown to 90% confluence then induced and treated with tetracycline (1 jg/ml)
and sodium butyrate (5 mM) for 48 hours. Plates were scrape harvested, solubilized, and
the processed lysate subjected to immunoaffinity purification using rholD4 antibody
linked to sepharose beads for capture. Bound proteins were washed and then eluted using
the nonapeptide TETSQVAPA. Samples were subjected to SDS-PAGE followed by
either western immunoblotting with rholD4 antibody (A) or total protein staining with
Sypro Ruby (B). Black triangles indicate the 30 and 32 kD monomer forms. Tot, total
lysate; FT, flow through; W, wash; E, elution.
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Figure 3.5 - Full purification of hOR17-4 extracted from 50 x 150 mm culture plates.
(A) Size exclusion chromatography (SEC) on immunoaffinity-purified hOR17-4.
Absorbance was simultaneously recorded at 280 nm (black line, values on left axis) and
215 nm (grey line, values on right axis). The peaks indicated by numbers were pooled
and concentrated. Peak 5 consists of the elution nonapeptide from the immunoaffinity
purification. (B) Total protein staining of SEC peak fractions. Load is the original
immunoaffinity purified sample applied to the chromatography column. Peak numbers
refer to those designated in (A). Peak 3 contains monomeric hOR17-4 at >90% purity.
Total monomer yield was 2.6 jig per 150 mm culture plate.
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filtration column on an Akta HPLC system. Column flow through was monitored by UV
absorption (280 nm and 215 nm) and separated into fractions by an auto-fraction
collector. As seen in Figure 3.5A, five distinct peaks were observed. The peak fractions
were then pooled, concentrated and subjected to SDS-PAGE followed by total protein
staining. As seen in Figure 3.5B, peak 3 contains monomeric hOR17-4 (>90% purity)
while earlier peaks contained largely dimeric (peak 2) and aggregated/oligomerized (peak
1) forms. Peak 4 showed no visible protein and peak 5 corresponds to the residual elution
peptide (TETSQVAPA) from the immunoaffinity purification. The final yield of purified
hOR17-4 monomer was 0.13 milligrams (2.6 pg per plate). Thus, using a two-step
procedure we have successfully obtained significant amounts of hOR17-4 in a highly
pure form.
3.4 Discussion
In this study, we successfully developed methods for the construction of inducible
mammalian cell lines that generate large quantities of olfactory receptor on demand. To
out knowledge this is the first olfactory receptor to be purified from a mammalian cell
line. Currently, we have demonstrated the production of the human olfactory receptor
hOR17-4 in a stable tetracycline-inducible human embryonic kidney cell line
(HEK293S). Expressed OR genes were fabricated from scratch using PCR-based gene
synthesis (polymerase construction and amplification, a.k.a. PCA), which facilitated
codon optimization for high level expression and attachment of affinity tags for detection
and purification. The HEK293S cells can be grown and OR expression induced in
adherent cultures (yield of -30 micrograms/I 50-mm plate). Using methods originally
adapted from the production and purification of the GPCR rhodopsin [20-22] and further
optimized (including the full-spectrum screening of over 70 detergents), the olfactory
receptor is solubilized and extracted from the cells using fos-choline-14. The OR protein
is then isolated using a two-step purification method (immunoaffinity followed by size-
exclusion chromatography) which yields hOR17-4 monomer at greater than 90% purity
(Figure 3.5B).
There have been a host of previous studies that have expressed and studied
olfactory receptors in native and heterologous systems. However, to date there has not
been a case where olfactory receptors have been overexpressed and purified to
homogeneity in significant quantities. While purification of ORs has been attempted in
bacterial [33] and Sf9 insect systems [26-27], these were unable to produce large
quantities of native full-length olfactory receptor. Additionally, these organisms lack
mammalian post-translational machinery and thus purified receptors may be improperly
folded or missing critical modifications. It is known that most, if not all, GPCRs are
glycosylated, and indeed the olfactory receptors have conserved N-linked glycosylation
sites (Asn-X-Ser/Thr) at their N-terminus [34-35]. Several studies have indicated that loss
of glycosylation can lead to improper folding and targeting, resulting in decreased
function and compromised structure [36-37]. Loss of either N-terminal glycosylation site
(Asn-2 or Asn-15) of rhodopsin is sufficient to cause loss of signal transduction despite
no apparent change in localization or folding [38-39]. This indicates that purification of
olfactory receptors from mammalian systems might be crucial for functional expression
and purification.
Characterization of purified hOR17-4
It is interesting to note that the engineered hOR1 7-4-rho protein (with theoretical
molecular mass of 36.2 kD) migrates slightly faster than expected on SDS-PAGE gels
(30 kD and 32 kD). One possible explanation for this discrepancy is incomplete receptor
denaturation by SDS since boiling the samples results in aggregation. Indeed, many other
membrane proteins have been found to migrate faster than their actual size on SDS-
PAGE, and this has been reported for other olfactory receptors as well [27, 33]. We
believe both monomer forms of the expressed hOR17-4 receptor to be intact, full-length
proteins as evidenced by: 1) detection by the C-terminal rho lD4 monoclonal antibody, 2)
detection by custom anti-hOR17-4 polyclonal antibodies raised against the hOR17-4 N-
terminus or C-terminus, 3) detection of a 30 kD N-terminally 6xHis-tagged hOR17-4
variant using anti-His antibodies (data not shown). Additionally, we see only the 32 kD
form at low levels of induction while the 30 kD form only begins to appear at higher
levels of induction. One explanation is that the receptor is glycosylated at low induction
but that the toxicity associated with higher expression causes the receptor to begin to
accumulate in the ER and not be properly processed.
The appearance of two distinct hOR17-4 monomer bands following purification
could pose a problem for structural studies using X-ray crystallography, since typically a
high degree of protein homogeneity is required for protein crystallization. We initially
believed that it was possible to obtain primarily 32 kD form using lower levels of
induction (Figure 3.3B). However, we have observed that the rholD4 immunoaffinity
purification appears to increase the proportion of 30 kD monomer form relative to 32 kD
form given the original treatment. For example, the treatment dosages for the small-scale
(Figure 3.4) and large-scale (Figure 3.5) purifications were chosen (based on data in
Figure 3.3b) to result in equal amounts of both forms or primarily 32 kD form,
respectively. However, following immunoaffinity purification the resulting elution
samples were enriched in the 30 kD monomer form. One hypothesis is that the 30 kD
(potentially non-glycosylated form) binds more readily to the rholD4-coupled bead
matrix. Therefore, to obtain truly homogeneous hOR17-4 monomer it might be necessary
to use even lower levels of induction where no 30 kD form exists. Another option would
be to mutate the asparagine in the consensus N-glycosylation site of the receptor, located
at amino acid position 5. We predict such a change to result in exclusive production of
the 30 kD monomer form. However, the functional effect of abolishing glycosylation on
the receptor is unknown.
There have been numerous reports in the literature citing difficulties in expressing
functional olfactory receptors in heterologous systems. The main problem seems to be
improper membrane targeting and resulting cytosolic localization of the majority of ORs
[35-36, 40-41]. Several studies have been able to alleviate this problem by the addition of
putative membrane import signals to the N-terminus of the olfactory receptor [42-43].
However, more recent studies [44-45] have expressed functional olfactory receptors in
HEK293 cells without the use of such signal tags. We also investigated the use of an N-
terminal "membrane import" sequence composed of the first twenty amino acids of
bovine rhodopsin but found no significant increase in receptor yield or localization
(results not shown).
Our largest adherent culture experiment consisted of fifty 150 mm tissue culture
plates. While the total yield of crude hOR17-4 following immunoaffinity purification was
1.5 milligrams, the subsequent size exclusion chromatography and associated
concentration steps reduced this yield to 0.13 milligrams of purified hOR17-4 monomer
(2.6 ptg per plate). The monomer was >90% pure, with the only other major
contaminating band consisting of hOR17-4 dimer. While this represents a significant
milestone, using adherent culture for milligram-scale purification of the receptor
monomer poses a substantial challenge. However, the HEK293S cell line is capable of
suspension culture, and we plan to scale-up purification yields by adapting the system to
culture in a large volume (5-10 liter) liquid bioreactor. The high cell densities allowed
should allow the production and subsequent purification of milligram quantities of
olfactory receptors, which will be necessary for future experiments in determining
receptor structure and function.
General application for the purification of other olfactory receptors
Here we show that a GPCR olfactory receptor gene can be designed, synthesized,
placed into an inducible mammalian expression system and the resulting full-length
protein purified to near homogeneity in a two-step process. In addition to our experiments
on hOR17-4, we have constructed optimized synthetic genes for several mouse olfactory
receptors and initial expression trials have proven successful. The small size of the
rho 1 D4 tag and its extremely mild elution conditions provide a minimum of disruption to
the purified protein. In contrast to previous attempts at OR purification using bacterial
systems which required fusion to GST and truncated or mutated OR protein sequences
[33], the system described here allows for the production of full-length wild-type OR.
The application of this technique to other olfactory receptors could feasibly lead to a
generalized method for obtaining large quantities of any olfactory receptor in a rapid and
si mple manner. Such methods could prove extremely useful in elucidating the structural
and functional mechanism(s) of olfactory receptors and in their integration into OR-based
biosensor devices.
3.5 Methods
Gene Construction
The protein sequence for hOR17-4 (also known as OR1D2) was obtained from
GenBank (NCBI Accession # NP002539). DNAWorks online software
(http://helixweb.nih.gov/dnaworks) was used in protein mode to design the synthetic gene
and parse it into an oligonucleotide set. To adapt the synthetic hOR17-4 olfactory
receptor gene for use in mammalian cell expression and purification, the following
sequence modifications were made: i) human codon optimization; ii) addition of a C-
terminal rholD4 epitope tag (TETSQVAPA) preceded by a two glycine linker to
facilitate detection and purification; iii) addition of a Kozak consensus sequence
(GCCACCACC) immediately 5' to the ATG start codon; iv) addition of an EcoRI
restriction site at the 5' end and a NotI restriction site at 3' end of the gene to enable
cloning into expression vectors. The synthetic hOR17-4 gene consisted of 1004 bp, of
which 969 bp code for the 323 amino acid hOR17-4-GlyGly-rholD4 protein. The
designed oligonucleotide primers were purchased from IDT (Coralville, IA) with a
maximum length of 45 bp. PCR-based gene synthesis was performed using a 2-step
assembly/amplification protocol [46] with the exception that the assembly PCR was run
for 45 cycles. PCR reactions were then analyzed by gel electrophoresis and stained with
ethidium bromide. Full-length product was excised, extracted, and then digested with the
pertinent restriction enzymes. The genes were then ligated into the T-REx pcDNA4/To
inducible expression plasmid (Invitrogen, Carlsbad, CA), sequenced, and a correct clones
grown up using a MaxiPrep kit (Qiagen, Valencia, CA). The plasmid containing the
optimized hOR17-4 gene was designated pcDNA4/To-hOR1 7-4-rho 1 D4.
Generation of Stable Inducible Cell Lines
HEK293S (suspension adapted HEK293 cells) containing the stable expression of
pcDNA6/Tr (Invitrogen) that encodes the Tet repressor protein (TetR) had previously
been generated and cloned [21]. HEK293S cell monolayers were grown in DMEM/F 12
with GlutaMAX (Invitrogen catalog # 10565-042) supplemented with fetal bovine serum
(10%), HEPES (15 mM), non-essential amino acids (0.1 mM), sodium pyruvate (0.5
mM), penicillin (100 units/ml), streptomycin (100 pg/mil) and grown at 37*C at 5% C0 2.
All tissue culture and media components were purchased from Invitrogen unless
otherwise noted. The pcDNA4/To-hORl7-4-rholD4 plasmid was then transfected into
these cells using Lipofectamine 2000 and after 48 hours cells were subjected to drug
selection in 5 pig/ml blasticidin and 250 pg/ml zeocin for 2 weeks and then subcloned. 28
colonies were expanded and screened for inducible expression using media supplemented
with or without 1 pg/ml tetracycline for 48 hours. Samples were then scrape harvested,
solubilized in phosphate buffered saline (PBS) with 2% w/v Fos-Choline-14 (Anatrace,
Maumee, OH) and Complete Protease Inhibitor Cocktail (Roche, Basel, CH) for 1 hour at
4'C. Expression was assayed via dot blotting and SDS-PAGE western blotting using the
mouse monoclonal antibody rholD4. Clone 5, the colony showing the best expression of
hOR17-4 under induction conditions while maintaining undetectable expression without
induction, was selected and expanded into large-scale culture and used for all subsequent
experiments. The hOR17-4-inducible HEK293S cell line was maintained using 5 ptg/ml
blasticidin and 250 ptg/ml zeocin.
Cell Extract Preparation
Buffers used were as follows: PBS buffer: 137 mM NaCl, 2.7 mM KCl, 1.8 mM
KH2PO4, 10 mM Na2HPO4 (pH 7.4); Solubilization buffer: PBS containing Complete
Protease Inhibitor Cocktail (Roche, Basel, Switzerland) and 2% wt/vol FC14; and Wash
buffer: PBS containing 0.2% FC14; Elution buffer: Wash buffer containing 100 pM Ac-
TETSQVAPA-CONH 2 elution peptide. The detergent FCl4 was purchased from
Anatrace (Maumee, OH). Sodium butyrate was purchased from Sigma (Saint Louis,
MO).
For initial dosage and time course experiments, hOR17-4-inducible HEK293S
cells were grown to 80-90% confluency at 37*C in 6-well tissue culture plates, treated as
indicated and then scrape harvested into ice-cold PBS containing Complete Protease
Inhibitor Cocktail. The hOR17-4 was then solubilized by resuspending the cell pellets in
150 pl solubilization buffer and rotating for 1 hour at 4*C. The non-solubilized fraction
was then pelleted using at 13,000g for 30 minutes. The supernatant was then removed
and analyzed by SDS-PAGE.
For purification experiments, up to fifty 150 mm tissue culture plates were used
per experiment. Briefly, hOR17-4-inducible HEK293S cells were seeded at a density of 5
x 106 cells per 150 mm dish and grown for 72 hours at 37*C, at which point they reached
80-90% confluency. The cells were then induced with medium containing tetracycline (1
pg/ml) plus sodium butyrate (as indicated). After 48 hours, the cells were harvested by
scraping (at 4*C) each plate into 2 ml PBS containing Complete Protease Inhibitor
Cocktail. The cells were then pooled and snap frozen in liquid nitrogen and stored at -
80'C until purification was carried out. On the day of purification, cells were thawed on
wet ice and spun down by centrifugation at 4000g for 1 minute. All further steps were
performed at 4*C unless noted. The hOR17-4 was then solubilized by resuspending the
cells in solubilization buffer (1-2 ml per 150 mm plate) and rotating for 4 hours. The non-
soiubilized fraction was then pelleted using an ultracentrifuge at >100,000g for 30
minutes. The resulting supernatant was removed and put at 4*C. A small amount of
supernatant (100 gl) was set aside, labeled "total lysate" and stored at -200C. The
remainder was directly applied to immunoaffinity purification.
Immunoblotting and Total Protein Staining
Samples were assayed via polyacrylamide gel electrophoresis (SDS-PAGE) under
both reducing and denaturing conditions. Samples were prepared and loaded according to
standard Novex gel protocols with the exception that the samples were incubated at room
temperature prior to loading, as boiling caused membrane protein aggregation. Full
Range Rainbow (GE Healthcare, Waukesha, WI) molecular weight marker was loaded as
the protein size standard. Samples were resolved on Novex 10% Bis-Tris SDS-PAGE
gels (Invitrogen) were run using NuPAGE MOPS buffer at 1 OOV and were subsequently
transferred to a 0.45 pm nitrocellulose membrane and subjected to western
immunoblotting using the rholD4 as primary antibody, followed by a secondary HRP-
linked goat anti-mouse IgG (Pierce, Rockford, IL) and detection using the ECL-Plus Kit
(GE Healthcare). For total protein staining, SDS-PAGE gels were run as above, stained
using SYPRO-Ruby (a more sensitive alternative to Coomassie; Invitrogen), and
visualized by fluorescence using UV transillumination (excitation wavelength 300 nn).
All western blot and SYPRO-Ruby images were captured using a Fluor Chem gel
documentation system (Alpha Innotech, San Leandro, CA).
limmunoaffinity Purification
For immunoaffinity purification we utilized rholD4 monoclonal antibody (Cell
Essentials, Cambridge, MA) chemically linked to CNBr-activated Sepharose 4B beads
(GE Healthcare). The rho lD4 elution peptide Ac-TETSQVAPA-CONH 2 was synthesized
by CBC Scientific (San Jose, CA). RholD4-sepharose immunoaffinity purification has
been described previously [21]. Briefly, the cell extract supernatant was mixed with
rholD4-coupled sepharose bead slurry (binding capacity 0.7 mg/ml) and rotated
overnight at 4"C to capture the rho lD4-tagged olfactory receptors. The beads were then
pelleted by centrifugation at 2000g for one minute and the supernatant collected, labeled
as "flow-through" and saved for future analysis. The beads were then resuspended in 100
bead volumes of cold wash buffer (PBS + 0.2% Fos-Choline-14), rotated for 10 minutes
at 4*C, then repelleted. A total of five washes were carried out and 100 pl of each
sequential wash was saved for subsequent analysis. After the final wash, the beads were
pelleted again and transferred to a new tube for elution. A series of five elutions (each
rotated 1 hour at room temperature) was then carried out, each using 1 bead volume of
elution buffer (PBS + 0.2% FC14 + 100 pM TETSQVAPA peptide). Total protein
concentration was measured using BCA assay (Pierce).
Mass Spectrometry
Immunoaffinity-purified samples of hOR17-4 were separated via SDS-PAGE,
stained with SYPRO-Ruby and gel bands at 30 kD, 32 kD, and 60 kD were excised into
sterile, methanol-rinsed microcentrifuge tubes. The samples subjected to trypsin digestion
and the resulting fragments analyzed by Ion Trap LCMS for protein identification by the
MIT Biopolymers Laboratory (Cambridge, MA). All bands were identified as hOR17-4,
indicating monomeric and dimeric forms.
Size Exclusion Chromatography
For further purification, hOR17-4 proteins were subjected to gel filtration
chromatography using a HiLoad 16/60 Superdex 200 column on an Akta Purifier HPLC
system (GE Healthcare). The column was first equilibrated using wash buffer (PBS +
0.2% w/v Fos-Choline-14). Pooled hOR17-4 elution fractions from the rholD4
immunoaffinity purification were concentrated to 0.75 mg/ml using a 1OkD MWCO filter
column (Millipore, Billerica, MA) and then applied to the Akta system. After loading, the
column was run with wash buffer at 1 ml/min and column flow through monitored via
UV absorbance at 280 nm and 215 nm. Protein fractions were collected using an
automated fraction collector. Peak fractions were then pooled, concentrated and subjected
to SDS-PAGE and analysis via Sypro Ruby staining. Total protein concentration was
measured using BCA assay (Pierce).
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CHAPTER 4
PRODUCTION OF hOR17-4 USING
SUSPENSION CELL CULTURES
NOTE: This chapter is an expansion of a manuscript submitted to Proceedings of the
National Academy of Sciences (PNAS):
Cook BL, Steuerwald D, Vanberghem V, Kaiser L, Graveland-Bikker J, Herlihy
K, Pick H, Vogel H, Berke AP & Zhang S. Large-Scale Production and Study of a
Synthetic Human Olfactory Receptor. Submitted to PNAS (2008).
4.1 Abstract
In order to investigate the elusive biochemistry and molecular mechanism(s) of
olfaction, we have developed a mammalian expression system for the large-scale
production and purification of a functional olfactory receptor (OR) protein in milligram
quantities. Here we report the study of human OR17-4 purified from a HEK293S
tetracycline-inducible system. Scale-up of production yield was achieved through
suspension culture in a. bioreactor, which enabled the preparation of >10mg of
monomeric hOR17-4 receptor following immunoaffinity and size exclusion
chromatography, with expression yields reaching 3 mg per liter of culture medium. Final
monomeric hOR17-4 protein was >90% pure, with the only major contaminant being
dimeric receptor, and was thus directly applicable for subsequent characterization studies
and crystallization screening for X-ray diffraction experiments. Thus this system
constitutes a viable method for producing the large quantities of olfactory receptor
necessary for structural and functional analyses.
4.2 Introduction
Animal noses have evolved the ability to rapidly detect a seemingly infinite array
of odors at minute concentrations. The basis of this sensitivity are the olfactory (smell)
receptors - a large, highly related class of sensory G-protein coupled receptors (GPCRs)
that function together combinatorially to allow discrimination between a wide range of
volatile and soluble molecules [1, 2]. As GPCRs, all olfactory receptors (ORs) are
integral membrane proteins with seven transmembrane domains arranged in a barrel-like
conformation. Despite the fact that olfactory receptors represent the largest class of
known membrane proteins, no detailed structure exists for any OR and the functional
mechanisms of these amazing receptors remains unknown. The crucial first step to enable
such pivotal biochemical and structural analyses is to engineer systems with the capacity
to generate and purify milligram quantities of an olfactory receptor.
The human olfactory receptor 17-4 (hOR17-4, alternately known as OR1D2) is of
particular interest since, in addition to olfactory neurons, it is also expressed on the
midpiece of human spermatozoa [3]. Sperm expressing hOR17-4 were found to migrate
towards known hOR17-4-responsive odorants such as bourgeonal, lilial, and floralozone
[3]. Thus the receptor serves a dual role in that it recognizes odorants in the nose as well
as plays a potential role in sperm chemotaxis and fertilization. Structural studies of
hOR17-4 would not only provide information crucial to understanding the molecular
mechanism(s) of olfaction but also have application to human reproduction.
To date, crystal structures exist for only three GPCR proteins: retina-purified
bovine opsin [4-6] and highly engineered versions of human beta2-adrenergic receptor [7,
8] and turkey betal -adrenergic receptor [9], both expressed in Sf9 insect cells. We have
recently developed an OR expression system [10] using stably-inducible mammalian
HEK293S cell lines by optimizing methods originally developed in the Khorana lab to
generate milligram quantities of functional rhodopsin [11-13]. In adherent culture, this
adapted rho-tag system was used express and purify monomeric hOR17-4 to >90% purity
[10]. Here we show that this system can be scaled up using bioreactor culture to facilitate
the production and purification of milligram amounts of hOR17-4. Key to the efficient
extraction of hOR17-4 was a comprehensive screen of diverse detergents and the
selection of zwitter-ionic fos-choline detergents as solubilizing agents, as all non-ionic
detergents proved ineffective. The purified hOR17-4 protein was also structurally and
functionally characterized using several spectroscopy methods. To our knowledge this is
the first time milligram quantities of functional olfactory receptor have been purified
from any heterologous system.
4.3 Results
Construction of stable hOR17-4-inducible HEK293S GnTr cell lines
In Chapter 3, I described the fabrication of a synthetic hOR17-4 gene using PCR-
based gene synthesis and the subsequent construction of stable HEK293S cell lines with
tetiacycline-inducible expression of the hOR17-4 receptor protein [10]. When induced
with a combination of tetracycline and sodium butyrate, these HEK293S cells could
generate over 30 micrograms of hOR17-4 per 15-cm plate. However, when assayed by
SDS-PAGE, the receptor monomer migrated as a doublet at approximately 30 kD and 32
kD (the full-length rho-tagged hOR17-4 protein, with theoretical molecular mass of 36.2
kD, migrates slightly faster on SDS-PAGE gels). Our initial hypothesis was that the 32
kD band constituted a glycosylated form of the receptor. As heterogeneity could
potentially interfere with future structural analysis and crystallization, we sought to
achieve a homogeneous glycosylation pattern by porting the hOR17-4-inducible
expression system into a HEK293S N-acetylglucosaminyltransferase I-negative (GnTT)
cell line shown to produce homogeneously glycosylated rhodopsin [13]. During colony
screening we isolated subclonal strains that exclusively expressed the slower migrating
(32 kD) form of the receptor even under high-level expression (Figure 4.1a).
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Figure 4.1 - Construction of hOR17-4-inducible HEK293S GnT1-/- cell lines for use
in liquid bioreactor culture. Clones were tested for induction after 48 hours in plain
media (-) or media supplemented with 1 ug/mL tetracycline (+) or tetracycline plus 5
mM sodium butyrate enhancer (++). Arrows indicate the position of the 32 kD and 30
kD monomer forms. (A) Levels of hOR17-4 were probed via SDS-PAGE western
blotting against the rho tag (rholD4 monoclonal antibody). Clones 3 and 8 show high
levels of induction following the addition of sodium butyrate but have low levels of the
potentially unglycosylated 30 kD monomer form of hOR17-4, unlike Clone 11 and
previous clones in the HEK293S system. Clone 3 was selected for subsequent bioreactor
experiments. (B) In order to investigate the potential N-linked glycosylation of hOR17-
4, the consensus glycosylation sequence (-Asn-Gln-Ser-) was altered using site directed
mutagenesis to change the asparagine at position 5 to glutamine (N5Q mutation).
Following the generation of new stable hOR17-4(N5Q) inducible clones, the SDS-
PAGE migration pattern of receptor monomer was compared to wild-type following
induction. Mutation of the glycosylation site (N5Q) eliminated the upper form (32kD) of
hOR17-4 monomer and only lower form (30kD) is present, indicating the size
discrepancy is indeed due to glycosylation on Asn5.
Olfactory receptors possess a conserved N-linked glycosylation consensus
sequence (Asn-X-Ser/Thr) at their N-termini [14], and the resulting glycosylation may be
important for receptor functionality and proper folding [15], as is the case for other
GPCRs [16]. To investigate whether the observed size discrepancy was due to N-linked
glycosylation, we generated a stable cell line that expressed a mutated form of hOR17-4
(N5Q) where the consensus asparagine was replaced by a glutamine. This hOR17-4 N5Q
mutant ran solely at 30 kD with no 32 kD form present (Figure 4.1b), indicating that the
32 kD form of wild-type hOR17-4 is N-glycosylated on Asn5. As lack of glycosylation
could potentially compromise receptor function, all subsequent experiments were
performed using the wild-type hOR17-4 inducible cell line (Clone 3, Figure 4.1a).
Detergent Screen and optimization of hOR17-4 solubilization from HEK293S cells
Initial transient transfections into HEK293S cells and subsequent solubilization
using the detergent dodecyl maltoside (DDM), which has been successfully used to
solubilize several other GPCRs [12, 13, 17], revealed low levels of hOR17-4 protein
yield in comparison to constructs encoding opsin. To investigate whether DDM was
insufficient to solubilize hOR17-4, we performed a large detergent screen that included
representatives from the non-ionic, zwitter-ionic, polar, and ionic detergent classes.
Immunoblot analysis showed that the majority of commercially available detergents were
poor choices for extracting the hOR17-4 GPCR protein from HEK293S cells (Figure
4.2). However, the fos-choline class of detergents proved highly effective and showed a
clear relationship between chain length and solubilization yield, with fos-choline-16
(FC16) showing a >10-fold increase over DDM. However, the critical micelle
concentration (CMC) of FC16 is so low (0.00053%) as to make any subsequent detergent
exchange nearly impossible. Therefore, fos-choline-14 (FC14), with a CMC nearly 1Ox
higher (0.0046%) was selected as the ideal solubilization agent. Importantly, FC14
showed greater hOR17-4 yield than solubilization with harsher ionic detergents such as
sarcosine and deoxycholate. The fos-choline detergents are structurally related to
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Figure 4.2. Detergent screen for optimal solubilization of hOR17-4 expressed in
1HtK293S cells. Expression of hOR17-4 was induced with tetracycline (1 jg/mi) and
sodium butyrate (5 mM) for 48 hours and receptors solubilized in PBS containing
detergents for 4 hours at 4"C. All detergents were used at a concentration of 2% wt/vol
uiiless otherwise indicated. Relative solubilization corresponds to the fold increase over
dodecyl maltoside (DDM) in solubilizing hOR17-4 monomer/dimer. Detergent
abbreviations used are: DM, decyl maltoside; DDM, dodecyl maltoside; C/C, CHAPS
(1%) and Cholesterol hemisuccinate (0.2%); 0G, octyl glucoside; NG, nonyl glucoside;
NP40, nonidet P40; DAO, n-decyl-N,N-dimethylamine-N-oxide; DDAO, n-dodecyl[
N,N-dimethylamine-N-oxide; TDAO, n-tetradecyl-N,N-dimethylamine-N-oxide;
DMiDPO, dimethyldecyiphosphine oxide; DDMG, n-decyl-N-N-dimethylglycine;
DODMG, n-dodecyl-N-N-dimethylglycine; sarcosine, sodium dodecanoyl sarcosine;
DOC, deoxycholate.
phosphatidylcholine (PC), a phospholipid and major constituent of the lipid bilayer of
rnammalian cells. Additional solubilization yield studies were carried out to determine
the optimal FCl4 concentration and extraction buffer (Materials and Methods). Addition
of glycerol or increasing salt concentration was found to substantially decrease receptor
yield (data not shown).
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After solubilization of hOR17-4 from native cell membranes, we attempted to
exchange the zwitter-ionic fos-choline for the milder non-ionic dodecyl maltoside (DDM)
during the immunoaffinity bead immobilization, as DDM has been successfully used to
keep many other GPCRs soluble. However, this resulted in a near total loss of hOR17-4
yield due to aggregation (data not shown), indicating that FC14 is crucial not only for OR
extraction but to maintain the solubility of OR proteins in solution.
Milligram-scale bioreactor production of hOR17-4 and subsequent purification
The use of adherent culture for milligram-scale purification of the receptor
monomer poses a substantial challenge, as many hundreds of plates would be required.
As the HEK293S GnTI cell line is capable of suspension culture at high cell densities,
we chose to scale-up production using a bioreactor and methods previously optimized for
the milligram-scale production of bovine rhodopsin [12]. Each bioreactor run consisted of
1.25 - 1.40 liters of culture media (see Methods) inoculated with hOR17-4-inducible
HEK293S GnTI~ cells at an initial density of 6 - 8 x 105 cells/mL. The media was
supplemented on day 5 and hOR17-4 expression induced on day 6 using tetracycline and
sodium butyrate (see Methods) and harvested 40 hours later (day 8). Cell density at time
of induction was 6.0 x 106 cells/mL and had increased to 9.6 x 106 cells/mL at the time of
harvest. Thus a single 1.25 liter bioreactor run produced 12 billion cells (a cell pellet of
16.3 grams), the equivalent of approximately 200 x 15-cm tissue culture plates.
Cell pellets from two separate bioreactor runs were combined and subjected to
solubilization using FCl4 followed by immunoaffinity purification using the rholD4
monoclonal antibody conjugated to sepharose beads in order capture the rho-tagged
hOR17-4 protein. The eluate (containing 10.3 milligrams of hOR17-4) was then
subjected to size exclusion chromatography to isolate the monomeric receptor fraction
using gel filtration. Several peaks were observed (Figure 4.3a) and were found to
correspond to aggregate, dimeric, and monomeric receptor (Figure 4.3b). The dimeric
and monomer peaks eluted at 63.4 mL (0.51 CV) and 72.1 mL (0.58 CV), respectively,
which was identical to that observed in our hOR17-4 purification using adherent culture
[10]. Using gel filtration standards we estimated the apparent masses of the hOR17-4-
detergent complexes at 140 kD (monomer) and 275 kD (dimer), indicating that each
hOR17-4 protein is solubilized in a complex with approximately 270 molecules of FC14
(2.8 g of FC14 / g of protein). While this might seem high, the mass of bound detergent is
greater than the micellar mass (47 kD for FC14 [18]) for most membrane proteins,
including monomeric rhodopsin/DDM complexes (126 kD) [19]. Were our 140 kD
complex to contain dimeric hOR17-4, each would be complexed with approximately 90
molecules of FC14, which is well below the aggregation number of 120 [18].
Peak fractions were collected, pooled and concentrated and subjected to SDS-
PAGE (Figure 4.3b). The final yield of hOR17-4 monomer was 2.68 milligrams at >90%
purity, the only other band visible being dimeric hOR17-4. Additionally, the putative
dimer peak contained a total of 2.45 mg of largely dimeric receptor. Importantly, the
appearance of monomer form in earlier peaks is likely due to the effects of SDS
dissociating the dimeric and oligomeric receptor forms.
Following the initial milligram scale purification, we repeated the experiment
using two additional bioreactor runs (2.5 liters of suspension culture). However, a large
excess of rholD4-sepharose beads (60 mL bead slurry, total binding capacity 42 mg) was
added to ensure complete capture of solubilized hOR17-4. Total yield of receptor
following immunoaffinity chromatography was 30.5 milligrams, which led to the
a b
amo
200
40
200
0 so ao
70 SO 0 100 110 120 130
Volume (m.)
1 2 3 4 5 Load
Figure 4.3 - Full purification of hOR17-4 from 2.65 liters of bioreactor cultured
cells. (A) Size exclusion chromatography (SEC) on immunoaffinity-purified hOR17-4,
Absorbance was recorded at 280 nm (black), 254 nm (red), and 215 nm (blue). Peaks 1-5
(indicated by numbers) were pooled and concentrated. The predicted monomer peak was
pooled into an early fraction (4) and a late fraction (5). Peak 6 contains the nine amino
acid elution peptide TETSQVAPA from the immunoaffinity purification. (B) Total
protein staining of SEC peak fractions. Column fractions were collected and subjected to
SDS-PAGE followed by staining with Sypro Ruby. Load is the original immunopurified
sample applied to the chromatography column. Peak numbers refer to those designated in
(A). Peaks 4 and 5 contain monomeric hOR17-4 at >90% purity.
purification of 7.5 milligrams of hOR17-4 monomer following gel filtration
chromatography. This constitutes nearly a three-fold increase over the first run and a
yield of 3 mg/L for purified hOR17-4 monomer. As the resulting protein is at sufficiently
high purity (>90%), it can immediately be concentrated and subjected to crystallization
screening.
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4.4 Discussion
The major obstacle to structural and functional studies on membrane proteins is
the notorious difficulty involved in expressing and purifying the large quantities of
receptor protein sample required for such techniques as X-ray crystallography. A
testament to this is the fact that as of September 2008, there are only 171 unique
membrane protein structures known [20], which constitutes less than 1% of all known
protein structures. There have been a host of previous studies that have expressed and
studied olfactory receptors in native and heterologous systems. While purification of ORs
has been attempted in bacterial [21] and Sf9 insect [22, 23] systems, these were unable to
produce large quantities of native full-length olfactory receptor. The methods and results
presented here constitute the first cell-based platform for the production of milligram
quantities of purified olfactory receptor.
The appearance of two distinct hOR17-4 monomer bands following purification
could pose a problem for structural studies using X-ray crystallography, since typically a
high degree of protein homogeneity is required for protein crystallization. We initially
believed that it was possible to obtain primarily 32 kD form using the new HEK293S
GnTIl cell line clones (Figure 4.1a). However, the rholD4 immunoaffinity purification
appears to significantly increase the proportion of 30 kD monomer form relative to 32 kD
form, as seen in Figure 4.3b. One hypothesis is that the 30 kD (potentially non-
glycosylated form) binds more readily to the rholD4-coupled bead matrix. Therefore, to
obtain truly homogeneous hOR17-4 monomer it might be necessary to perform
purifications using the hOR17-4(N5Q) mutant cell line (Figure 4.1b), where only the 30
kD monomer form is produced. However, the functional effect of abolishing
glycosylation on this receptor is unknown. Several studies have indicated that loss of
GPCR glycosylation can lead to improper folding and targeting, resulting in decreased
function and compromised structure and stability [16]. Loss of either N-terminal
glycosylation site (Asn-2 or Asn-15) of rhodopsin is sufficient to cause loss of signal
transduction despite no apparent change in localization or folding [24, 25]. Additionally,
mutating out the glycosylation site of a mouse OR (mOR-EG) was found to completely
abolished its ability to localize to the membrane [15], indicating that this modification
may be necessary for OR function. As other heterologous expression systems (bacterial,
insect, etc) lack mammalian post-translational machinery, purification of olfactory
receptors from mammalian systems might be crucial for functional production. It is
worthwhile to note that retina-derived bovine opsin, which has been crystallized, is not
heterogeneously glycosylated but contains at least three N-glycan variants (70%
Man3GlcNAc3, 10% Man4GlcNAc 3, and 20% Man5GlcNAc 3) [26].
In addition to the N-glycosylation site at Asn5, hOR17-4 has a potential site at
Asn195. However, this residue does not appear to be heavily glycosylated in this system
as evidenced by: i) the N5Q mutation causes a complete shift in mobility from 32 kD
(glycosylated) to the 30 kD form, which corresponds to the mass of the deglycosylated
hOR17-4 protein [23]; ii) mass spectrometry analysis did not detect glycosylation at this
site but did detect unglycosylated peptides containing Asn195; iii) the consensus
sequence is at the hypothetical EC2/TM5 border and thus is not likely to have the
flexibility required for N-linked glycosylation. We did see a minor band running at ~33
kD for both the wild-type and N5Q mutant versions of hOR17-4 (Figure 4.3b, Figure
4.1b), which we have not yet ruled out as due to potential Asn195 glycosylation. Since
this band does not appear to shift with N5Q mutation, were this band glycosylated it
would be on Asn195 alone (and not both sites). Should this be the case, a double mutant
(N5Q, N195Q) might be advantageous, as it would eliminate both forms.
Here we demonstrated the utility of the fos-choline-based detergents (most
notably FC14) in extracting and solubilizing olfactory receptors. Fos-choline-12 was
recently found to refold the integral membrane protein diacylglycerol kinase and
maintain its functional state [27]. Additionally, Fos-choline-14 was used in the
crystallization of the E. Coli mechanosensitive ion channel MscS for a successful
structure [28]. The promise of this detergent class in future membrane protein research is
underscored by our recent findings which identified the fos-choline series as the best
detergent class for extracting and solubilizing the human chemokine receptors CCR3,
CCR5, CXCR4 and CX3CR1 [29].
In summary, we have developed methods for the construction of inducible
mammalian cell lines that generate milligram quantities of olfactory receptor on demand.
Currently, we have demonstrated the production of >10 milligrams of full-length human
olfactory receptor hOR17-4 in a stable tetracycline-inducible human embryonic kidney
cell line (HEK293S GnTI-). Using methods originally adapted from the production and
purification of the GPCR rhodopsin [11-13] and further optimized (including the full-
spectrum screening of over 45 detergents), the olfactory receptor is solubilized and
extracted from the cells using fos-choline-14. The OR protein is then isolated using a
two-step purification method which yields hOR17-4 monomer at greater than 90% purity
(Figure 4.3b). The system described is capable of generating up to 3 mg / liter of
monomeric hOR17-4, the yield of which approaches that of rhodopsin and rhodopsin
mutants when similarly expressed [12]. The application of this technique to other
olfactory receptors could feasibly lead to a generalized method for obtaining large
quantities of any olfactory receptor in a rapid and simple manner. Such methods could
prove extremely useful in elucidating the structural and functional mechanism(s) of
olfactory receptors and in their integration into OR-based biosensor devices.
4.5 Methods
Buffers and solutions
Buffers used were as follows: PBS buffer: 137 mM NaCl, 2.7 mM KCl, 1.8 mM
KH 2PO4, 10 mM Na2HPO4 (pH 7.4); Solubilization buffer: PBS containing Complete
Protease Inhibitor Cocktail (Roche, Basel, Switzerland) and 2% wt/vol FC14; Wash
buffer: PBS containing 0.2% FC14; Elution buffer: Wash buffer containing 100 pM Ac-
TETSQVAPA-CONH 2 elution peptide. The detergent FC14 was purchased from
Anatrace (Maumee, OH). All tissue culture and media components were purchased from
Invitrogen unless otherwise noted. Sodium butyrate was purchased from Sigma (Saint
Louis, MO).
Site Directed Mutagenesis
The pcDNA4/To-hOR17-4-rho plasmid, containing a synthetic, codon optimized
hOR17-4-rho gene construct [10], was mutated to eliminate the hOR17-4 N-linked
glycosylation consensus sequence. The codon corresponding to hOR17-4 residue Asn5
was converted from AAC (Asn) to CAG (Gln) by site directed mutagenesis using the
Quikchange kit (Stratagene) according to the manufacturer's instructions. The
oligonucleotides used were: 5'-CCATGGACGGAGGCCAGCAAAGCGAGGGCAG-3'
(top) and 5'-CTGCCCTCGCTTTGCTGGCCTCCGTCCATGG-3' (bottom). The
sticcessfully mutated plasmid was designated pcDNA4/To-hOR17-4(N5Q)-rho.
Generation of Stable hOR17-4-Inducible Cell Lines
HEK293S GnTl (suspension adapted, N-acetylglucosaminyltransferase I-
negative HEK293) cells containing the stable expression of pcDNA6/Tr (Invitrogen) that
encodes the Tet repressor protein (TetR) had previously been generated and cloned [13].
Adherent HEK293 S GnTI- cell monolayers were grown in DMEM/F 12 with GlutaMAX
(Invitrogen catalog # 10565-042) supplemented with fetal bovine serum (10%), HEPES
(15 mM), non-essential amino acids (0.1 mM), sodium pyruvate (0.5 mM), penicillin
(100 units/ml), streptomycin (100 jig/ml) and grown at 37*C at 5% Co2. Either the
pcDNA4/To-hOR17-4-rho plasmid, containing a synthetic, codon optimized, rho-tagged
hOR17-4 gene construct (hOR17-4-GG-TETSQVAPA) [10] or the pcDNA4/To-hORl7-
4(N5Q)-rho plasmid were then transfected into these cells using Lipofectamine 2000 and
after 48 hours cells were subjected to drug selection in 5 pg/ml blasticidin and 50 pg/ml
zeocin for 2 weeks and then subcloned. For each variant, at least 25 colonies were
expanded and screened for inducible expression in 6-well plates using plain media
(control) or media supplemented with 1 ug/mL tetracycline or tetracycline plus 5 mM
sodium butyrate. 48 hours post-treatment, samples were scrape harvested into ice-cold
PBS containing Complete Protease Inhibitor Cocktail (Roche, Basel, CH). The hOR17-4
was then solubilized by resuspending the cell pellets in 150 pl solubilization buffer and
rotating for 1 hour at 4*C. The non-solubilized fraction was then pelleted by
centrifugation at 13,000g for 30 minutes. The supernatant was then removed and OR
expression assayed via dot blotting and SDS-PAGE western blotting using the mouse
monoclonal antibody rholD4. For wild-type hOR17-4, Clone 3 was selected and
expanded into large-scale culture and used for all subsequent experiments. The hOR17-4-
inducible HEK293S GnTI- cell lines were maintained using 5 pg/ml blasticidin and 25
pg/ml zeocin.
Detergent Screening
For initial solubilization trials, the wild-type pcDNA4/To-hOR17-4-rho plasmid
was transiently transfected into 150mm tissue culture plates of HEK293S cells using
Lipofectamine 2000. After 48 hours, cells were scrape harvested and pooled. Cells were
spun down and resuspended in ice cold PBS containing Complete Protease Inhibitor
Cocktail at a density of 2x10 7 cells/ml and then aliquotted into microcentrifuge tubes
(120g1 each). 30gl of detergent was then added from stock solutions (10% wt/vol) such
that the final concentration was 2%, except where noted. Care was taken not to vortex or
pipette-mix the samples after detergent was added in order to avoid breaking cell nuclei.
Samples were then rotated at 4*C for 4 hours before being centrifuged at 13,000g for 30
minutes to pellet insoluble material. Supernatants were then removed and subjected to dot
blot and SDS-PAGE analysis using the rholD4 mAb. As dot blotting also detects
aggregated/oligomerized receptor, the solubilization was quantified via SDS-PAGE
western blotting as the total amount of monomeric and dimeric hOR17-4 present, as
determined by spot densitometry. Relative solubilization corresponds to the fold increase
over dodecyl maltoside (DDM). All detergents were purchased from Anatrace (Maumee,
OH) except digitonin, which was purchased from Sigma.
Growth of HEK293S GnTr suspension cultures in a bioreactor
Suspension culture was carried out in a Celligen Plus bioreactor (New Brunswick
Scientific, Edison, NJ) according to the protocol developed by Reeves, et al [12]. Media
formulation was identical except that Primatone RL-UF used at 3.0 g/L. On day 0, the
bioreactor media was inoculated with cells trypsinized from 6-9 confluent 15-cm tissue
culture plates such that the inoculation density was 6 x 105 cells/mL. The four-gas
mixture (air, 02, N2, and CO2 ) was supplied by direct sparge only. Gas flow rate was
initially 21 ml/min but was increased as needed throughout the run to regulate the pH and
dissolved oxygen. If required, 20 mL of 8% sodium bicarbonate was added to increase
the buffering capacity of the media if the gas mixture was unable to adequately regulate
the pH. On day 5, the reactor was supplemented with 30 mL of 10% Primatone RL-UF
and 10 mL of 20% glucose. On day 6, the expression of hOR17-4 was induced by the
addition of tetracycline (2 pg/mL) and sodium butyrate (2 mM) and the cells harvested
40 hours post-induction. Harvested cells were pelleted and washed with cold PBS
containing complete protease inhibitor cocktail. The cell pellets were then weighed and
snap-frozen in liquid nitrogen and stored at -80*C until purification was carried out. On
the day of purification, cells were thawed on wet ice and spun down by centrifugation at
4000g for 1 minute. All further steps were performed at 4*C unless noted. The hOR174
was then solubilized by resuspending the cells in solubilization buffer (12.5 ml per gram
of cell pellet) and rotating for 4 hours. The non-solubilized fraction was then pelleted
using an ultracentrifuge at >100,000 g for 45 minutes. The resulting supematant was
removed and put at 4*C. A small amount of supernatant (100 pl) was set aside, labeled
"total lysate" and stored at -20*C. The remainder was directly applied to immunoaffinity
purification.
Iinmunoblotting and Total Protein Staining
Samples were assayed via polyacrylamide gel electrophoresis (SDS-PAGE) under
both reducing and denaturing conditions. Samples were prepared and loaded according to
standard Novex gel protocols with the exception that the samples were incubated at room
temperature prior to loading, as boiling caused membrane protein aggregation. Full
Range Rainbow (GE Healthcare, Waukesha, WI) molecular weight marker was loaded as
the protein size standard. Samples were resolved on Novex 10% Bis-Tris SDS-PAGE
gels (Invitrogen) using NuPAGE MOPS buffer, run at 1 OOV and were subsequently
transferred to a 0.45 ptm nitrocellulose membrane and subjected to western
immunoblotting using the rholD4 as primary antibody, followed by a secondary HRP-
linked goat anti-mouse IgG (Pierce, Rockford, IL) and detection using the ECL-Plus Kit
(GE Healthcare). For total protein staining, SDS-PAGE gels were run as above, stained
using SYPRO-Ruby (a more sensitive alternative to Coomassie; Invitrogen), and
visualized by fluorescence using UV transillumination (excitation wavelength 300 nm).
All western blot and SYPRO-Ruby images were captured using a Fluor Chem gel
documentation system (Alpha Innotech, San Leandro, CA).
Imnmunoaffmity Purfication
For immunoaffinity purification we utilized rholD4 monoclonal antibody (Cell
Essentials, Cambridge, MA) chemically linked to CNBr-activated Sepharose 4B beads
(GE Healthcare). The rho lD4 elution peptide Ac-TETSQVAPA-CONH 2 was synthesized
by CBC Scientific (San Jose, CA). RholD4-sepharose immunoaffinity purification has
been described previously [12]. Briefly, the cell extract supernatant was mixed with
rholD4-coupled sepharose bead slurry (binding capacity 0.7 mg/ml) and rotated
overnight at 4*C to capture the rho-tagged olfactory receptors. The beads were then
pelleted by centrifugation at 2000g for one minute and the supernatant collected, labeled
as "flow-through" and saved for future analysis. The beads were then resuspended in 100
bead volumes of cold wash buffer (PBS + 0.2% fos-choline-14), rotated for 10 minutes at
4*C, then repelleted. The procedure was repeated until the supernatant had a UV
absorbance at 280nm of less than 0.01. After the final wash, the beads were pelleted
again and transferred to a new tube for elution. A series of elutions (each rotated 1 hour at
room temperature) was then carried out, each using 1 bead volume of elution buffer (PBS
+ 0.2% FC14 + 100 gM TETSQVAPA peptide). Elutions were repeated until the UV
absorbance at 280nm was less than 0.1. Total protein concentration was measured by
BCA assay (Pierce).
Site Exclusion Chromatography
For further purification, hOR17-4 proteins were subjected to gel filtration
chromatography using a HiLoad 16/60 Superdex 200 column on an Akta Purifier HPLC
system (GE Healthcare). The column was first equilibrated using wash buffer (PBS +
0.2% w/v fos-choline-14). Pooled hOR17-4 elution fractions from the rholD4
immunoaffinity purification were concentrated to 3 mg/ml using a 10kD MWCO filter
column (Millipore, Billerica, MA) and then applied to the Akta system. After loading, the
column was run with wash buffer at 0.3 ml/min and column flow through monitored via
UV absorbance at 280 nm, 254 nm and 215 nm. Protein fractions were collected using an
automated fraction collector. Peak fractions were then pooled, concentrated and subjected
to SDS-PAGE and analysis via Sypro Ruby staining. Total protein concentration was
measured using BCA assay (Pierce). The molecular mass of hOR17-4-detergent
complexes was estimated by calibrating the column with gel-filtration standard mixture
(Bio-Rad). Molecular mass was correlated to retention volume using a power law curve-
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CHAPTER 5
CHARACTERIZATION OF PURIFIED
hOR17-4
NOTE: This chapter is an expansion of a manuscript submitted to Proceedings of the
National Academy of Sciences (PNAS):
Cook BL, Steuerwald D, Vanberghem V, Kaiser L, Graveland-Bikker J, Herlihy
K, Pick H, Vogel H, Berke AP & Zhang S. Large-Scale Production and Study of a
Synthetic Human Olfactory Receptor. Submitted to PNAS (2008).
5.1 Abstract
To characterize the previously purified hOR17-4 receptor protein, we subjected it
to several spectroscopic modes of analysis in order to determine if the solubilized
receptor was correctly folded and retained functional activity. Analysis by far-UV
circular dichroism showed the receptor to have correct secondary structure (~50% alpha-
helical), while near-UV spectra were indicative of a defined tertiary structure. Using a
surface plasmon resonance (SPR) assay, extracted hOR17-4 specifically bound its known
odorants lilial and floralozone in vitro, while denatured receptor had no binding activity.
At least 50% of the receptors bound odorants as estimated from bound SPR mass. The
synthetic hOR17-4 also recognized specific odorants on the surface of HEK293S cells as
determined by calcium-release assay. Additionally, analysis using mass spectrometry
confirmed the presence of several post-translational modifications. Thus, the engineered
mammalian expression system and optimized purification protocols developed during
this thesis are capable of producing milligram quantities of correctly folded and
functionally active olfactory receptor.
5.2 Introduction
No method currently exists with which to ascertain the functionality of detergent
solubilized (non-membrane bound) olfactory receptor proteins. We subjected our purified
hOR17-4 receptor to a range of spectroscopic and analytical techniques in order to
confirm correct folding, function, and post-translational modifications. Additionally, we
tested the functionality of the protein in the native cell membrane in order to confirm that
the rho-tagged, synthetic gene truly encoded a functional protein capable of normal G
protein-mediated signal transduction. The techniques applied were:
i. Circular dichroism (CD) spectroscopy - quantitates secondary structural
components and provides information on tertiary structure through differential
absorption of circularly-polarized light (see section 1.5). Changes in CD spectra
can indicate changes in secondary structure and protein folding.
ii. Fluorescence spectroscopy - light reemitted from excited states of tryptophan and
other aromatic amino acid residues at characteristic wavelengths. Alterations in
emission spectra can be used to measure changes in protein conformation.
iii. Surface plasmon resonance (SPR) - detects molecular interactions in real-time
due to changes in refractive index near the surface (see section 1.6).
iv. Liquid Chromatography-Mass Spectrometry - protein is digested using a protease
and resulting fragments are size separated and the masses precisely determined so
that the peptides can be identified. Post-translational modifications can also be
determined.
5.3 Results
5.3.1 Circular dichroism and fluorescence spectroscopy
We asked if the purified, FC 14-solubilized hOR17-4 retained proper structure and
functionality. Our prediction for hOR17-4 secondary structure, based on structural
modeling [1] and transmembrane domain calculations [2], was 47% alpha-helix. When
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Figure 5.1 - Circular dichroism analysis of purified hOR17-4. Purified hOR17-4
monomer was analyzed by both circular dichroism spectroscopy and fluorescence
spectroscopy. (A) Far-UV CD spectrum of hOR17-4 displaying correct secondary
structure (49% alpha helix). Spectrum shown is the average of 5 replicate scans. Mean
residue ellipticity [0] has units of degree*cm2 *dmol~1. (B) Near-UV CD spectrum of
hOR17-4 showing distinct tertiary structure peaks. Spectrum shown is the average of 3
replicate scans. Functional bovine rhodopsin has a similar peak in this region, while non-
functional opsin mutants show flat spectra characteristic of a misfolded globular state.
subjected to far-UV circular dichroism spectroscopy, the monomeric hOR17-4 displayed
a spectrum characteristic of alpha helix with minima at 208 nm and 222 nm (Figure
54la). Analysis of the spectrum using the K2D algorithm [3] returned values of 49%
alpha helix, 18% beta sheet, and 33% random coil content, confirming a correct hOR17-4
secondary structure.
To probe tertiary structure, we subjected hOR17-4 to near-UV circular dichroism
spectroscopy. Since this technique requires milligram quantities of pure protein, this is to
our knowledge the first instance of a near-UV spectrum for an olfactory receptor (Figure
5.ib). Several significant peaks were observed which suggest a defined tertiary structure.
Wild-type opsin has similar near-UV peaks in this region, whereas functionally inactive
opsin mutants showed flat spectra, indicating misfolded protein [4]. Characterization by
tryptophan fluorescence spectroscopy using excitation at 280 nm showed an emission
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maximum at 335 nm (Figure 5.2), which is similar to the value experimentally
determined for rat OR5 of 328 nm [5].
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Figure 5.2 - Fluorescence spectroscopy on purified hOR17-4 monomer. Excitation at
280 nm resulted in a clear emission peak at 335 nm. The hOR17-4 amino acid sequence
has 2 tryptophans, 17 tyrosines, and 19 phenylalanines. The spectrum shown is the
average of 3 replicate scans. This agrees with previous characterization of rat OR5
receptor showing a 328 nm emission peak from excitation at 280 nm.
5.3.2 Calcium- release assays of cell surface expressed hOR17-4
We also confirmed that our synthetic hOR17-4 displayed wild-type function in
the HEK293S cell membranes. The functional activity and specificity of induced hOR17-
4 was measured on the surface of HEK293S cells by calcium- release assay and
visualized using time-lapse confocal microscopy. In our heterologous HEK293S system,
ORs can signal through the inositol triphosphate (IP 3) pathway to release intracellular
CaF+ from the ER by signaling through the "promiscuous" G-protein G.q. Induced cells
responded to the specific odorant bourgeonal at concentrations as low as 1 pM (Figure
5.3). Odorant response could be blocked by co-application of the hOR17-4 antagonist
undecanal. No response seen for the non-specific odorants octanal and anithole (data not
shown).
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Figure 5.3 - Calcium- release assays of cell surface-expressed hOR17-4. hOR17-4
expressed in a stable inducible HEK293S cell line exhibits specific activation by its
cognate ligand bourgeonal. (A) Transient changes of the cytosolic Ca2+ concentration
were recorded with confocal microscopy using Fura-Red (Ex 488 nm/Em 650 nm) as a
fluorescent Ca2+ indicator. The decrease of the fluorescence signal induced by receptor
activation in response to bourgeonal (100 sM) corresponds to an increase of the cytosolic
Ca+ concentration. The application of 200 stM adenosine triphosphate (ATP) served as a
control of HEK293S cell excitability. (B) In a randomly selected field of view, Fura Red
fluorescence intensities of odorant-induced Ca 2+ responses were recorded on four
individual cells (1, 2, 3, 4) as a function of time. hOR17-4 induces transient Ca2 *
signaling to consecutive stimulations by bourgeonal (1 sM; 100 [iM). Arrows indicate
the time point of odorant application. The preincubation (black bar) with the hOR1 ' 4
antagonist undecanal (100 sM) inhibited hOR17-4 activation by bourgeonal (100 [M)
during co-application (arrow) with undecanal (100 [LM). After subsequent odorant
washout, cells were again excitable with bourgeonal (100 RM).
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5.3.3 Analysis of OR17-4 odorant binding using surface plasmon resonance
To assay the functionality of purified (non-membrane-bound) hOR17-4, we
developed an assay method using surface plasmon resonance (SPR) to demonstrate that
the solubilized receptor retains selectivity in binding odorant ligands in a concentration-
dependent manner. The rholD4 monoclonal antibody was covalently attached to the
dextran surface of a Biacore CM4 chip using standard amine-coupling chemistry. The
hOR17-4 receptor protein was then non-covalently bound to the antibody via its C-
terminal rho tag (TETSQVAPA). Figure 5.4 displays the SPR readout during the surface
assembly on the CM4 chip. Odorant ligands were then applied and odorant binding
detected in real time via the associated mass increase. Solubilized hOR17-4 receptors
bound the odorant bourgeonal in a concentration-dependent manner (Figure 5.5), and a
dissociation constant was fitted to the data using the steady-state equation [6]:
[ 40 <1>
Y4r/, [ Al+#,
ZFmax 10+'
Where y is the fractional saturation and [L] denotes the odorant concentration. This
equation also assumes no ligand depletion ( [L] ~ [L]o ), which is valid as the
concentration of odorant far exceeds that of the immobilized olfactory receptor. The
fitted Kd was 9.5 pM, which is a rather weak interaction, as many other receptors have
ligand affinities in the nanomolar range. Solubilized hOR17-4 receptors also bound the
specific odorants
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Figure 5.4 - Preparation of SPR chip surface for odorant binding assay. (A) Chip
surface is activated, followed by covalent attachment of rholD4 mAb by amine
chemistry, followed by a blocking step to react all remaining ester groups. The OR
protein is then applied and immobilized on the surface via its C-terminal rho-tag epitope
(B). The asterisk (*) denotes the zero RU point for the subsequent odorant binding
assays. The inset shows a depiction of the assembled chip surface.
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Figure 5.5 - SPR determination of hOR17-4 affinity for bourgeonal. (A) Immobilized
hOR17-4 binds increasing concentrations of bourgeonal in a dose-specific manner. These
measurements were used to fit a dissociation constant of Kd = 9.5 pM using the steady-
state relation (B).
lilial and floralozone in a dose-dependent manner (Figure 5.6). Due to low odorant
solubility, the dissociation constant for these odorants could not be rigorously
determined, but was approximately in the low micromolar range. No binding was
detected for the non-specific odorant sulfurol acetate and no odorants were bound when
the receptor was denatured using guanidium HCl (data not shown). Thus, these results
indicate that hOR17-4 receptor retains its functionality in the solubilized state.
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Figure 5.6. Functional assay of purified hOR17-4 functionality using surface
plasmon resonance (SPR). Detection of functional OR-odorant interactions was
monitored in real time using a Biacore A100. The hOR17-4 was adsorbed onto the SPR
chip surface using the rho ID4 monoclonal antibody, and spectra were recorded following
odorant application. Immobilized receptor bound increasing concentrations of the specific
odorant ligands lilial (A) and floralozone (B). Odorant binding curves shown are: blank
control (black), 5 pM (red), 10 pM (light blue), 20 pM (dark blue), and 40 pM (green).
No response was seen for the control odorant sulferol acetate (result not shown).
Guanidium HCl-denatured hOR17-4 did not bind any odorants (result not shown). All
results are simultaneously subtracted from a reference channel containing mAb and blank
buffer.
5.3.4 Quantitation of hOR17-4 activity
Although we confirmed the purified hOR17-4 to be functional via SPR, it is
possible that only a small fraction of the receptor is truly functional and binding odorants
while the remainder is inert. Such concerns are warranted given the fact that the receptor
is solubilized by a zwitter-ionic detergent, which, as a class, are generally harsher than
non-ionic detergents, and it is possible that the bulk of the receptor is not functionally
active. Thus we performed quantitative analysis on the SPR data in an effort to determine
what percentage of the purified hOR17-4 receptor is binding specific odorants, based on
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bound mass detected by SPR. Such techniques have been previously used to quantitate
ligand binding for the GPCR chemokine receptors CXCR4 and CCR5 [7].
In SPR, the response units (RUs) are a measurement of the dielectric constant in
the region near the surface, which is directly related to the index of refraction (n). Thus,
SPR signals are not truly proportional to mass bound but instead are governed by the
equation [8]:
z(/A = X C <2>
Where X is a proportionality constant, C is concentration, and the quantity (dn/dc)
represents the refractive index increment (also known as differential refractive index). In
practical terms, (dn/dc) represents how much the refractive index changes for a given
change in concentration. In SPR, it is known that for proteins, 1 RU ~1 pg/mm2 and that
the (dn/dc) is 0.18 mL/g [8]. This relation hold for a large range of protein types and
sizes. However, it does not necessarily hold for small molecules such as odorants. This
protein relation can, however, be used to rearrange the above RU equation to a more
useful form:
C = <3>
Using this equation, we only need the (dn/dc) for the odorant ligand in order to calculate
its concentration (and thus the number of molecules bound by the immobilized hOR17-
4). Since this data is unavailable for the odorants in question, we can obtain a rough
estimate by using the Dale-Gladstone relation [9], which is typically accurate to within a
few percent for a variety of small molecules, including odorants such as benzene [10] and
n-alkanes [9]:
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Where n is the index of refraction of the odorant, nsovIent is the index of refraction of the
solvent (1.33 for the HBS saline buffer [11]), and p is the odorant density. These odorant
properties are readily available on web-based chemical databases, and values were
obtained from [12] for lilial and [13] for floralozone. The values obtained were used to
calculate the odorant (dn/dc) values using equation <4> and these were in turn used in
equation <3> to calculate the concentration of odorant bound. The concentration of
immobilized hOR17-4 was also calculated using equation <2> using the standard protein
relation. Results for lilial and floralozone are shown in Table 3.
Table 3 - Quantitation of purified hOR17-4 receptor functionality.
Molecule RUs bound (dn/dc) fmol/mm2 bound
hOR17-4 2800 0.18 73
Lilial 8.1 0.172 41
Floralozone 7.6 0.187 38
We can see that the calculated odorant (dn/dc) values are nearly equal to that of
protein. The majority of immobilized hOR17-4 receptors bound specific odorants (56%
bound lilial and 52% bound floralozone). Additionally, since odorant solubility limits our
these ligand concentrations, we are not capable of completely saturating the receptors
(see equation <1>) and our estimate is that only -80% saturation is possible if the
receptors were 100% active, given a Kd ~ 10 ttM. Thus we feel confident in stating that
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the majority (>50%) of the purified, detergent-solubilized hOR17-4 receptors are
functionally active.
5.3.5 Characterization of hOR17-4 post-translational modifications
Olfactory receptors are believed to possess two disulfide bonds between fou-
conserved cysteine residues located in extracellular loops 1 and 2 (ECI and EC2) [14].
For hOR17-4, these two bonds are Cys97-Cys179 (EC1-EC2) and Cys169-Cys189 (EC2-
EC2). Analysis by mass spectrometry (chymotrypsin digest followed by LC-MS)
confirmed the presence of one of the two disulfide bonds (Cys 1 69-Cys 189) predicted for
olfactory receptors (Table 3). No corresponding unlinked peptides were detected,
indicating homogeneity. Presence of the remaining disulfide bond (Cys97-Cys 179) was
unconfirmed, as no corresponding peptides (disulfide-linked or unlinked) were detected,
presumably due to the resistance of the detergent-solubilized OR to complete protease
digestion.
Additionally, the N-linked glycosylation present on Asn-5 was determined to be
Man3GlcNac3. To our knowledge this is the first characterization of olfactory receptor
glycosylation. This hexasaccharide is also the predominant glycosylation seen in retina-
derived bovine opsin on Asn-2 and Asn-15 [15]. However, it is worthwhile to note that
rhodopsin heterologously prepared using the HEK293S GnTI~ cell line was found to have
the N-glycan Man5GlcNac2 [16], indicating hOR17-4 follows a different glycosylation
pathway in this system.
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Position
290-323
290-323
114-136
61-82
267-289
73-94
123-143
99-118
267-283
277-288
83-94
277-288
83-94
28-36
28-36
267-277
267-277
73-82
73-82
277-286
267-276
Assigned peptide sequence
(Y)SLRNKD...SQVAPA( ) - ox
(Y)SLRNKD.. .SQVAPA()
(L)ILAVMA... HYTTAM(S)
(Y)FFLANL...TIPKML(V)
(Y)SVKDSV...MNPFIY(S)
(F)FVTNTL ..NKAISY(A)
(R)YVAICC...PKLCIL(L)
(L)TQLYFL...LILAVM(A)
(Y)SVKDSV.. .AVVTPM(M)
(Y)AVVTPMMNPFIY(S) - ox
(L)VNLQSHNKAISY(A) - ox
(Y)AVVTPMMNPFIY(S)
(L)VNLQSHNKAISY(A)
(L)FWMFLSMYL(V) - ox
(L)FWMFLSMYL(V)
(Y)SVKDSVATVMY(A) - ox
(Y)SVKDSVATVMY(A)
(F)FVTNTIPKML(V) - ox
(F)FVTNTIPKML(V)
(Y)AVVTPMMNPF(I)
(Y)SVKDSVATVM(Y)
Measured mass
3720.1
3704.1
2617.3
2578.3
2562.3
2517.4
2339.1
2235.2
1796.9
1397.7
1388.7
1381.7
1372.8
1252.6
1236.6
1214.6
1198.6
1178.7
1162.7
1105.6
1035.6
1-14 ()MDGGN*QSEGSEFLL(L)
(F)C*GSRKIHYIF(C)
(L)RMAC*SNIQINHTVL(I)
2578.3 2578.33
*Asn-5 modified with Man3-GlcNAc3
2819.1 2819.44
*Peptides linked via disulfide bond
Table 3 - Analysis of purified hOR17-4 by mass spectrometry. List of chymotryptic
hOR17-4 peptides identified by LC-MS. Amino acids in parentheses are those before and
after the assigned peptide in the protein sequence. "Ox" indicates oxidation (e.g. of Met).
5.4 Discussion
This work has confirmed that the engineered synthetic hOR17-4-rho gene encodes
a receptor protein with wild-type function in the cell membrane and the protein retains
this functionality, as ascertained by an SPR-based odorant binding assay, in the FC14-
solubilized state. The purified protein also had correct secondary structure and possessed
a near-UV CD spectrum indicative of a defined tertiary structure. Predicted post-
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169-178
186-199
Calc. (M+H)+ m/z
3720.97
3704.98
2618.26
2579.36
2563.26
2518.41
2340.16
2236.27
1797.91
1398.68
1389.71
1382.68
1373.72
1253.57
1237.58
1215.59
1199.60
1179.64
1163.65
1106.54
1036.53
translational modifications were confirmed, including a homogeneous disulfide bond in
the second extracellular loop and an N-linked hexasaccharide glycosylation on Asn5.
Despite the success of the SPR assay, a simpler, faster alternative would be
desirable as the assay is time consuming and requires significant optimization and is thus
not easily applicable to screening many odorant-OR combinations. However, now that
one method to measure solubilized-OR functionality is in place, we can, by correlating
with the SPR assay, begin to investigate more rapid methods of ascertaining olfactory
receptor functionality. Other membrane proteins have been shown to display changes in
spectroscopic characteristics as they degrade, unfold and lose function. Two such
examples are photosystem-I [17] and rhodopsin [18]. Despite the fact that this might be
expected as these are both light-sensitive proteins, spectroscopic shifts could correlating
with odorant binding or loss of receptor function.
To explore this, a number of techniques can be investigated, such as shifts in
tryptophan fluorescence upon odorant binding. Another technique that holds promise
would be to perform far-UV CD measurements on OR secondary structure with the
addition of odorants. Such assays have already been shown to detect ligand binding in the
GPCR 5-HT4a, a result of disulfide bond shifting [19].
OR stabilization using surfactant-like peptides
An addition avenue to explore is the functional stabilization of ORs in solution.
While the detergent-solubilized hOR17-4-rho protein was functionally active in our SPR
assay, the lifespan of this activity has not been tested yet. However, the SPR and CD
assays will allow us to investigate means of stabilizing the olfactory receptors in solution
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using other detergents and surfactant-like peptides. Previous work of this lab has
successfully kept membrane proteins functionally stable in both wet (aqueous) and dry
(powdered) states for periods as long as several weeks with the use of the peptide
detergents such as A6K and V6D [17, 20]. Stabilized proteins were additionally found to
be resistant to high temperature thermal denaturation.
Self-assembling surfactant-like peptides are key tools in the study of membrane
proteins. These short peptides consist of a charged or polar head group followed by a
string of hydrophobic amino acids, thus mimicking an amphipathic lipid. These
molecules show the remarkable ability to spontaneously self-assembly into
macromolecular structures such as micelles, nanotubes, and nanovesicles [21]. The
designed peptide detergents also have several advantages for study of diverse membrane
proteins: 1) Their biochemical properties resemble common detergents with similar
critical aggregation concentrations (CACs) and appear not to denature membrane proteins
and membrane protein complexes. 2) They are chemically and structurally simple and
can be custom tailored for a variety of uses. 3) They are obtainable at high purity, readily
soluble in water, and stable at ambient temperature. 4) They can be used together in a
combinatorial manner and in conjunction with commercial detergents.
Due to their detergent properties, the small peptides can extract integral proteins
from membranes and enhance their solubility in aqueous solutions (see Figure 5.7). This
peptide coating can effectively mimic the natural environment of the lipid membrane, and
work by the Zhang lab has demonstrated that membrane proteins can be stabilized and
remain functional both in liquid as well as dry (powdered) environments for many weeks.
Additionally, self-assembling surfactant peptides have been shown to facilitate
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crystallization of membrane proteins, potentially leading to X-ray diffraction data aid
ultimately to valuable structural information. All of these aspects are directly applicable
to our study on olfactory receptors.
peptde detergent
displacement
0-cationkI peptide surfactant (e.g.. A6K)
Figure 5.7 - Depiction of surfactant-like peptide solubilization and stabilization of
membrane proteins.
Surfactant-like peptide can be varied in several parameters such as the type
(charged / polar) and number of hydrophilic residue(s) used, hydrophobic tail length, and
type of hydrophobic residues used. See Figure 5.8 for a diagram of surfactant-like
peptide structure. Additionally, multiple types of surfactant-like peptides can be used in
conjunction to synergistically stabilize the receptors. We hypothesize that such a
combinatorial screening method would further assist in the solubilization and purification
of olfactory receptors.
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Figure 5.8 - Molecular model of surfactant-like peptides. A6K is cationic while V6D
is anionic. Ac refers to acetylation of the N-terminus, which aids in peptide stability.
5.5 Methods
Circular Dichroism Spectroscopy
Spectra were recorded at 15*C using a CD spectrometer (Aviv Associates, Model
202). Far-UV CD spectra were measured over the wavelength range of 195-260 nm with
a step size of 1 nm and an averaging time of 5 s. Near-UV CD spectra were measured
over the wavelength range of 250-350 nm with a step size of 1 nm and an averaging time
of 10 s. All spectra were the average of 5 replicate scans. Spectra shown for purified
hOR17-4 were blanked to wash buffer (concentrated to same extent as hOR17-4 sample)
to remove effects of the detergent FC 14. All measurements are reported in mean residue
ellipticity (degrees * centimeter squared per decimole). Protein concentration was
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determined from the aromatic absorption in 6 M Guanidinium HCl, pH 6.5 [22]. The
secondary structural content was estimated using the online resource K2D
(http://www.embl-heidelberg.de/%7Eandrade/k2d.html) [3].
Fluorescent Spectroscopy
Spectra were recorded at 25*C in a 1 cm path length semi-micro quartz cuvette
(Hellma) using a Fluoromax-2 spectrofluorometer (Instruments SA, Inc., Jobin Yvon-
Spex). Samples were excited at 280 nm and emission spectra collected from 300 - 500
nm with a step size of 1 nm and an integration time of 0.1 s. All spectra were the average
of 3 replicate scans. Purified hOR17-4 was diluted in wash buffer to a concentration of 25
pg/ml to avoid signal saturation, and spectra were blanked a control wash buffer to
remove effects of the detergent FC14.
Calcium Signaling
hOR17-4 expression in the stable HEK293S cell line was induced by 48 hour
incubation in DMEM/F12 medium with GlutaMAX (Invitrogen), supplemented with i
pg/ml tetracycline. Then cells were loaded at 37 *C for 30 min with 10 mM Fura-Red-
AM (Molecular Probes) in serum-free DMEM/F12 medium and were subsequently
washed with PBS and incubated in DMEM/F12 medium containing 10% FCS for 30 min
to allow complete hydrolysis of intracellular Fura-Red-AM. Cytosolic Ca2 responses
were recorded by confocal fluorescence microscopy (Zeiss LSM 510) using a water
immersion objective (Zeiss Achroplan 63 NA 1.2). Excitation was at 488 nm (Ar+ laser);
the 650 nm long pass emission filter was used to image Fura-Red at a rate of 1 image per
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second. Stock solutions of the tested odorants were prepared freshly in
dimethylsulphoxide and diluted 1000-fold into phosphate-buffered saline (PBS) to give
the desired concentrations.
Surface plasma resonance (Biacore A100) odorant binding assay
All odorant binding experiments were performed on a BiacoreTM A100 (GE
Healthcare, Uppsala, Sweden) at 25*C. A BiacoreTM A100 was used in the present
studies since it has a parallel flow configuration thus allowing assay development (e.g.,
solubilization conditions) to be tested and optimized in parallel in a multiplexed format.
The sensor chip CM4, amine coupling kit, HBS (10 mM Hepes, 0.15 M NaCl, pH 7.4)
and PBS were from (GE Healthcare, Uppsala, Sweden).
The rholD4 monoclonal antibody (40 pg/ml in 10 mM sodium acetate, pH 5.5)
was immobilized onto a series S sensor chip using standard amine-coupling chemistry in
HBS running buffer at 10 pl/min [23]. The amount of coupled rholD4 was about 5500
RU. Control surfaces were prepared similarly without protein derivatization and utilized
as a reference surfaces for odorant binding experiments.
HEK293S hOR17-4-rho cells were induced with 1 ug/mL tetracycline plus 5 mM
sodium butyrate for 48 hours and then scrape harvested 48 hours post-induction. The
cells (5 x 106 cells/ml) were lysed with 1.5% FC-14 for 90 min at 44C. The lysed cell
suspension was centrifuged for 10 minutes at 14000 x g at 4 *C to remove cell debris.
The supernatant, containing the solubilized olfactory receptor, was immediately captured
on the surface plasmon resonance (SPR) chip using PBS, 1 mM Anzergent 3-14
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(5xCMC), 5 mM TCEP, and 1.5 % (v/v) ethanol as running buffer at 10 pl/min. A four-
minute injection resulted in a surface density of about 2800RU.
Fresh odorant solutions were made as follows. Pure odorant was diluted in
ethanol to 0.5 M. This solution was diluted 67 times in PBS, 1 mM Anzergent 3-14, 5
mM TCEP, to obtain a 7.5 mM odorant solution in running buffer with 1.5 % (v/v)
ethanol. Further dilutions were made in running buffer containing 1.5% (v/v) ethanol to
obtain a concentration series of 5pM, 10pM, 20pM and 40pM of the odorants.
For the actual odorant binding measurements, the odorant concentration series
were injected from low to high concentration over control and derivatized surfaces for 30
seconds with a flow rate of 60 pl/min. Zero concentration blank buffer cycles were
included as negative control samples. Solvent correction procedures were included to
compensate for any ethanol related bulk refractive index variations and performed as
described previously [24]. Non-specific binding effects to sensor surface CM4 were
absent for all analyses reported. Data analysis was carried out using Biacore A100
evaluation software. Data were prepared by subtraction of reference surface data and
blank buffer sample data, a procedure commonly referred to as double referencing [25].
Solvent correction was then applied as described previously [24].
Mass Spectrometry
Liquid samples of purified monomeric hOR17-4 were subjected to chymotrypsin
digestion and the resulting fragments analyzed using LC-MS by the MIT Koch Institute
Proteomics Core Facility (Cambridge, MA). Proteolytic peptides were separated using
0.075 mm x 15 cm Ci8 column on a nano-HPLC system (TEMPO from Applied
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Biosystems). Gradient elution with a water-acetonitrile-formic acid solvent system of
peptides was carried out at a flow rate of 250 nL/min over 87 min. Electrospray mass
spectra were acquired with a quadrupole time-of-flight mass spectrometer (QSTAR Elite
from Applied Biosystems).
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APPENDIX A
ADDITIONAL EXPERIMENTS
A.1 Crystallization Screening
No detailed structure for any olfactory receptor has ever been resolved by X-ray
diffraction. For an excellent review of the current state of membrane protein purification
and crystallization, see [26] on the previous page. Current structures are rough
estimations based on computational modeling and comparisons to rhodopsin. In order to
find suitable crystallization conditions, many thousands of solutions must be screened.
Following the initial bioreactor purification, we sent 1.5 mg (300 pLL of 5 mg/mL hOR17-
4 monomer) to Dr. Duncan McRee at Active Sight in San Diego. The protein was then
subjected to automated crystal screening using the Phoenix system, which is capable of
sub-microliter condition volumes. Over 1200 conditions were tested, using Qiagen kits
(MB I & II, MEMFAC, JCSG, JCSG CORE 1 - 4, PEG I & II, PEG ION, INDEX).
Crystals were grown at 4"C and 20"C. Additionally, I set up 148 conditions here in
conventional hanging drop plates at room temperature for potential diffraction-grade
crystals. Several promising conditions were discovered, as seen in Figure A.1. Notably,
all used the precipitant polyethylene-glycol-400 (PEG-400) and alkaline pH.
Following the second bioreactor purification, we sent 7.5 mg (750 pL of 10
mg/mL hOR17-4 monomer) to Dr. Eva Pebay-Peyroula at the Institute for Structural
Biology in Grenoble, France for high-throughput crystal screening (started 7/16/08).
They set up screening trials using both classical detergent-solubilized methods as well as
cubic lipid phase crystallization. Additionally, the PEG-400 and high pH conditions are
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35% PEG-400 36% PEG-400 34% PEG-400 35% PEG-400
0.1M TrisHCI, pH 8.7 0.1M CAPSO, pH 9.2 0.1M CAPSO, pH 9.4
C.
2
Figure A.1 - Hanging drop crystallization of purified monomeric hOR17-4. Control
consists of the same solubilization buffer used during OR purification
(solution was concentrated to same extent as OR sample to ensure equivalent detergent
concentration).
being more thoroughly explored due to the results from my hanging drop crystallization
experiments. As crystallization can take many months to generate results, we are awaiting
the latest screening data and hope that a suitable condition can be found so that we can
proceed to X-ray diffraction in the hopes of obtaining the first high-resolution structure
for an olfactory receptor.
Early studies in collaborating laboratories have shown that surfactant-like
peptides can facilitate and enhance membrane protein crystallization (Joanne Yeh, Brown
University, unpublished data). These surfactant-like peptides could prove vitally
important in future attempts at the crystallization of hOR17-4 and other ORs.
Additionally, the use of ORs known to bind to certain odorants will yield the possibility
of getting structures for receptor-odorant complexes.
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A.2 Additional Cell Lines Constructed
In addition to the previously discussed HEK293 stable cell lines constructed to
express either rho-tagged hOR17-4 or hOR17-4(N5Q), we constructed and subcloned
HEK293S stable cell lines which had tetracycline-inducible expression of several
differently tagged versions of hOR17-4 to explore alternate purification. In each case, the
corresponding gene was designed, synthesized and inserted into the pcDNA4/To T-REx
vector, and stable cell lines were grown, subcloned, and screened as described earlier in
Chapter 3 and in Appendix B.3. All subcloned stable-inducible lines have been
cryopreserved for future use.
His-tagged hOR17-4
The His-tag (comprising a stretch of six histidine residues) has been ubiquitous in
general protein purification as it is efficient, simple, and low cost. As the rholD4-based
purification method relies on a rather expensive antibody ($6000 per gram), we also
investigated whether His-tag purification could be used as an alternative. A custom
hOR17-4 gene was synthesized by PCR-based gene assembly to contain an N-terminal
fusion to both a His-tag (for purification) and a FLAG-tag (for immunodetection)
epitope. The FLAG tag (DYKDDDDK) can also be used for purification using the anti-
FLAG M2 antibody affinity resin available from Sigma-Aldrich. The peptide sequence
was MRGSHHHHHHGGDYKDDDDK followed by a two-glycine linker sequence. No
C-terminal rho-tag was used in this construct. The construct was designated HF-hOR17-4
(HF standing for His-FLAG). Stable cell lines in HEK293 cells were constructed as
described in Chapter 3.
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When expression of HF-hOR17-4 was induced using either tetracycline alone or
tetracycline plus sodium butyrate enhancer and analyzed via SDS-PAGE western
blotting, we discovered that only the 30 kD monomer form of the receptor was present.
This could be due to the N-terminal fusion tag interfering with the N-linked glycosylation
known to produce the 32 kD monomer form. We also noticed that, when compared to
hOR17-4-rho, the same induction treatment led to significantly greater toxicity in the HF-
hOR17-4 construct, even when comparing multiple subclones. Whereas significant
toxicity was only observed for hOR17-4-rho under very high induction conditions (1
pg/mL tetracycline plus 5 mM sodium butyrate), a similar amount of toxicity was
observed for HF-hOR17-4 under tetracycline alone. Thus it is possible that the His-
FLAG-tagged variant is inherently more toxic to the cells, and this effect precludes its
further processing by glycosylation.
Nevertheless, we attempted to purify the HF-hOR17-4 using immobilized metal
ion affinity chromatography (IMAC) followed by gel filtration chromatography. As can
be seen in Figure A.2, the IMAC eluate contained a significant number of contaminating
bands, due to non-specific interactions of other proteins with the nickel column. Even
after a two-step purification (IMAC followed by size exclusion chromatography), the
monomeric HF-hOR17-4 could not be separated from the contaminants and only 70%
purity could be obtained (whereas >90% was possible using the rho-tagged construct).
The yield of HF-hOR17-4 was approximately 40 micrograms per 150 mm tissue culture
plate and we were able to purify 0.4 milligrams of the monomeric fraction, though still
impure. The HF-hOR17-4 protein also readily precipitated when concentrated, unlike the
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rho-tagged version. We therefore chose to abandon this method in favor of the much
more successful rho lD4 immunoaffinity method described in the body of this thesis.
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Figure A.2 - Analysis of His-FLAG-tagged hOR17-4. (A) SDS-PAGE anti-FLAG
immunoblot of HF-hOR17-4 induction in stable HEK293S cell line (Clone 23). Only the
30 kD monomer form is seen, even under low levels of induction (tet only). (B)
Comparison of affinity purified hOR17-4 variants, either rho-tagged (rho1D4
immunoaffinity chromatography) or his-flag-tagged (IMAC). (C) Comparison of variants
after two-step purification (affinity followed by size exclusion chromatography). Gel
filtration fractions loaded were early aggregate (A), dimeric (D), and monomeric (M).
Even after two stages of purification, the his-tagged "monomeric" fraction still contains a
large amount of contaminants.
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Untagged hOR17-4
We have also generated stable inducible HEK293S cells that express an untagged
version of hOR17-4, should future research show that the C-terminal rho-tag interferes
with structure or function. This required the use of custom anti-hOR17-4 polyclonal
antibodies in order to detect the wild-type receptor. Both anti-N-terminal and anti-C-
terminal antibodies were raised by rabbit immunization using synthesized peptides
corresponding to hOR17-4 amino acid sequences. These epitope sequences needed to be
easily accessible and so we selected sequences at the extreme termini and made sure they
ended at least five amino acids away from the predicted transmembrane regions. The
peptides used were DGGNQSEGSEFC for the N-terminus and CRLLDKHFKRLT for
the C-terminus. The rabbit inoculation and antibody purification (by affinity) were
performed by Genscript (www.genscript.com).
Following construction of the untagged hOR17-4 gene and subsequent
establishment of a subcloned stable-inducible HEK293S cell line, the expressed hOR17-4
was characterized by SDS-PAGE immunoblotting using the custom antibodies against
both termini of hOR1 7-4. As was the case for the His-FLAG-tagged variant, the untagged
version showed significantly higher cellular toxicity than the hOR17-4-rho construct, and
cell death was seen even when inducing with tetracycline alone. The immunoblots were
considerably dirtier than the monoclonal rholD4 western blots, and numerous non-
specific bands were seen. Importantly, only the 30 kD monomer form was seen (Figure
A.3), as was the case for HF-hOR17-4-rho. Another observation is that both antibodies
reacted to a 15 kD band, which could be a cleaved form of the receptor (essentially cut in
half). This band is also seen in His-FLAG-tagged hOR17-4 (see Figure A.2b and A.2c),
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but not in rho-tagged hOR17-4 (see Figure A.3). Thus it is reasonable to conclude that is
the increased toxicity (and likely ER accumulation and stalling of post-translational
processing) of both the untagged and His-FLAG-tagged versions of hOR17-4 that
prevents their glycosylation on Asn5 and potentially causes degradation. Exactly why the
rho-tagged version is less toxic remains to be seen, as the protein still retains normal
signal transduction and functional activity when assayed by cell surface calcium imaging,
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Figure A.3 - Analysis of untagged hOR17-4 expression. Three separate hOR17-4
expressing clones are shown (w3, w2, and w6), either untreated (-) or treated for 48 hours
with 1 pg/mL tetracycline (+) or tetracycline plus 1 mM sodium butyrate (++). SDS-
PAGE was followed by immunoblotting with both anti-N-terminal and anti-C-terminal
custom polyclonal antibodies.
Additional hOR17-4 mutant versions
In addition to the hOR17-4(N5Q) mutant cell line, which was deficient for N-
linked glycosylation on Asn5, we constructed three additional inducible HEK293S cell
lines carrying mutated versions of hOR17-4. As hOR17-4 contains another potential
glycosylation site at Asn195, we thought to eliminate this site as well, in order to ensure
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completely homogeneous receptor monomer should future research require it. Thus we
constructed genes and subsequently produced cell lines that inducible express either
hOR17-4(N195Q) or hOR17-4(N5Q,N195Q). Expression in these cell lines have not
been fully characterized yet, but we would expect the N195Q variant to have little effect
on the 32 kD monomer form, but could Asn195 glycosylation could perhaps be
responsible for the faint band we frequently see at ~33 kD. The double mutant
(N5Q,N195Q) should therefore eliminate both of these forms, resulting in only the 30 kD
form being expressed.
After constructing the original hOR17-4-rho gene, additional human genome
sequence data showed a polymorphism to exist at amino acid residue 25, with the two
major variants in the population being glutamine (Q) or arginine (R). Our original
construct had a glutamine at this position, so for future research we also created the
alternate variant hOR17-4(Q25R) gene and stably-inducible cell line.
A.3 Detection Using Custom Antibodies
In section A.2, I described the generation and use of custom anti-hOR17-4
polyclonal antibodies raised against the N-terminus or C-terminus of the hOR174
protein. In addition to using these to construct and characterize untagged hOR17-4-
expressing cell lines, these antibodies were also used to probe both the rho-tagged and
His-FLAG-tagged variants of the receptor via SDS-PAGE immunoblotting. Prior to the
experiment, I hypothesized that the anti-C-terminal antibody might have trouble detecting
hOR17-4-rho, as the C-terminal rho-tag could presumably interfere with antibody
binding. Similarly, the anti-N-terminal antibody might have difficulty detecting the HF-
hOR17-4 protein due to its N-terminal His-FLAG tag. Additionally, the glycosylation
127
seen for the hOR17-4-rho protein should prevent the anti-N-terminal antibody from
recognizing the 32 kD monomer band since Asn5 comprises part of its epitope.
When the immunoblots were performed on induced cell samples (Figure A.4), all
these hypotheses were confirmed, with the exception that the anti-N-terminal antibody
had no trouble recognizing the HF-hOR17-4 protein. The 15 kD band, which could
potentially be a cleaved form of hOR17-4, was seen for the His-FLAG tagged protein but
was absent for the rho-tagged version. This is further evidence that the hOR17-4-rho
protein is more stable in this cell line and can be correctly processed via glycosylation
and targeted to the cell membrane.
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Figure A.4 - Detection of tagged hOR17-4 variants using custom polyclonal
antibodies. Either HF-hOR17-4 (HisFlag) or hOR17-4-rho (Rho) expressing clones were
either untreated (-) or treated for 48 hours with 1 pg/mL tetracycline (+) or tetracycline
plus 5 mM sodium butyrate (++). SDS-PAGE was followed by immunoblotting with the
indicated antibody. The anti-C-terminal antibody had difficulty recognizing the rho-
tagged variant, while the anti-N-terminal antibody did not effectively bind the 32 kD
(glycosylated) monomer form of hOR17-4-rho, despite equal amounts of the two forms
(see anti-rho blot).
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APPENDIX B:
EXPERIMENTAL PROTOCOLS
B.1 Gene Design Using DNAWorks
Go to:
http://helixweb.nih.gov/dnaworks/
1. Enter job name (such as hOR174)
2. Enter your email address
3. Do not check mutant run
4. Codon Frequency - check either "H. Sapiens" (for mammalian cell expression) or
"E. Coli Class II" (for bacterial expression)
5. Parameters:
a. Annealing Temp: 60"C
b. Oligo Length: 40-50 nt
i. Try 40 first (shorter usually gives lower error rate in synthesis)
ii. You can also enter a range (from 40-50) and just put 60"C in both
temperature fields
iii. Or, you can try length of 50 and selecting the "random" option
(this will allow the lengths to be non-uniform)
c. Codon Frequency Threshold: 19% (human) / 15% STRICT (e. coli)
d. Oligo concentration: 25E-9 M (25 nM)
e. Na+/K+ concentration: 0.05 M (50 mM) - default value
f. Mg2+ concentration: 0.002 M (2 mM) - default value
g. Number of solutions: 10
h. TBIO mode: do not check
6. Restriction site screen:
a. Non-degenerate, select EcoRI and NotI (or whatever sites you are using to
clone in your gene)
b. Be sure to hold down command to select BOTH sites!
7. Sequences:
a. Click "Add sequence field" twice (for the 5' and 3' headers)
b. Sequence 1: 5' DNA sequence leader (restriction sites, ribosome binding
site)
(example: EcoRI/Kozak header CCTGAATTCGCCGCCACC)
c. Sequence 2: your protein sequence with any tags included in single letter
amino acid format
i. Be sure to end protein coding sequence with an X (for stop codon)
ii. for rho lD4 tag, add GGTETSQVAPA to C-terminus (BEFORE
the stop codon, of course)
iii. also add other tags to N- or C- terminus (be sure to add glycine
linkers!)
d. Sequence 3: 3' DNA sequence flanker
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(example: NotI flanker GCGGCCGCGAGAAG)
8. Click "Design Oligos"
9. Results will be emailed to you
a. Lower scores are better (and lower Tm range). An score of less than 1.000
is desirable.
b. Examine and compare the lowest scoring oligo sets and choose the best
one to order.
c. Note that the NotI site will always give you some repeat, GC-rich, and
pattern score
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Sample of a DNAWorks3.1 output trial
Trial shown was used in the design of the olfactory receptor M71-rho
gene.
PARAMETERS FOR TRIAL 67
---- ---------------------------------------------------------
Total Size Of Gene ......... 995 nt
Protein Residues ........... 321
Mutatable Residues ......... 307
Fixed Nucleotides .......... 74 nt
Oligo Size ................. 46 nt
Annealing Temp ....... .60 +/- 1*C
Oligo Concentration ..... 2.50E-8 M
Sodium Concentration .... 5.00E-2 M
Mg2+ Concentration ..... 2.OOE-3 M
Codon Frequency Threshold .. 19%
Repeat Threshold ........ 8 nt
Mispriming Threshold ... . 8/18 (6 exact) nt
-----------------------------------------------
The DNA sequence # 67 is:
-------------------------------------------
1 CCTGAATTCGCCGCCACCATGACCGCTGAAAACCAAAGCACCGTGACCGAGTTTATCCTC
61 GGAGGGCTCACAAATAGGCCTGAACTGCAGCTCCCCCTCTTCCTCCTGTTTCTGGGGATC
121 TACGTGGTGACAATGGTGGGCAATCTGGGCATGATCACTCTGATTGGCCTCAACAGCCAA
181 CTGCACACCCCCATGTACTTTTTTCTGAGCAACCTGAGCCTGGTGGACCTGTGCTATTCC
241 AGCGTCATCACACCCAAAATGCTGATCAACTTCGTGAGCCAAAGGAATCTCATCAGCTAT
301 GTGGGATGCATGAGCCAGCTGTATTTCTTCCTGGTGTTCGTGATCGCCGAGTGCTACATG
361 CTGACAGTGATGGCCTATGACAGGTACGTCGCCATCTGCCAGCCCCTGCTCTACAACATT
421 ATCATGTCCCCCGCACTGTGCAGCCTGCTGGTGGCCTTCGTCTACGCTGTGGGGCTGATC
481 GGCAGCGCCATCGAGACCGGACTGATGCTGAAGCTCAACTACTGCGAGGACCTCATCTCC
541 CACTACTTCTGCGACATCCTGCCACTCATGAAACTGTCCTGCTCCAGCACATACGACGTG
601 GAGATGGCCGTGTTCTTTCTGGCCGGCTTCGACATCATCGTCACCAGCCTCACCGTCCTG
661 ATCTCCTACGCCTTCATTCTGTCCAGCATTCTCAGGATTTCCTCCAACGAGGGCCGGAGC
721 AAAGCCTTTAGCACCTGCAGCAGCCACTTCGCTGCTGTCGGCCTGTTCTACGGCAGCACT
781 GCATTCATGTACCTGAAGCCCAGCACCGCCTCCTCCCTGGCACAGGAGAACGTGGCCTCC
841 GTCTTCTATACCACCGTCATCCCTATGTTCAACCCCCTGATTTACTCCCTCAGGAACAAG
901 GAGGTGAAGACCGCCCTGGACAAGACCCTGCGGCGGAAGGTCTTTGGCGGCACCGAAACA
961 AGCCAGGTCGCTCCCGCCTGAGCGGCCGCGAGAAG
The oligonucleotide assembly is:
-------------------------------------------
1 10 20 30 40 50 60
1 1 1 | | I 1
1 --- > 3 --- >
1 CCTGAATTCGCCGCCACCATGACCGCTGAAAACCAAAGCACCGTG ttatcctc
GACTTTTGGTTTCGTGGCACTGGCTCAAATAGGAG
M T A E N Q S T V T E F I L
I 5 - > | | I
5 --- >
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61 ggagggctcacaaataggcctgaactgcagctccccct GTTTCTGGGGATC
CCTCCCGAGTG cttgacgtcgagggggagaaggaggacaaagacccctag
<--- 2
G G L T N R P E L Q L P L F L L F L G I
7 --- >
121 TACGTGGTGACAATGGTGGGCAATCTGGGCATG ttggcctcaacagccaa
atgcacc CACCCGTTAGACCCGTACTAGTGAGACTAACCGGAGTTGTCGGTT
<--- 4 <---
Y V V T M V G N L G M I T L I G L N S Q
9 --- >
181 ctgcacacccccatgtacttttttctgag AGCCTGGTGGACCTGTGCTATTCC
G gggggtacatgaaaaaagactcgttggactcggaccacctggacac
6 <--- 8
L H T P M Y F F L S N L S L V D L C Y S
I I I | | | |
11 --- >
241 AGCGTCATCACACCCAAAATGC aacttcgtgagccaaaggaatctcatcagctat
GCAGTAGTGTGGGTTTTACGACTAGTTGAAGCACTCGGTTTCCTTA gtcgata
<--- 10
S V I T P K M L I N F V S Q R N L I S Y
13 --- >
301 gtgggatgcatga GCTGTATTTCTTCCTGGTGTTCGTGATCGCCGAGTGCTACATG
caccctacgtactcggtcgacataaagaaggaccacaag CGGCTCACGATGTAC
<--- 12
V G C M S Q L Y F F L V F V I A E C Y M
I | I I I 1 1
15 --- >
361 CTG gcctatgacaggtacgtcgccatctgccagcccctgctctacaaca
GACTGTCACTACCGGATACTGTCCATGCAGC tcggggacgagatgttgtaa
<--- 14
421
481
L T V M A Y D R Y V A I C Q P L L Y N I
I I I I I | |
17 --- >
CCGCACTGTGCAGCCTGCTGGTGGCCTTCGTCTACGCTGTGGGGCT
tagtacagggggcgtgacacgtcgga CAGATGCGACACCCCGACTAG
<--- 16
I M S P A L C S L L V A F V Y A V G L I
I I I I I 1 1
19 --- >
ccatcgagaccggactgatgctgaagctcaactactgcgaggacct
CCGTCGCGGTAGCTCTGGCCTGACT agttgatgacgctcctggagtagagg
132
<--- 18
G S A I E T G L M L K L N Y C E D L I S
I I I I I 1 1
21 --- > 23 --
541 CACTACTTCTGCGACATCCTGCCACTCATGAAACTGTCCTGCTCCA acgtg
gtgatgaagacgctgtagga GTACTTTGACAGGACGAGGTCGTGTATGCTGCAC
<--- 20
H Y F C D I L P L M K L S C S S T Y D V
-> 25 --- >
601 gagatggccgtgttctttctggccggcttcgacatcatcgt TCACCGTCCTG
CTCTACCGGCAC gccgaagctgtagtagcagtggtcggagtggcaggac
<--- 22
E M A V F F L A G F D I I V T S L T V L
I I | |
27 --- >
661 ATCTCCTACGCCTTCATTCTGTCCAGCATTCTCAG caacgagggccggagc
tagaggatg GTAAGACAGGTCGTAAGAGTCCTAAAGGAGGTTGCTCCCGGCCTCG
<--- 24 <--- 26
I S Y A F I L S S I L R I S S N E G R S
I I I I I I
29 --- >
721 aaagcctttagcacctgcagcagccacttc CCTGTTCTACGGCAGCACT
ggacgtcgtcggtgaagcgacgacagccggacaagatgccgtcgtg
<--- 28
K A F S T C S S H F A A V G L F Y G S T
31 --- >
781 GCATTCATGTACCTGAAGCCCAGCACC gcacaggagaacgtggcctcc
TGGACTTCGGGTCGTGGCGGAGGAGGGACCGTGTCCTCTTGCACCG
<--- 30
A F M Y L K P S T A S S L A Q E N V A S
I |
33 --- >
841 gtcttctataccaccgtcatcccta AACCCCCTGATTTACTCCCTCAGGAACAAG
agatatggtggcagtagggatacaagttgggggactaaatgaggga C
<--- 32
V F Y T T V I P M F N P L I Y S L R N K
I I | | | | |
35 --- >
901 GAGGTGAAGACCGCCC tgcggcggaaggtctttggcggcaccgaaaca
CTCCACTTCTGGCGGGACCTGTTCTGGGACGCCGCCTTCCAGAAA tgt
<--- 34
E V K T A L D K T L R R K V F G G T E T
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961 agccaggtcgctcc
** ** * * * *
** ** * * * * *
< repeat
< GC rich
tcggtccagcgagggcggactcgccggcgctcttc
<--- 36
S Q V A P A X
total
total
total
total
total
total
total
total
codon usage score ...........
length score ................
melting temperature score ...
repeat score.................
pattern score ................
mispriming score.............
AT content score.............
GC content score.............
The OVERALL score......
0.000
0.000
0.000
0.322
0.322
0.000
0.000
0.322
0.965
DETAILED CODON FREQUENCY REPORT
Codon, AA, Frequency, # of times used in coding sequence ]
0.46
0.54
0.08
0.13
0.13
0.20
0.07
0.40
0.36
0.47
0.17
1.00
0.18
0.24
0.12
0.47
TCT
TCC
TCA
TCG
CCT
CCC
CCA
CCG
ACT
ACC
ACA
ACG
GCT
GCC
GCA
GCG
0.19
0.22
0.15
0.06
0.28
0.33
0.28
0.11
0.25
0.36
0.28
0.11
0.26
0.40
0.23
0.11
TAT
TAC
TAA
TAG
CAT
CAC
CAA
CAG
AAT
AAC
AAA
AAG
GAT
GAC
GAA
GAG
0.44
0.56
0.30
0.23
0.42
0.58
0.26
0.74
0.47
0.53
0.43
0.57
0.46
0.54
0.42
0.58
TGT
TGC
TGA
TGG
CGT
CGC
CGA
CGG
AGT
AGC
AGA
AGG
GGT
GGC
GGA
GGG
0.45
0.55
0.47
1.00
0.08
0.19
0.11
0.20
0.15
0.24
0.21
0.21
0.16
0.34
0.25
0.25
Frequency Range
0% - 4%
5% - 9%
10% - 14%
15% - 19%
20% - 24%
25% - 29%
30% - 34%
35% - 39%
Number of Codons
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The
The
The
The
The
The
The
The
TTT
TTC
TTA
TTG
CTT
CTC
CTA
CTG
ATT
ATC
ATA
ATG
GTT
GTC
GTA
GTG
40% - 44% 11
45% - 49% 44
>= 50% 90
Total Codons Used = 321
Tm Range # of Overlaps
<57 0
57 0
58 0
59 18
60 17
61 0
62 0
63 0
64 0
>=65 0
Tm Range = 1.7
Ovrlap Len Range # of Oligos
<15 0
15 0
16 2
17 10
18 7
19 3
20 8
21 3
22 2
23 0
24 0
>=25 0
Lowest Overlap = 16
Length Range # of Oligos
<37 0
37-38 1
39-40 0
41-42 0
43-44 0
45-46 35
47-48 0
49-50 0
51-52 0
53-54 0
55-56 0
>=57 0
Longest 46
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1 repeats greater than 8 nt:
PR Posl = 982 Pos2 = 982 Size = 8 Seql = GCGGCCGC
Seq2 = GCGGCCGC
Sequence Patterns Screened (As Supplied By User)
Name
EcoRI
NotI
Seq Pos Notes
GAATTC 4 forward
GCGGCCGC 982 forward
36 oligonucleotides need to be synthesized
i CCTGAATTCGCCGCCACCATGACCGCTGAAAACCAAAGCACCGTG 45
2 GTGAGCCCTCCGAGGATAAACTCGGTCACGGTGCTTTGGTTTTCAG 46
3 TTATCCTCGGAGGGCTCACAAATAGGCCTGAACTGCAGCTCCCCCT 46
4 CCACGTAGATCCCCAGAAACAGGAGGAAGAGGGGGAGCTGCAGTTC 46
5 GTTTCTGGGGATCTACGTGGTGACAATGGTGGGCAATCTGGGCATG 46
6 GTTGGCTGTTGAGGCCAATCAGAGTGATCATGCCCAGATTGCCCAC 46
7 TTGGCCTCAACAGCCAACTGCACACCCCCATGTACTTTTTTCTGAG 46
8 CACAGGTCCACCAGGCTCAGGTTGCTCAGAAAAAAGTACATGGGGG 46
9 AGCCTGGTGGACCTGTGCTATTCCAGCGTCATCACACCCAAAATGC 46
10 ATTCCTTTGGCTCACGAAGTTGATCAGCATTTTGGGTGTGATGACG 46
11 AACTTCGTGAGCCAAAGGAATCTCATCAGCTATGTGGGATGCATGA 46
12 GAACACCAGGAAGAAATACAGCTGGCTCATGCATCCCACATAGCTG 46
13 GCTGTATTTCTTCCTGGTGTTCGTGATCGCCGAGTGCTACATGCTG 46
14 CGACGTACCTGTCATAGGCCATCACTGTCAGCATGTAGCACTCGGC 46
15 GCCTATGACAGGTACGTCGCCATCTGCCAGCCCCTGCTCTACAACA 46
16 AGGCTGCACAGTGCGGGGGACATGATAATGTTGTAGAGCAGGGGCT 46
17 CCGCACTGTGCAGCCTGCTGGTGGCCTTCGTCTACGCTGTGGGGCT 46
18 TCAGTCCGGTCTCGATGGCGCTGCCGATCAGCCCCACAGCGTAGAC 46
19 CCATCGAGACCGGACTGATGCTGAAGCTCAACTACTGCGAGGACCT 46
20 AGGATGTCGCAGAAGTAGTGGGAGATGAGGTCCTCGCAGTAGTTGA 46
21 CACTACTTCTGCGACATCCTGCCACTCATGAAACTGTCCTGCTCCA 46
22 CACGGCCATCTCCACGTCGTATGTGCTGGAGCAGGACAGTTTCATG 46
23 ACGTGGAGATGGCCGTGTTCTTTCTGGCCGGCTTCGACATCATCGT 46
24 GTAGGAGATCAGGACGGTGAGGCTGGTGACGATGATGTCGAAGCCG 46
25 TCACCGTCCTGATCTCCTACGCCTTCATTCTGTCCAGCATTCTCAG 46
26 GCTCCGGCCCTCGTTGGAGGAAATCCTGAGAATGCTGGACAGAATG 46
21 CAACGAGGGCCGGAGCAAAGCCTTTAGCACCTGCAGCAGCCACTTC 46
28 GTGCTGCCGTAGAACAGGCCGACAGCAGCGAAGTGGCTGCTGCAGG 46
29 CCTGTTCTACGGCAGCACTGCATTCATGTACCTGAAGCCCAGCACC 46
30 GCCACGTTCTCCTGTGCCAGGGAGGAGGCGGTGCTGGGCTTCAGGT 46
31 GCACAGGAGAACGTGGCCTCCGTCTTCTATACCACCGTCATCCCTA 46
32 AGGGAGTAAATCAGGGGGTTGAACATAGGGATGACGGTGGTATAGA 46
33 AACCCCCTGATTTACTCCCTCAGGAACAAGGAGGTGAAGACCGCCC 46
34 AAAGACCTTCCGCCGCAGGGTCTTGTCCAGGGCGGTCTTCACCTCC 46
35 TGCGGCGGAAGGTCTTTGGCGGCACCGAAACAAGCCAGGTCGCTCC 46
36 CTTCTCGCGGCCGCTCAGGCGGGAGCGACCTGGCTTGT 38
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there are
B.2 PCR-based Gene Assembly (PCA)
We highly recommend oligos to be ordered from IDT (idtdna.com) as they consistently
have the lowest error rates. Oligos from IDT come in plate format at 50uM concentration.
For the PCR reactions we recommend Pfu Turbo Hotstart polymerase (Stratagene).
Combine oligos for assembly in equal proportions (for example, ~20 ul each). Vortex
well to mix. Final concentration will be 50uM total, but 50/(# oligos) uM for each oligo.
Thus, having a pool of 34 oligos means each is at 1.47 uM.
Also combine end oligos (10 ul each) and add 8 parts milliQ H20 (80 ul), so that final
concentration of each is 5 uM. This is the primer end mix used in PCR 2.
OCR 1: Assembly, 50 ul reactions
volume reagent initial conc final conc
5 uL lOx cloned buffer (for Pfu lox lx
Turbo Hotstart)
1.25 uL dNTP mix 10 mM each 250 uM each
0.5 uL pooled oligos 50/# uM each 500/# nM each
(50 uM total) (500 nM total)
1 uL polymerase (Pfu Turbo 2.5 Units
Hotstart)
42.25 uL distilled water
50 uL total
* Note: some reactions appear to work better if individual oligo conc is constant (25 nM
each oligo) and not total oligo conc. Thus, for 34 oligos you would add 0.85 uL pooled
oligos (instead of 0.5 uL) - in this case, total oligo conc would then be 850 nM. Note that
in this method, there is a risk of dNTP depletion.
Average oligo extension is -1/2 gene length
In 5OuL rxn, have 50 nmol total dNTPs and 25 pmol total oligos (if 500 nM total)
Thus about 2000 fold excess of dNTPs
If gene is lkB, then FULL extension will only use about 25% of dNTPs
If keep each oligo constant, then will use up more dNTPs (43% if have 34 oligos)
PCR1 program:
94 C hot-start - 2 minutes
30-50 cycles (we use 40 by default; occasionally, more are needed)
94 C denaturation 30 seconds
55 C annealing 30 seconds
72 C extension 1.5 minutes
72 C final extension 2 minutes
4 C hold
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If the products of this reaction are run on a gel, the normal result is a smear, with the
lower edge running about the same as the lengths of the oligos, and the upper edge
slightly higher than the expected product length.
PCR 2: Amplification, 50 ul reactions
The 2"d PCR is more like normal PCR, using two primers to selectively amplify the
correct length fragment from the mixture created by assembly PCR above. These primers
can simply be the oligos .used at the beginning (5' end) of each strand for gene assembly
in PCR 1. CAUTION: the small amount of PCR
contain some Pfu polymerase which has already
procedure. Thus, it is a good idea to add the 1 ul
the program.
product from the previous reaction will
been activated by the hot-start
of PCR product last, just before starting
amount reagent initial conc final conc
5 uL 1 Ox cloned buffer (for Pfu Turbo 1Ox lx
Hotstart)
1.25 uL dNTP mix 10 mM each 250 uM each
3 uL Primer ends mix 5 uM 300 nM
1 uL product from assembly PCR ? ?
1 uL polymerase (Pfu Turbo Hotstart) 2.5 Units
38.75 uL distilled water
50 uL total
PCR2 program:
94 Celsius hot-start - 2 minutes
30 cycles:
94 C denaturation 30 seconds
58 C annealing 30 seconds (varies depending on the particular primers, we'll
typically use 50 C)
72 C extension 1 minute (for sequences > 1 kb, use 1 minute per kb)
72 C incubation 2 minutes
4 C hold
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B3 Stable HEK293S Colony Subcloning and Screening
Cells were transfected using Lipofectamine 2000 (Invitrogen) for 16 hours, according to
the manufacturer's protocol for HEK293 cells. Two days later the media was changed to
selective plate media containing blasticidin and zeocin:
Blasticidin Zeocin (selection)
HEK293S cells: 5 pg/mL 250 pg/mL
HEK293 GnTI- cells: 5 pg/mL 50 pg/mL*
, Once the cell line has been established, use 25 pg/mL zeocin (half as much) in
HEK293 GnTI- cells to maintain the stable cells.
After three weeks, a stable cell line had been established. In order to establish syngeneic
colonies, the cell culture was split to yield a very low density of one single cell per low-
power microscope field (approximately 50-100 cells per 150mm culture plate). Colonies
were grown in selective media until they reached a size of 1-3 millimeters, whereupon
the media was changed to PBS. Single colonies were aspirated using the a sterile pipette,
and transferred to a new well of a 24-well plate containing 1 00pL trypsin and broken up
and resuspended by pipetting up and down. After 1 minute, 1 mL of selective plate media
was added to inactivate the trypsin, and cells were incubated overnight to allow
attachment. Media was then changed again and cells were grown until confluence,
whereupon they were split for inducible-expression screening.
To split grown-up colonies for treatment:
(note: it's generally easier to do the following procedure 3 wells at a time (thus filling up
a complete 12-well plate with each set))
1. Aspirate media and add ImL PBS to well
2. Aspirate and add 1OOuL trypsin to well
3. Place in incubator for several minutes
4. Resuspend with ImL of media (will be 1.lmL with the trypsin) and distribute to 4
wells of a 12-well plate as follows:
a. Top 3 wells get 340uL
b. Last well gets remainder (will use later to grow up the cell line)
c. Then add lmL media to each of those 4 new wells
d. Rock plate (or bonk against table) to distribute cells evenly
5. Repeat for rest of colonies (can thus put 3 colony trials on one 12-well plate)
6. Once cells are near confluence, treat with drugs:
a. [-] Untreated, [+] tet only (1 ug/mL), [++] tet + NaBu 2.5-5mM, untreated
(grow up to establish the cell line)
b. Be sure to change the media on the untreated wells too!
c. Harvest the 3 treated wells (-, +, ++) after 48 hours (see above)
d. Keep the final well growing. After analyzing the samples, pick the best
ones and split them into 100mm plates to establish the cell line. Maintain
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the presence of the T-REx system by growing in media containing
blasticidin and zeocin. Keep growing up for purification experiments and
be sure to cryopreserve some aliquots for future use.
To harvest treated samples:
(note: if many samples, easiest to do in "shifts" of 18 since cold room centrifuge can only
hold 18 tubes)
1. Aspirate media and add 1 mL PBS to well
2. Pipette up and down over entire well surface to resuspend cells, then transfer to a
labeled microcentrifuge tube
3. Spin down cells at 10,000 rpm for 5 minutes at RT
4. Remove PBS
5. Resuspend cell pellet in 120uL of cold PBS + protease inhibitors
6. Add 3OuL of cold 10% FC14 detergent (in PBS) - final concentration will be 2%
o Ensure cells are suspended when detergent is added (vortex if necessary)
o Do not pipette up and down after detergent addition!
7. Invert tube to mix and solubilize receptors by rotating for 60 minutes at 4*C
o Use the rotator in the cold room
o If many tubes, can pack 6 per 50mL conical and then rubber band those in
place on the rotator
8. Spin in cold-room centrifuge at 13,000rpm for 30 minutes to pellet insoluble
material
9. Transfer 1 OOuL of supernatant to a new tube (PCR tube strips work well)
o Take 1OOuL from the top and avoid the pellet!
10. Freeze solubilized supernatant samples at -20*C (freezer) and discard pellets
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D.4 Immunoblotting Protocol
Gel electrophoresis (NuPAGE)
* Thaw samples to run on ice
* Prepare IL of NuPAGE MOPS buffer (50mL of the stock + 950mL diH20)
o MOPS buffer stock is under the electrophoresis bench area in a white box
o After making, put in cold room so it gets to 4*C
* Prepare samples according to Novex NuPAGE procedure card
o Usually run the following:
- 1-4 uL of sample
- 2.5 uL of 4x LDS
- 1 uL of 1 Ox reducing agent
- milliQ H20 to 10 uL total volume
o For ladder there is no need to add anything else
* Let samples sit at RT for >15 minutes (don't heat samples as it causes aggregation)
* Prepare Novex NuPAGE 10% Bis-Tris gel and place into an assembled Novex gel
box. Pour about 1 OOmL of MOPS buffer into bottom of gel box
e Put 200mL of MOPS buffer in new bottle and add 500uL antioxidant, then fill inner
chamber with this solution
* Add regular MOPS buffer to outer chamber until half full
* With a 200uL pipettor, briefly rinse out each well
* Apply samples to wells using gel loading tips (20uL pipettor)
o Be careful of bubbles! (watch the tip and stop when sample is at the end)
o Best method is to keep tip close to the well bottom as you apply sample.
This results in less mixing of sample with the MOPS buffer.
o Load 1 OuL of Rainbow marker for all ladder lanes
* Move gel box to cold room and run at 1 OOV (constant voltage) until the blue dye
runs off the bottom. This will take several hours. For best resolution of hOR17-4,
you can run until the green marker (25kD) is about 2cm from the bottom.
* After the SDS-PAGE is complete:
o For immunoblotting, perform transfer protocol (below) followed by
western protocol (below)
o For total protein staining, stain gel with Sypro Ruby (Molecular Probes)
using the manufacturer protocol.
Transfer (Bio-Rad MiniTrans Blot)
1) Get out a Nitrocellulose Membrane sandwich (from Bio-Rad). They are in a small
box under the gel electrophoresis bench. They are precut squares about the same
size as the gels we use. (Filter paper I Membrane I Filter paper)
2) Get out transfer case (green) with the red/black/white stuff inside.
3) Fill ice tray (pack down) and place in case
141
4) Fill up transfer case ~2/3 full with 1x transfer buffer (newer)
5) Ensure small magnetic stir bar is in bottom of case
6) Get out plastic tub (above my bench) as well as glass roller
7) In tub, place one transfer cassette open, black on right side, put 1 pad (white
sponge) on each side, and put membrane sandwich on left (clear side)
8) Pour a layer of 1x transfer buffer (older) into tub and wet pads and membrane
sandwich
9) Take gels out of NuPAGE box and crack open perimeter using tool above the sink.
10) Gel will stick to one of the plates -just throw out the other one
a. Note - if gel sticks to the taller plate it will effectively be flipped over (left
to right) from how you loaded it. Be sure to flip it over again with your
fingers during step 12
11) Use a razor blade to trim off bottom "lip" of gel as well as the well combs.
12) Use water and fingers to loosen gel from plate (flip it over with fingers, if
necessary)
13) Use tweezers to move top piece of filter paper (on membrane sandwich) over to
right (black) side, exposing the membrane. Ensure membrane is wetted with
transfer buffer.
14) Place trimmed gel (right side up!) on top of membrane & gently roll out bubbles
with glass roller.
15) Place filter paper (from black side) back on top and gently roll out bubbles
16) Place right hand side pad on top, fold over black side and secure the clamp
a. Note: make sure gel is between membrane and black side, or else proteins
will transfer OUT INTO THE BUFFER!
17) Place transfer sandwich in transfer case with black side to black side
18) Repeat for 2 "d gel, or else just place empty sandwich in 2nd slot
19) Fill case with 1x transfer buffer until ~1cm from lip and put on lid
20) Run in cold room (4*C) while stirring at 0.25 amps = 250 milliamps (constant
amps) for 1 hour
a. Note: can also run overnight at 30V
b. Transfer buffer can be reused several times)
21) Disassemble transfer cassettes and ensure that protein has transferred to gel
a. can tell by looking at membrane for reflection of protein bands AND by
transfer of colored protein ladder
b. note that smaller proteins transfer faster than larger ones (so should
increase transfer time for very large (>1 OOkD) proteins)
22) Mark (dot with lab marker) protein ladder bands (since they can fade in
subsequent steps)
Dt Blotting:
For dot blots (useful for comparing the relative expression levels of many samples),
simply pipette 1 ptL of each sample onto a nitrocellulose membrane in a grid pattern.
Allow to air dry for 20 minutes, then follow western blotting procedure below.
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Western Blotting:
* Block membrane in 50mL blocking buffer (TBST + 5% milk)
o Shake lhr at RT or overnight at 4"C
* Dilute primary antibody in new blocking buffer
o For my square membrane containers, 30mL total is fine
o For rholD4 (anti-rho tag), dilute antibody 1:2000 (so 15uL into 30mL)
o For anti-N-term, anti-C-term, and anti-FLAG, dilute antibody 1:3000 (so
1OuL into 3OmL)
* Incubate membranes in primary antibody (shaking) for 2 hours at RT or overnight
at 40C
o Can cut up membranes if necessary (e.g., one side rho, other side N-term)
* Pour off antibody solution and save in fridge
* Wash membrane briefly in about 20mL TBST (no milk)
* Wash 5x with 50mL TBST, 5 minutes each (shake)
* Dilute secondary antibody in new blocking buffer
o For my square membrane containers, 50mL total is fine
o Dilute antibody 1:5000 (so lOuL into 50mL)
o Goat anti-mouse antibody HRP for mouse primaries (like the anti-rho and
anti-FLAG)
o Goat anti-rabbit antibody HRP for rabbit primaries (like the anti-N-term
and anti-C-term)
* Incubate membranes in secondary antibody (shaking) for 1 hour at RT
* Discard secondary and wash membrane as before (5 x 50mL, 5 mins each, with
TBST)
* Detect using ECL Plus Kit (GE Healthcare)
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B.5 Bioreactor Media Preparation
For 1 Liter: For 1.1L
Dissolve the following in 1 liter of milliQ-filtered water:
* 13.7g DMEM powder (calcium free, from Atlanta Biologicals) 15.07g
* 3.7g Sodium Bicarbonate (NaHCO3) 4.07g
pH to 7.0 and add:
* 0.3g Dextran Sulfate (Mr-5000, from Sigma) 0.33g
* 3g Primatone RL-UF (from Quest International) 3.3g
Sterilize by filtering through 0.2um filter into a sterile bottle.
Now add the following sterile components:
* 1OOmL FBS (to 10% vol/vol) 1lOmL
* 1OmL Pen-Strep (to 1% vol/vol) 11 mL
* 1OmL L-glutamine (to 2mM) 11mL
* 1OmL 10% Pluronic F-68 (to 0.1% wt/vol) 11 mL
To make sterile 10% Pluronic F-68 solution (wt/vol):
* Dissolve lOg Pluronic F-68 in 1OOmL milliQ H20
* Sterilize by filtering through 0.2um filter into a sterile bottle
* Store at RT
Also make sterile supplements same way:
* 2mM L-glutamine (2.92g in 1OOmL, store at 4*C)
* 8% Sodium Bicarbonate (8g in 100mL, store at RT) add 20mL if necessary...
* 20% glucose (20g in 1OOmL, store at RT) add 1OmL for d5 supplement
* 10% Primatone RL-UF (3g in 30mL, make fresh) add 30mL for d5 supplement
To induce cells:
* We use tetracycline and sodium butyrate at slightly higher levels [Prashen uses
tetracycline at 2 ug/mL (2x) and sodium butyrate at 7.5mM (1.5x)]
e For ORs, use 2 ug/mL tetracycline and 2.5mM NaBu
* To induce 1L of cells:
o 20mL of 50x induction = 0.1 mg/mL tetracycline and 125mM NaBu (=
13.76 mg/mL)
o Dissolve the following in 18mL of milliQ H20:
o 2 mL of 1 mg/mL tetracycline stock (total of 2 mg)
o 0.275g of sodium butyrate
o Gives 20mL total
144
B.6 Bioreactor Operation
(optimized for 1.25L final culture volume):
Day 0: Make up 1. 1L of media (recipe). With FBS and other ingredients
the final volume will come out to about 1.25L total volume. Put 1OOmL in a
separate sterile bottle to use cell resuspension, and add rest to reactor using sterile
siphon into INPUT PORT 1 (after draining PBS).
Split 6-8 confluent 150mm plates of cells, resuspend in remaining media (1 OOmL)
and inoculate reactor with cells using siphon into INPUT PORT 2 (final cell
density should be 3-5 x 105 cells/mL).
* Day 1-4: Monitor reactor conditions and adjust as necessary. If pH begins
dropping and increased gas flow (up to flow rate of 25) cannot compensate, add
20mL of the sterile 8% NaHCO3 solution through INPUT PORT 4 by siphon.
* Day 5: Growth supplement
Add 3.4g of Primatone RL-UF to 34mL of PBS and dissolve by heating in water bath
to -50*C. Use a stir bar to get it completely dissolved so that solution is totally clear.
In the sterile hood, add 11 mL of the sterile 20% glucose solution and mix again - we
want the Primatone to be completely dissolved or else it will clog the filter later!
Once it's dissolved, sterile filter through a 0.2CA zap cap into a sterile 250mL bottle.
Then siphon transfer into reactor using INPUT PORT 3.
* Day 6: OR induction.
Induce expression using 2 ug/mL tetracycline and 2.5mM sodium butyrate final
concentration.
To 23.4mL of PBS add 0.286g of sodium butyrate powder. Stir to dissolve. Then
inside sterile hood, add 2.6mL of tetracycline stock (1 mg/mL). Stir to mix, then
sterile filter. It might be more practical to use a syringe filter (0.2um) than a Zap cap
- just be careful to keep it sterile and filter into a sterile container like a 50mL
conical. Then transfer to sterile 250mL bottle and siphon to reactor using INPUT
PORT 4.
* Day 8: Harvesting cells. -> Harvest @ 40hr post-induction
Make up 1 OOmL of PBS plus protease inhibitors. Thus drop 2 of the Complete
EDTA-free tablets (NOT mini) into 1 OOmL total. Once made, put on ice to cool to
40C.
At reactor, use total drain line to siphon all cells into a clean/sterile 2L bottle. (note - we
don't really need to be absolutely sterile from this point on, but still try to be clean!)
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***Take lmL of the reactor harvest and put in a microcentrifuge tube for later cell-
counting analysis. Spin down cells in centrifuge for 2 minutes at 10000 rpm and keep on
ice until freezing in liquid nitrogen later. * * *
Transfer cells to 6 big centrifuge bottles (the kind we use for bacteria - be sure to
thoroughly clean them out first!!!). Balance the bottles, then spin in the centrifuge
(Sorvall, GSA rotor) for 20 minutes at 8000 rpm at 4*C. Afterwards, all cells should be
pelleted and media supernatant totally clear - if not, centrifuge again. Once OK, pour off
supernatant. Resuspend cells in cold PBS + inhibs solution by vortexing thoroughly (with
lid on) and then pipetting to break up clumps. Pool together into two 50mL conicals and
centrifuge for 20 minutes at 5000 g at 40C.
You can then snap freeze the pellets in liquid nitrogen and store at -800C until the day of
purification.
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B7 RholD4-bead Coupling
The antibody is rho lD4 monoclonal antibody (from Hybridoma 1B4-1) from Cell
Essentials. They will produce and purify it for you (protein A purification) at a cost of
roughly $6000 per gram.
NOTE: to avoid the hassle of dialyzing the antibody, be sure to have Cell
Essentials ship the antibody in the coupling buffer (0.25M NaHCO3, 0.5M NaCl, pH
8.3) and NOT in phosphate buffer.
If antibody is not in coupling buffer, dialyze as follows:
1) Before coupling to beads, antibody must be dialyzed into coupling buffer
(0.25M NaHCO3, 0.5M NaCl, pH 8.3) !
a. pH must be 8-10 for efficient coupling
b. Bicarbonate or borate buffers must be used, as Tris and other buffer salts
will couple to the gel !
c. High salt content (0.5M NaCl) is crucial as it prevents aggregates and
minimizes protein-protein adsorption
2) Wash dialysis tube ("Spectra/Por 2" RC membrane w/ 12-14kD MWCO
[could be higher]) thoroughly with distilled water, then fill with antibody
solution
3) Dialyze against 5-10 L coupling buffer (at least 100 volumes, if possible)
overnight at 4*C. Change dialysis buffer at least 3 times.
4) Determine protein concentration using A280 (1.383 AU == 1 mg/mL)
a. (GE Healthcare recommends 5-10 mg/mL (2-8 is optimal, NOT
HIGHER!)
0eads: CNBr-activated Sepharose 4B (GE Healthcare)
lg of dried bead powder will equate to 3.5 mL of final gel volume (bead slurry)
1) Suspend beads in 1mM HCl (beads swell -> gel)
2) Wash for 15 minutes with 1mM HCl on a sintered glass filter
a. Wash procedure: Use sintered glass funnel and vacuum flask. Resuspend
without suction. Wait ~1 minute. Apply vacuum until a dry cake is
obtained. Do not over dry.
b. Use about 200mL wash per gram of powder, added in several aliquots
3) After washing, add bead slurry to antibody (now in coupling buffer)
a. Add 20 mL bead slurry to 130-200 mg antibody equivalent
b. Thus, 50 mL slurry is plenty for our 326.70 mg antibody
c. (Rule from GE Healthcare is 5 mL coupling solution per gram of dried
bead powder) - 5 mL solution / 3.5 mL bead slurry
4) Mix and rotate at 4"C (4 hours to overnight)
a. Monitor antibody concentration in supernatant using A280 (spin down
beads for 5 mins first, 2000 rpm)
b. Can stop when antibody concentration is below 5% of starting value
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5) Discard supernatant (spin down beads first)
6) (optional) Wash away excess antibody with 5 gel volumes of coupling buffer
7) Block any remaining active groups on the beads
a. Use IM ethanolamine, pH 8.0
b. Volume should be equal to original supernatant volume (antibody
solution)
c. Rotate overnight at 4"C (16 hours) or 2h at RT
8) Remove excess of uncoupled antibody
a. Wash beads on sintered glass filter 4 times with alternating solutions of
coupling buffer and acetate buffer (0. 1M NaOAc, 0.5M NaCl, pH 4.0)
b. Wash volume should be at least 5 times original gel volume (recall 1 g dry
beads = 3.5 mL gel slurry)
9) Suspend beads in 1 gel volume of PBS pH 7.2 + 0.05% NaN3
a. Will be 50% slurry
b. Aliquot and store at 40C
SOLUTIONS:
H1Ci buffer: (1mM HCl) - for 1 L
For HCl, 36, 37, 38% concentration stocks are 1 1.64M, 12.02M, and 12.39M
85.9 uL 36% HCl stock into 1 L milliQ H20
81.3 uL 37% HCl stock
80.7 uL 38% HCl stock
Coupling buffer: (0.25M NaHCO3, 0.5M NaCl, pH 8.3) - for 1 L
29.221 g NaCl
21 g Sodium Bicarbonate (NaHCO3)
900 mL milliQ H20
pH to 8.3 (w/ NaOH), then bring volume up to 1 L
Blocking buffer: (IM ethanolamine, pH 8.0) - for 100 mL
6 ML ethanolamine (99.5% liquid stock is 16.5 M)
93 mL milliQ H20
pH to 8.0 w/ HCl
Acetate buffer: (0. 1M NaOAc, 0.5M NaCl, pH 4.0) - for 1 L
29.221 g NaCl
8.206 g Anhydrods Sodium Acetate (CH3COONa)
(13.608 g if trihydrous CH3COONa*3(H20))
900 mL milliQ H20
pH to 4.0, then bring up to 1 L
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1.6 Immunoaffinity Purification
1) Solubilize cells in PBS + 2% FC-14 + protease inhibitors (Roche Complete
tabs) for 4 hr (rotate at 4*C)
a. Use 1-2mL per 150mm plate, or 12.5mL per gram of bioreactor pellet
2) Spin down at 100,000g for 30 mins at 4*C
3) Transfer supernatant to new tube (discard nuclear pellets)
4) SAVE a small amount (-50uL) for western blot later - label as "total lysate"
5) Mix bead/buffer solution (either by tapping or pipetting) to form a slurry
6) Add r1D4-coupled bead slurry (Pharmacia Sepharose-4B, CNBr activated) to
remainder of supernatant [Binding capacity of bead slurry is -0.7 mg/mL (so
1 OOuL of slurry will bind -70ug protein)]
7) Rotate at 40C (>4 hrs, overnight is better)
8) Spin down beads 2K rpm for 1-2 min at 4"C
9) Remove supernatant, SAVE a small amount (~1OOuL) for western blot (label
as "flow thru" (probably better to save all FT in case doesn't work)
10) Wash beads with >100 bead volumes (1 OOmL for every 1mL bead slurry) of
PBS + 0.2% FC-14 (without protease inhibitors, since proteases will wash
away). Make sure beads are suspended and mixing during the rotation.
a. Do 5 washes for 10 mins each (rotate at 4"C) - wash until absorbance
280nm is less than 0.01.
b. (SAVE -OOuL of each supernatant (label as "wash 1", "wash 2", etc) and
discard remainder of supernatant)
c. For large scale purifications, use disposable filter columns for washing.
After rotating, simply drain the column instead of centrifuging beads.
d. For small batches, spin down beads (2K rpm, 1-2 min) between washes
11) Make elution buffer (PBS + 0.2% FC-14 + 1OOuM peptide (TETSQVAPA),
without protease inhibitors) - keep at ROOM TEMPERATURE
a. To elute, add 1 bead volume elution buffer to beads and incubate 1 hr
(rotate at ROOM TEMPERATURE). Make sure beads are suspended and
mixing during the rotation.
b. Repeat elutions until absorbance of eluate at 280nm is less than 0.1
(usually 6-7 elutions are required).
c. For large batches, continue to use disposable filter column. Drain and
collect elution as above.
d. For small batches, a microcentrifuge or PCR tube works best. Spin down
beads (2K rpm, 1-2 min) between elutions fractions.
12) Used beads can be regenerated for re-use by washing the medium with 2-3
column volumes of alternating high pH (0.1 M Tris-HCl, 0.5 M NaCl, pH 8.5)
and low pH (0.1 M sodium acetate, 0.5 M NaCl, pH 4.5) buffers. This cycle
should be repeated 3 times followed by re-equilibration in binding buffer.
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APPENDIX C:
OR GENE SEQUENCES
The following is a list of all OR genes (and corresponding
protein sequences) constructed during this thesis.
All genes were optimized with human codon preferences and with 5' EcoRI
and 3' NotI restriction sites for cloning into mammalian expression
vectors such as pcDNA4/To. A Kozak ribosome binding site (RBS)
consisting of the DNA sequence GCCGCCACC was placed immediately before
the ATG start codon.
To enable cloning into the wheat germ cell-free expression vector
pIVEX1.3, we also incorporated a 5' NcoI site (CCATGG) at the start
ATG. As NcoI requires a G following the start ATG, certain genes had to
be modified by inserting either a glycine (GGC) or alanine (GCC) codon
after the start ATG. This is noted in the sequences.
The majority of genes constructed contained a C-terminal rho tag
sequence (-GGTETSQVAPA), designated "-rho" in the gene title.
In the course of the thesis, genes using several other tag sequences
were constructed and tested. The abbreviations are:
R-: N-terminal "membrane import sequence" consisting of the first 20
amino acids of bovine rhodopsin) (MNGTEGPNFYVPFSNKTGVVGG-)
HP-: N-terminal His/FLAG tag sequence (MRGSHHHHHHGGDYKDDDDKGG-)
HFR-: HF plus an N-terminal rhodopsin "membrane import sequence"
MRGSHHHHHHGGDYKDDDDKGG-MNGTEGPNFYVPFSNKTGVVGG-
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hOR17-4-rho (OR1D2)
*already contains an NcoI site (no modification necessary)
D14A
1 CCTGAATTCG
51 GTTTCTGCTG
101 TTTGGATGTT
151 ATTATCCTCG
201 CTTTCTGGCT
251 TTCCCAAAAT
301 GCCGGCTGCC
351 TAATCTGATT
401 GCCCTCTCCA
451 CTGTCCCTGT
501 GCTCATGACA
551 TCTGCGAAAT
601 AACCATACCG
651 CGGATTCGTG
701 TCCCTTCCGT
751 CTGGGAGCCG
801 ACCTCTCCAC
851 CCGTCGTCAC
901 GATATGCATG
951 GACCGGAGGC
1001 GAAG
Protein
1 MDGGNQSEGS
51 SDSRLHTPVY
101 LYFLVSLVAL
151 LSVLYGLIHT
201 ATGCFIFLIP
251 FYGTLCMVYL
301 GRLLDKHFKR
CCGCCACCAT
CTGGGCATGT
TCTGAGCATG
CTATTAGCTC
AACCTCTCCT
GCTCGTCAAC
TCACACAACT
CTCGCCGTCA
CTATACAACA
GCTGGGTGCT
AGAGTGACCT
GTACGTCCTC
TGCTGATTGC
ATCATCAGCT
CAGCAAAAAA
TCAGCCTGTT
ACCTACAGCG
CCCCATGATG
GCGCTCTCGG
ACAGAGACAT
EFLLLGMSES
FFLANLSFTD
DNLILAVMAY
LLMTRVTFCG
FGFVIISYVL
KPLHTYSVKD
GGACGGAGGC
CCGAGAGCCC
TATCTGGTCA
CGACAGCAGA
TTACAGACCT
CTCCAAAGCC
CTATTTTCTC
TGGCTTACGA
GCTATGAGCC
CTCCGTGCTG
TTTGTGGCTC
CTCCGGATGG
TACCGGATGC
ACGTCCTCAT
TATAAGGCTT
TTATGGAACA
TCAAGGACTC
AACCCCTTCA
AAGACTCCTG
CCCAAGTCGC
PEQQQILFWM
LFFVTNTIPK
DRYVAICCPL
SRKIHYIFCE
IIRAILRIPS
SVATVMYAVV
AACCAAAGCG
CGAGCAACAG
CCGTGGTCGG
CTCCATACCC
GTTTTTCGTC
ACAACAAAGC
GTGAGCCTGG
TCGGTACGTG
CTAAACTGTG
TATGGACTCA
CAGAAAGATC
CCTGTAGCAA
TTTATTTTCC
TATCAGAGCC
TCAGCACCTG
CTGTGTATGG
CGTCGCTACA
TCTACTCCCT
GACAAACACT
TCCTGCTTAA
FLSMYLVTVV
MLVNLQSHNK
HYTTAMSPKL
MYVLLRMACS
VSKKYKAFST
TPMMNPFIYS
AGGGCAGCGA
CAGATCCTCT
AAATGTCCTG
CCGTCTACTT
ACAAACACCA
TATTAGCTAT
TGGCCCTGGA
GCTATTTGTT
CATCCTGCTC
TTCACACACT
CACTACATTT
CATTCAGATT
TCATCCCCTT
ATTCTCCGGA
TGCCAGCCAT
TCTATCTCAA
GTGATGTATG
CAGAAACAAA
TTAAAAGACT
GCGGCCGCGA
GNVLIILAIS
AISYAGCLTQ
CILLLSLCWV
NIQINHTVLI
CASHLGAVSL
LRNKDMHGAL
LT-GG-TETSQVAPA
Mutations: additional mutant versions of this gene were made via site-
directed mutagenesis (SDM) to either alter N-linked glycosylation
sequences or to generate a SNP variation.
N5Q: The asparagine at position 5 (codon AAC) was mutated to a
glutamine (CAG)
N195Q: The asparagine at position 195 (codon AAC) was mutated to a
glutamine (CAG)
N5Q,N195Q: Both asparagines positions were mutated
Q25R: The glutamine at position 24 (codon CAG) was mutated to an
arginine (codon AGG). A single-nucleotide polymorphism
(SNP) causes population variation at this amino acid (Q/R).
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h0k17-4 (untagged)
*already contains an NcoI site (no modification necessary)
DNA
1 CCTGAATTCG
51 GTTCCTGCTG
101 TCTGGATGTT
151 ATCATTCTCG
201 TTTCCTGGCT
251 TCCCCAAGAT
301 GCCGGGTGCC
351 CAACctGATC
401 GCCCCCTGCA
451 CTCTCTCTGT
501 GCTGATGacc
551 TTTGCGAAAT
601 AACCACACCG
651 TGGCTTCGTG
1O1 TTCCCTCCGT
751 CTGGGGGCAG
801 GCCCCTCCAT
851 CTGTGGTGAC
901 GATATGCACG
951 GACATGAGCG
Protein
1 MDGGNQSEGS
.51 SDSRLHTPVY
101 LYFLVSLVAL
151 LSVLYGLIHT
201 ATGCFIFLIP
251 FYGTLCMVYL
301 GRLLDKHFKR
CCGCCACCAT
CTCGGCATGT
TCTGAGCATG
CCATTTCCTC
AACCTGAGCT
GCTGGTCAAC
TCACCCAGCT
CTCGCAGTCA
CTACACCACC
GCTGGGTCCT
AGGGTGACCT
GTATGTCCTC
TGCTGATCGC
ATCATCTCTT
CAGCAAGAAG
TGAGCCTGTT
ACCTACAGCG
CCCCATGATG
GCGCACTGGG
GCCGCGAGAA
EFLLLGMSES
FFLANLSFTD
DNLILAVMAY
LLMTRVTFCG
FGFVIISYVL
KPLHTYSVKD
LT
GGACGGCGGA
CCGAAAGCCC
TACCTCGTCA
CGATAGCAGG
TTACCGACCT
CTGCAGAGCC
GTACTTCCTG
TGGCTTATGA
GCCATGTCCC
CAGCGTGCTG
TCTGCGGATC
CTCCGCATGG
CACCGGCTGC
ACGTGCTCAT
TATAAAGCCT
TTACGGCACT
TGAAGGATAG
AATCCATTTA
CAGGCTCCTG
G
PEQQQILFWM
LFFVTNTIPK
DRYVAICCPL
SRKIHYIFCE
IIRAILRIPS
SVATVMYAVV
AACCAGTCTG
AGAGCAACAG
CCGTGGTGGG
CTGCACACCC
CTTCTTTGTG
ACAACAAGGC
GTCTCCCTGG
CAGGTACGTC
CTAAGCTGTG
TACGGGCTCA
TAGGAAGATC
CCTGCTCCAA
TTCATTTTCC
TATCAGGGCC
TTAGCACTTG
CTGTGTatGG
CGTGGCAACC
TCTACTCCCT
GACAAGCATT
FLSMYLVTVV
MLVNLQSHNK
HYTTAMSPKL
MYVLLRMACS
VSKKYKAFST
TPMMNPFIYS
AGGGCAGCGA
CAAATCCTGT
CAATGTCCTG
CCGTGTACTT
ACCAACACCA
AATCAGCTAC
TGGCCCTCGA
GCCATCTGTT
CATCCTCCTG
TTCACACCCT
CACTACATTT
TATCCAAATT
TCATCCCCTT
ATTCTGAGGA
CGCCAGCCAC
TGTACCTGAA
GTGATGTACG
CAGGAACAAA
TCAAGAGGCT
GNVLIILAIS
AISYAGCLTQ
CILLLSLCWV
NIQINHTVLI
CASHLGAVSL
LRNKDMHGAL
152
R-hOR17-4-rho
DNA
1
51
101
151
201
251
301
351
401
451
501
551
601
651
701
151
1001
1051
Protein
1 MNGTEGPNFY
51 FWMFLSMYLV
101 IPKMLVNLQS
151 CPLHYTTAMS
201 FCEMYVLLRM
251 IPSVSKKYKA
301 AVVTPMMNPF
CCTGAATTCG
GCCCTTCAGC
AAAGCGAGGG
CAACAGCAGA
GGTCGGAAAT
ATACCCCCGT
TTCGTCACAA
CAAAGCTATT
GCCTGGTGGC
TACGTGGCTA
ACTGTGCATC
GACTCATTCA
AAGATCCACT
TAGCAACATT
TTTTCCTCAT
AGAGCCATTC
CACCTGTGCC
GTATGGTCTA
GCTACAGTGA
CTCCCTCAGA
AACACTTTAA
GCTTAAGCGG
CCGCCACCAT
AACAAGACCG
CAGCGAGTTT
TCCTCTTTTG
GTCCTGATTA
CTACTTCTTT
ACACCATTCC
AGCTATGCCG
CCTGGATAAT
TTTGTTGCCC
CTGCTCCTGT
CACACTGCTC
ACATTTTCTG
CAGATTAACC
CCCCTTCGGA
TCCGGATCCC
AGCCATCTGG
TCTCAAACCT
TGTATGCCGT
AACAAAGATA
AAGACTGACC
CCGCGAGAAG
VPFSNKTGVV
TVVGNVLIIL
HNKAISYAGC
PKLCILLLSL
ACSNIQINHT
FSTCASHLGA
IYSLRNKDMH
GG-MDGGNQS
AISSDSRLHT
LTQLYFLVSL
CWVLSVLYGL
VLIATGCFIF
VSLFYGTLCM
GALGRLLDKH
GAACGGCACA
GCGTGGTGGG
CTGCTGCTGG
GATGTTTCTG
TCCTCGCTAT
CTGGCTAACC
CAAAATGCTC
GCTGCCTCAC
CTGATTCTCG
TCTCCACTAT
CCCTGTGCTG
ATGACAAGAG
CGAAATGTAC
ATACCGTGCT
TTCGTGATCA
TTCCGTCAGC
GAGCCGTCAG
CTCCACACCT
CGTCACCCCC
TGCATGGCGC
GGAGGCACAG
GAGGGGCCCA
CGGCATGGAC
GCATGTCCGA
AGCATGTATC
TAGCTCCGAC
TCTCCTTTAC
GTCAACCTCC
ACAACTCTAT
CCGTCATGGC
ACAACAGCTA
GGTGCTCTCC
TGACCTTTTG
GTCCTCCTCC
GATTGCTACC
TCAGCTACGT
AAAAAATATA
CCTGTTTTAT
ACAGCGTCAA
ATGATGAACC
TCTCGGAAGA
AGACATCCCA
EGSEFLLLGM SESPEQQQIL
PVYFFLANLS FTDLFFVTNT
VALDNLILAV MAYDRYVAIC
IHTLLMTRVT FCGSRKIHYI
LIPFGFVIIS YVLIIRAILR
VYLKPLHTYS VKDSVATVMY
FKRLT-GGTETSQVAPA
153
ACTTCTACGT
GGAGGCAACC
GAGCCCCGAG
TGGTCACCGT
AGCAGACTCC
AGACCTGTTT
AAAGCCACAA
TTTCTCGTGA
TTACGATCGG
TGAGCCCTAA
GTGCTGTATG
TGGCTCCAGA
GGATGGCCTG
GGATGCTTTA
CCTCATTATC
AGGCTTTCAG
GGAACACTGT
GGACTCCGTC
CCTTCATCTA
CTCCTGGACA
AGTCGCTCCT
HF-hOR17-4 (OR1D2)
D1A
1 CCTGAATTCG
51 AGGCGACTAC
101 AGTCTGAGGG
151 CAACAGCAAA
201 GGTGGGCAAT
251 ACACCCCCGT
301 TTTGTGACCA
351 CAAGGCAATC
401 CCCTGGTGGC
451 TACGTCGCCA
501 GCTGTGCATC
551 GGCTCATTCA
601 AAGATCCACT
651 CTCCAATATC
701 TTTTCCTCAT
751 AGGGCCATTC
801 CACTTGCGCC
851 GTatGGTGTA
901 GCAACCGTGA
951 CTCCCTCAGG
1001 AGCATTTCAA
Protein
1 MRGSHHHHHH
51 FWMFLSMYLV
Ol IPKMLVNLQS
i51 CPLHYTTAMS
201 FCEMYVLLRM
251 IPSVSKKYKA
301 AVVTPMMNPF
CCGCCACCAT
AAGGACGATG
CAGCGAGTTC
TCCTGTTCTG
GTCCTGATCA
GTACTTTTTC
ACACCATCCC
AGCTACGCCG
CCTCGACAAC
TCTGTTGCCC
CTCCTGCTCT
CACCCTGCTG
ACATTTTTTG
CAAATTAACC
CCCCTTTGGC
TGAGGATTCC
AGCCACCTGG
CCTGAAGCCC
TGTACGCTGT
AACAAAGATA
GAGGCTGACA
GGDYKDDDDK
TVVGNVLIIL
HNKAISYAGC
PKLCILLLSL
ACSNIQINHT
FSTCASHLGA
IYSLRNKDMH
GAGAGGCTCT
ACGACAAGGG
CTGCTGCTCG
GATGTTTCTG
TTCTCGCCAT
CTGGCTAACC
CAAGATGCTG
GGTGCCTCAC
ctGATCCTCG
CCTGCACTAC
CTCTGTGCTG
ATGaccAGGG
CGAAATGTAT
ACACCGTGCT
TTCGTGATCA
CTCCGTCAGC
GGGCAGTGAG
CTCCATACCT
GGTGACCCCC
TGCACGGCGC
TGAGCGGCCG
GG-MDGGNQS
AISSDSRLHT
LTQLYFLVSL
CWVLSVLYGL
VLIATGCFIF
VSLFYGTLCM
GALGRLLDKH
CACCACCATC
CGGCATGGAC
GCATGTCCGA
AGCATGTACC
TTCCTCCGAT
TGAGCTTTAC
GTCAACCTGC
CCAGCTGTAC
CAGTCATGGC
ACCACCGCCA
GGTCCTCAGC
TGACCTTCTG
GTCCTCCTCC
GATCGCCACC
TCTCTTACGT
AAGAAGTATA
CCTGTTTTAC
ACAGCGTGAA
ATGATGAATC
ACTGGGCAGG
CGAGAAG
EGSEFLLLGM
PVYFFLANLS
VALDNLILAV
IHTLLMTRVT
LIPFGFVIIS
VYLKPLHTYS
FKRLT
ATCACCATGG
GGCGGAAACC
AAGCCCAGAG
TCGTCACCGT
AGCAGGCTGC
CGACCTCTTC
AGAGCCACAA
TTCCTGGTCT
TTATGACAGG
TGTCCCCTAA
GTGCTGTACG
CGGATCTAGG
GCATGGCCTG
GGCTGCTTCA
GCTCATTATC
AAGCCTTTAG
GGCACTCTGT
GGATAGCGTG
CATTTATCTA
CTCCTGGACA
SESPEQQQIL
FTDLFFVTNT
MAYDRYVAIC
FCGSRKIHYI
YVLIIRAILR
VKDSVATVMY
154
MPR-hOR17-4 (OR1D2)
EINA
1 CCTGAATTCG
51 AGGCGACTAC
101 GCCCCAACTT
151 ATGGACGGCG
201 GTCCGAAAGC
251 TGTACCTCGT
3O1 TCCGATAGCA
351 CTTTACCGAC
401 ACCTGCAGAG
451 CTGTACTTCC
501 CATGGCTTAT
551 CCGCCATGTC
601 CTCAGCGTGC
651 CTTCTGCGGA
701 TCCTCCGCAT
751 GCCACCGGCT
801 TTACGTGCTC
851 AGTATAAAGC
901 TTTTACGGCA
951 CGTGAAGGAT
1001 TGAATCCATT
1051 GGCAGGCTCC
1101 AAG
Protein
1 MRGSHHHHHH
51 QSEGSEFLLL
101 HTPVYFFLAN
151 SLVALDNLIL
201 GLIHTLLMTR
251 IFLIPFGFVI
301 CMVYLKPLHT
351 KHFKRLT
CCGCCACCAT
AAGGACGATG
CTATGTGCCC
GAAACCAGTC
CCAGAGCAAC
CACCGTGGTG
GGCTGCACAC
CTCTTCTTTG
CCACAACAAG
TGGTCTCCCT
GACAGGTACG
CCCTAAGCTG
TGTACGGGCT
TCTAGGAAGA
GGCCTGCTCC
GCTTCATTTT
ATTATCAGGG
CTTTAGCACT
CTCTGTGTat
AGCGTGGCAA
TATCTACTCC
TGGACAAGCA
GGDYKDDDDK
GMSESPEQQQ
LSFTDLFFVT
AVMAYDRYVA
VTFCGSRKIH
ISYVLIIRAI
YSVKDSVATV
GAGAGGCTCT
ACGACAAGGG
TTCAGCAACA
TGAGGGCAGC
AGCAAATCCT
GGCAATGTCC
CCCCGTGTAC
TGACCAACAC
GCAATCAGCT
GGTGGCCCTC
TCGCCATCTG
TGCATCCTCC
CATTCACACC
TCCACTACAT
AATATCCAAA
CCTCATCCCC
CCATTCTGAG
TGCGCCAGCC
GGTGTACCTG
CCGTGATGTA
CTCAGGAACA
TTTCAAGAGG
GGMNGTEGPN
ILFWMFLSMY
NTIPKMLVNL
ICCPLHYTTA
YIFCEMYVLL
LRIPSVSKKY
MYAVVTPMMN
CACCACCATC
GGGCATGAAC
AGACCGGCGT
GAGTTCCTGC
GTTCTGGATG
TGATCATTCT
TTTTTCCTGG
CATCCCCAAG
ACGCCGGGTG
GACAACctGA
TTGCCCCCTG
TGCTCTCTCT
CTGCTGATGa
TTTTTGCGAA
TTAACCACAC
TTTGGCTTCG
GATTCCCTCC
ACCTGGGGGC
AAGCCCCTCC
CGCTGTGGTG
AAGATATGCA
CTGACATGAG
FYVPFSNKTG
LVTVVGNVLI
QSHNKAISYA
MSPKLCILLL
RMACSNIQIN
KAFSTCASHL
PFIYSLRNKD
ATCACCATGG
GGGACCGAAG
GGTCGGCGGC
TGCTCGGCAT
TTTCTGAGCA
CGCCATTTCC
CTAACCTGAG
ATGCTGGTCA
CCTCACCCAG
TCCTCGCAGT
CACTACACCA
GTGCTGGGTC
ccAGGGTGAC
ATGTATGTCC
CGTGCTGATC
TGATCATCTC
GTCAGCAAGA
AGTGAGCCTG
ATACCTACAG
ACCCCCATGA
CGGCGCACTG
CGGCCGCGAG
VVGG-MDGGN
ILAISSDSRL
GCLTQLYFLV
SLCWVLSVLY
HTVLIATGCF
GAVSLFYGTL
MHGALGRLLD
155
S51-rho (mOR40-1)
*modified to have an NcoI site - inserted alanine GCC after ATG
ON1A
1 CCTGAATTCG
51 GAGCAACACC
101 CCAACTACCA
i51 TTTCTGCTGG
201 GGAGGCCAGC
251 TGCTGGACAT
301 TTCTGGTTCG
351 GTTCGTGATG
401 TGGCCTACGA
451 ATCATCACCG
501 GAACGGCATT
551 ACTGCGCCCG
601 AAGCTGAGCT
651 CGGCTGGACC
701 GCTTCATCCT
751 AAGGCCCTGA
801 CACCGTGCTG
851 CCCCCGACGT
901 GCCCTGAACC
951 CATCAGAAAC
10O1 TGGCCCCCGC
Protein
1 MAIRRQHMEA
51 ANATLLITIR
101 SIGFSSCFLQ
151 VVRAAIFVAA
201 ITFNKLYQFV
251 GSHFILILFF
301 YGVRTREIKQ
CCGCCACCAT
TCCAGCATCC
GACCTGGCAG
CTATGGGCGC
CTGCACGAGC
CGTGCTGTGC
ATAACAAGTC
AACTCCTTCC
CCGGTACGTG
ATCAGTTCGT
CTGACCATGC
GATCATCCGG
GCGACGACAT
CTCCTGGGCA
GAAGGCCGTG
GCACCTGCGG
CTGGTCCTGG
GCCCATCCTG
CCATCGTGTA
CTGCTGCGGC
CTGAGCGGCC
QSNTSSILAP
MEASLHEPMY
MFVMNSFLTM
RNGILTMPIP
IGWTLLGSDL
STVLLVLVIT
GGCCATCCGC
TGGCCCCCGA
CACTGGCTCA
CAACGCCACC
CCATGTACTA
CTGACCGTGA
CATCGGCTTC
TGACTATGGA
GCCATCTGCA
GGTGCGGGCC
CCATCCCTAT
AACTGCATCT
CACCTTCAAC
GCGACCTGAT
CTGCGGATCA
CAGCCACTTC
TGATCACCAA
CTGAACATCC
CGGCGTGCGG
GGAGACTGGG
GCGAGAAG
DFLLICFPNY
YLLSLLSLLD
ESCTFMVMAY
ILSSQLRYCA
ILIVLSYSFI
NLARERIPPD
CGCCAGCACA
CTTCCTGCTG
GCCTGCCCCT
CTCCTGATCA
CCTGCTGAGC
TCCCCAAGGT
AGCAGCTGCT
GAGCTGCACC
AGCCCCTGCA
GCCATCTTCG
CCTGAGCAGC
GCACCAACAT
AAGCTGTACC
CCTGATCGTC
AGGCCGAGGG
ATCCTCATCC
CCTGGCCCGG
TGCACCACCT
ACCCGGGAGA
CGGCACCGAG
QTWQHWLSLP
IVLCLTVIPK
DRYVAICKPL
RIIRNCICTN
LKAVLRIKAE
VPILLNILHH
TGGAGGCCCA
ATCTGCTTCC
GTCCCTGCTG
CCATCCGGAT
CTCCTGAGCC
GCTGGCCATC
TCCTGCAGAT
TTCATGGTGA
GTACCCCAGC
TGGCCGCTCG
CAGCTGCGGT
GAGCGTGAGC
AGTTCGTGAT
CTGTCCTACA
AGCCGTGGCC
TGTTCTTCAG
GAGCGGATCC
GATCCCTCCC
TTAAGCAGGG
ACCAGCCAGG
LSLLFLLAMG
VLAIFWFDNK
QYPSIITDQF
MSVSKLSCDD
GAVAKALSTC
LIPPALNPIV
GIRNLLRRRL-GGTETSQVAPA
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107-rho (MOR276-1)
*already contains an NcoI site (no modification necessary)
DNA
1 CCTGAATTCG
51 CGGCTTCATC
101 TCTTCTCCAC
151 CTGCTGATCC
201 CTTCTTCCTG
251 TCGTGCCCAA
301 TTCGCCGGCT
351 CGAGGGCCTG
401 GCCACCCCCT
451 ATCGCCGGCA
501 GGTGGCCGCC
551 TCTTCTGCGA
601 CTGTTCGATA
651 CTTCTCCATC
701 GGATGCACAG
751 CACCTGACCG
801 GCGGCCCCGG
851 TCTACACCGT
901 AACCGGGAGG
951 GGGCAGCCAG
1001 CGGCCGCGAG
Protein
1 MGIWLNESSV
51 YTDPRLHTPM
101 QIGFFVSLVG
151 AFGILDGIIQ
201 FACCVFMLLL
251 LFYGAAMFIY
301 ALRKGLDRCR
CCGCCACCAT
CTGCTGGGCA
CGTGATGCTC
TGCTGATTTA
AGCCAGCTGA
GATGGCCGTG
GCGGCATCCA
CTGCTGGGCC
GCACTACCCC
GCTCCTGGGC
ATGAGCCTGC
GGTGCCCGCC
CCCTGCTGTT
ATCGTGACCA
CGCCCAGAGC
CCGTGAGCCT
CGGTACCGGG
GCTGACCCCC
TGATGGGCGC
CACGGCGGCA
AAG
DGFILLGIFS
YFFLSQLSLM
SEGLLLGLMA
MVAAMSLPYC
PFSIIVTSYA
LRPRRYRAPS
GGGAATCTGG
TCTTCAGCCA
GTGTTCACCG
CACCGACCCC
GCCTGATGGA
AACTTCCTGT
GATCGGCTTC
TGATGGCCTA
ATCCTGATGA
TTTCGGCATC
CCTACTGCGG
CTGCTGAAGC
CGCCTGTTGC
GCTACGCCCG
CGGAAGAAGG
GTTCTACGGC
CCCCCAGCCA
ATGCTGAACC
CCTGCGGAAG
CCGAGACCAG
QSQTDLLLFS
DLMLVCNIVP
YDRYVAISHP
GSRYIDHFFC
RILGAVLRMH
HDKVVSIFYT
CTGAACGAGA
GAGCCAGACC
TGGCCCTGTG
CGGCTGCACA
CCTGATGCTG
CCGGCCGGAA
TTCGTGTCCC
CGACCGGTAC
GCCAGAAGGT
CTGGACGGCA
CAGCCGGTAC
TGGCCTGCGC
GTGTTCATGC
GATCCTGGGC
CCCTGGCCAC
GCCGCCATGT
CGACAAGGTG
CCCTGATCTA
GGCCTGGACC
CCAGGTGGCC
TVMLVFTVAL
KMAVNFLSGR
LHYPILMSQK
EVPALLKLAC
SAQSRKKALA
VLTPMLNPLI
GCAGCGTGGA
GACCTGCTGC
CGGCAACGTG
CCCCCATGTA
GTGTGCAACA
GAGCATCAGC
TGGTGGGCTC
GTGGCCATCA
GTGCCTGCAG
TCATCCAGAT
ATCGATCACT
CGATACAAGC
TGCTGCTGCC
GCCGTGCTGC
CTGCAGCAGC
TCATCTACCT
GTGAGCATCT
CAGCCTGCGG
GGTGCCGGGT
CCCGCCTGAG
CGNVLLILLI
KSISFAGCGI
VCLQIAGSSW
ADTSLFDTLL
TCSSHLTAVS
YSLRNREVMG
VGSQH-GGTETSQVAPA
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M71-rho (mOR171-2)
*modified to have an NcoI site - inserted glycine (GGC) after start ATG
DNA
1 CCTGAATTCG
51 CGAGTTTATC
1Ol TCTTCCTCCT
151 GGCATGATCA
201 CTTTTTTCTG
251 TCACACCCAA
301 TATGTGGGAT
351 CGAGTGCTAC
401 GCCAGCCCCT
451 CTGGTGGCCT
501 CGGACTGATG
551 TCTGCGACAT
601 GTGGAGATGG
651 CCTCACCGTC
701 TTTCCTCCAA
151 TTCGCTGCTG
801 GCCCAGCACC
851 ATACCACCGT
901 AAGGAGGTGA
951 CGGCACCGAA
Protein
1 MGTAENQSTV
51 GLNSQLHTPM
101 QLYFFLVFVI
151 AVGLIGSAIE
201 FLAGFDIIVT
251 FYGSTAFMYL
CCGCCACCAT
CTCGGAGGGC
GTTTCTGGGG
CTCTGATTGG
AGCAACCTGA
AATGCTGATC
GCATGAGCCA
ATGCTGACAG
GCTCTACAAC
TCGTCTACGC
CTGAAGCTCA
CCTGCCACTC
CCGTGTTCTT
CTGATCTCCT
CGAGGGCCGG
TCGGCCTGTT
GCCTCCTCCC
CATCCCTATG
AGACCGCCCT
ACAAGCCAGG
TEFILGGLTN
YFFLSNLSLV
AECYMLTVMA
TGLMLKLNYC
SLTVLISYAF
KPSTASSLAQ
GGGCACCGCT
TCACAAATAG
ATCTACGTGG
CCTCAACAGC
GCCTGGTGGA
AACTTCGTGA
GCTGTATTTC
TGATGGCCTA
ATTATCATGT
TGTGGGGCTG
ACTACTGCGA
ATGAAACTGT
TCTGGCCGGC
ACGCCTTCAT
AGCAAAGCCT
CTACGGCAGC
TGGCACAGGA
TTCAACCCCC
GGACAAGACC
TCGCTCCCGC
RPELQLPLFL
DLCYSSVITP
YDRYVAICQP
EDLISHYFCD
ILSSILRISS
ENVASVFYTT
GAAAACCAAA
GCCTGAACTG
TGACAATGGT
CAACTGCACA
CCTGTGCTAT
GCCAAAGGAA
TTCCTGGTGT
TGACAGGTAC
CCCCCGCACT
ATCGGCAGCG
GGACCTCATC
CCTGCTCCAG
TTCGACATCA
TCTGTCCAGC
TTAGCACCTG
ACTGCATTCA
GAACGTGGCC
TGATTTACTC
CTGCGGCGGA
CTGAGCGGCC
LFLGIYVVTM
KMLINFVSQR
LLYNIIMSPA
ILPLMKLSCS
NEGRSKAFST
VIPMFNPLIY
GCACCGTGAC
CAGCTCCCCC
GGGCAATCTG
CCCCCATGTA
TCCAGCGTCA
TCTCATCAGC
TCGTGATCGC
GTCGCCATCT
GTGCAGCCTG
CCATCGAGAC
TCCCACTACT
CACATACGAC
TCGTCACCAG
ATTCTCAGGA
CAGCAGCCAC
TGTACCTGAA
TCCGTCTTCT
CCTCAGGAAC
AGGTCTTTGG
GCGAGAAG
VGNLGMITLI
NLISYVGCMS
LCSLLVAFVY
STYDVEMAVF
CSSHFAAVGL
SLRNKEVKTA
301 LDKTLRRKVF-GGTETSQVAPA
158
OA23-rho (mOR267-13)
*modified to have an NcoI site - inserted glycine GGC after ATG
DNA
1
51
101
i5i
201
251
301
351
401
451
501
551
601
651
701
751
801
851
901
951
Protein
1 MGQRNNFTEV
51 HIDHHLHTPM
101 QMFFFVTLAT
i51 GTGLVMAVLH
201 GVSSFVILVP
251 HYGCASIAYL
CCTGAATTCG
CGAGTTCGTC
TGTTCGTCGT
ATTATCGTCA
CTTTTTTCTG
TTGTGCCTAG
CTCGCCGGGT
CAACTGCTTC
GCAACCCACT
CTCGTCTGCG
CCCCGCCATG
TCTGCGACAT
AACGAGATTA
CGGCCTCATC
TTGTGAGCAC
CTCACCGTGG
GCCCAAGAGC
ATACTATCAT
AAGGAGGTGA
CGGAACCGAA
CCGCCACCAT
TTCCTCGGCT
GTTCCTGACA
CAATCACCCA
TCCATGCTGG
AATGCTGTCC
GCGCCACACA
CTCCTGACCG
GAGGTACACC
GGAGCCTGGG
TTCCACCTCC
TTACCCCGTC
TCAATTACGG
TTCATCAGCT
CGAGGGGCAA
TCATCGTCCA
GAATCCTCCG
TACCCCTCTG
AGGACGCCCT
ACCAGCCAAG
IEFVFLGFSS
YFFLSMLASS
NNCFLLTAMG
VPAMFHLPFC
IGLIFISYVL
KPKSESSVEK
AACAATTTCA
CGGGAAACAC
TCACCCTCGC
CACCTGCACA
GACCGTCTAC
TTTACAACCT
TTCGTGACCC
CGACCGGTAC
GCAAGGGCAT
GTGATGGCTG
CACAGTGGTC
CCTGCGTCGA
TTTGTCATTC
CGTCAGCTCC
TCGCAACATG
GCAAGCATTG
TCTGCTGCTC
TGGTGTATTC
GTGGGAAGAA
CTAAGCGGCC
CCGAAGTGAT
CAGATCACCC
AGGCAACATC
CCCCCATGTA
ACACTGGTCA
CCCAATTAGC
TGGCCACTAA
GTCGCTATTT
GTGTGCACTG
TGCTCCACGT
GAGCACTTCT
CACCACCGTG
TCGTCCCCAT
ATTCTCAAAA
TGCAAGCCAC
CCTACCTGAA
TCCGTCACAT
CCTGAGAAAC
ATACCTCCGG
GCGAGAAG
GGGCCAGCGG
TTTCCAGCTT
ATCTACATCC
CATTGATCAC
CTAGCTCCGA
AGCCTGATCT
GATGTTCTTC
CTATGGGGTA
ATCATCATGA
CACCGGGCTG
CCTTCTGTGG
ATGAAGCTGT
CGTGAGCTCC
ATGTGCTGAT
AAGAAGGCTT
CTACGGCTGC
TCGAGAAGGA
CTGAACCCAG
GTGCAGAGCC
TGGCACCTGC
FGKHQITLFV
ETVYTLVIVP
YDRYVAICNP
GTVVEHFFCD
IVSSILKIVS
DLLLSVTYTI
301 LCRAVGRNTS-GGTETSQVAPA
159
VFLTIYILTL AGNIIIVTIT
RMLSSLIFYN LPISLAGCAT
LRYTIIMSKG MCALLVCGSL
IYPVMKLSCV DTTVNEIINY
TEGQKKAFAT CASHLTVVIV
ITPLLNPVVY SLRNKEVKDA
17-rho (mOR103-15)
*already contains an NcoI site (no modification necessary)
D1A
1 CCTGAATTCG
51 CGAGTTTGTC
101 TCTTCTTCCT
151 CTCATTATTA
201 CTTTTTTCTC
251 CCATTCCCAA
301 CAGCTCATTA
351 CCTCGGATGC
401 ACGTGGCCAT
451 CTGTGCGTCC
501 CATGGTCAAG
551 CCATCAACCA
601 ACTGATATGA
651 TCTGCTGGGG
701 GGGCAGTGAT
751 ACCTGTGCTA
801 CTTCATTTAT
851 TGGTCAGCGT
901 TACTGTCTGA
951 CCTGGCCCAG
1001 GCGGAACCGA
Protein
1 MERRNHTGRV
51 RNHPTLHKPM
101 ACMTQLYFFL
151 AGSWAGGFGI
201 ELTDFILAIF
251 TVVIIFYAAS
301 EVKKALRRTL
CCGCCACCAT
CTGCTCGGAT
GTCCCTGCTG
CAGCAATCAG
GCCAACATGT
AATGCTCGCC
GCTTCGAGGC
ACCGAGTGTG
CTGCCACCCA
AAATGGCAGC
GTCTTTCTCA
CTTCTTCTGC
GCACCGCCGA
CCTCTGTCCG
GCGGATCCCC
GCCATCTCAC
GCAAGGCCCA
CCTCTATGCT
GAAACCAGGA
GGGCAAGACG
GACCAGCCAA
SEFVLLGFPA
YFFLANMSFL
GLGCTECVLL
SMVKVFLISR
ILLGPLSVTG
IFIYARPKAL
HLAQGQDANT
GGAACGGAGA
TCCCCGCACC
GCATACGTGC
GAATCACCCC
CCTTCCTGGA
GGGTTTATTG
CTGCATGACC
TGCTCCTGGC
CTCCATTACC
CGGGTCCTGG
TCAGCAGACT
GATGTGAGCC
GCTCACCGAC
TGACCGGCGC
TCCGCCGCAG
TGTGGTCATC
AGGCTCTCAG
GTGATCGTGC
GGTGAAGAAA
CCAATACCAA
GTGGCTCCCG
PAPLRALLFF
EIWYVTVTIP
AVMAYDRYVA
LSYCGPNTIN
ASYMAITGAV
SAFDTNKLVS
AATCACACCG
CGCTCCTCTC
TCGTCCTGAC
ACACTGCACA
GATCTGGTAC
GGTCCGAGGA
CAGCTCTACT
CGTCATGGCC
CTGTCATTGT
GCTGGCGGCT
GAGCTACTGC
CTCTGCTCAA
TTTATCCTGG
AAGCTATATG
GCAGGCACAA
ATCTTCTACG
CGCCTTTGAT
CACTCCTGAA
GCCCTGCGGA
GAAAAGCAGC
CCTGAGCGGC
LSLLAYVLVL
KMLAGFIGSE
ICHPLHYPVI
HFFCDVSPLL
MRIPSAAGRH
VLYAVIVPLL
GACGGGTGAG
CGGGCACTGC
CGAAAACATT
AGCCCATGTA
GTGACAGTCA
GAACCACGGG
TCTTTCTGGG
TACGACAGAT
GTCCTCCAGA
TCGGGATTAG
GGCCCTAACA
CCTGAGCTGT
CAATTTTCAT
GCTATTACCG
AGCATTTAGC
CCGCTTCCAT
ACAAACAAGC
CCCTATCATC
GAACACTCCA
AGAGATGGAG
CGCGAGAAG
TENILIITAI
ENHGQLISFE
VSSRLCVQMA
NLSCTDMSTA
KAFSTCASHL
NPIIYCLRNQ
KKSSRDG-GGTETSQVAPA
160
ODR-10-rho (C. Elegans)
*modified to have an NcoI site - inserted glycine
DN1A
1 CCTGAATTCG
51 CGACACCGCC
101 TCCTCCTGGG
151 TACCTCATGG
201 GTTCATCCTC
251 TCAGCAGAAA
301 GCCTTTTACT
351 CTTCGTCTAT
401 TCAACCTCCC
451 ACCATGTGGG
501 CGAAGCCGCT
551 AGGAGAACGT
601 GTGAGGCATA
651 CGTGATGAGC
701 GGAAGACCAT
751 CAAAAGCAGC
801 TTTCATGTAC
851 TGAACCTGAA
901 CCTGGCCTGG
951 GACCATCTTC
1O01 GGTCCACCAC
1051 ACCAGCCAAG
Protein
1 MGSGELWITL
51 SVFSIFYAII
i0l FATSFVVSGV
151 VPVTMWASVS
201 ENGVRHIYLK
251 RALQKQLFKA
301 FLYPGLDPLI
CCGCCACCAT
GACATTGTGG
CCTGCTGAAG
CCTTTTTCTC
AGGCCAATTA
ACGGTTCAAC
GCGCCTGTTT
AGGTATTTCG
CACACTGCTG
CCAGCGTCTC
GTCACCAACG
GAGCTACATC
TCTATCTGAA
ATGACCTTCG
GAACGAGCAC
TGTTTAAGGC
GCTCCCACCG
CGCTAATGCT
ACCCACTCAT
AATTTCCTCT
TCGGGCTAAT
TCGCCCCAGC
VDTADIVGVT
EFILRPIMHI
HFVYRYFATC
YFLYPDTEYT
NLLGCFVHYF
LVLQTLIPTI
LILIIRDFRR
GGGCAGCGGC
GCGTCACCCT
ACTCGGGGGA
CGTGTTCAGC
TGCACATCGA
TACAGCACCA
CGCCACCTCC
CAACCTGCAA
CTGTGGCCCC
CTACTTCCTG
TGCTGAATAA
GCCTACGTGT
AAACCTGCTG
TGGTGATGTT
AAGGACGTGT
CCTGGTGCTC
GGGTCATGTT
AACTTCATTG
TCTGATCCTG
GTGGCAAGAA
CTGAGCCAGG
CTAAGCGGCC
LTFCVNIVLL
ENTTFFLISR
KLKYYNTLHR
EAAVTNVLNN
VMSMTFVVMF
FMYAPTGVMF
TIFNFLCGKK
GAGCTGTGGA
CACATTTTGC
AGAACCTCGG
ATCTTTTACG
GAACACCACC
AGCTCGGCAA
TTTGTCGTCA
GCCTAATCTC
TCGGCTGTAG
TACCCCGATA
CCACTACAAC
ATTACCAATA
GGCTGCTTCG
CTACTGCGGG
CCGACAGAAC
CAAACTCTCA
CATCGCCCCC
TGTTTTGCTC
ATCATCAGGG
AAACAGCGTC
TGCCAACTGG
GCGAGAAG
GLLKTRGKNL
KRFNYSTKLG
PNLLRLFNLP
HYNWIKKENV
YCGYATWKTM
IAPFFDVNLN
NSVDESRSTT
GGC after ATG
TTACCCTCGT
GTGAATATTG
GACCTACAAG
CAATCATCGA
TTCTTTCTCA
GATCAACAGC
GCGGCGTGCA
CTGCGGCTGT
CGTGCCAGTG
CCGAGTACAC
TGGATCAAGA
CGAGAACGGC
TCCACTACTT
TACGCCACTT
CCGGGCACTG
TCCCCACCAT
TTCTTCGACG
CTTCCTCTAC
ACTTCAGGCG
GATGAATCCC
CGGGACTGAA
GTYKYLMAFF
KINSAFYCAC
TLLLWPLGCS
SYIAYVYYQY
NEHKDVSDRT
ANANFIVFCS
RANLSQVPT-
351 GGTETSQVAPA
161
dR73-rho (mOR-EG, mOR174-9)
*modified to have an NcoI site - inserted glycine GGC after ATG
6MA
1
51
101
151
201
251
301
351
401
451
501
551
601
651
701
751
801
851
901
951
1001
CCGCCACCAT
ACCCTGCTCG
GATCTTTCTG
TCGTGATCAT
CTCAGCCACC
CAAGATGCTC
GGTGCCTGGT
TTTCTGCTGG
CCTCCTCTAC
TCGGAAGCTA
GCCCTGAACC
CGAATTTTCC
AACTGCTGCT
ATTATCCTGC
GTCCGCCAGC
CCGCTATCAC
AACAGCAAGA
TGTCGTCATC
ATGTCAAAGA
GGAGGCACCG
GGGCACCCTG
GGTTCAGCGA
ACTATCTACA
CAGGATTAAC
TGAGCTTCGT
GTCAACCTGG
GCAGTTCTTT
GAGTCATGGC
ACCGTGGCTA
TGCATGGGGC
TCTCCTTTTA
AGCCTGCTCT
CTTTGTCTTC
TGTCCTACGT
GGCAGGAGGA
CATCTTCCAC
ATAGCAGGCA
CCTATGCTCA
CACCGTCAAG
AGACCAGCCA
AGCGACGGGA
CTACCCCGAA
GCATCACCGT
CCCAAGCTCC
GGACTTCTGC
TGACCATGAA
TTCTTTTGCA
ATACGACAGG
TGAGCCAGAG
GTGGTCTGCA
CGGCTTCAAC
CCCTGTCCAG
GCCACTTTCA
GCTCATTGTG
AAGCCTTCAG
GGCACCATCC
TACTGTGAAG
ACCCCCTGAT
AAGATTATCG
GGTGGCCCCC
ACCACTCTGG
CTGACCATCC
CGTCGGCAAC
ACATCCCCAT
TACTCTTCTA
CCGCGGCATC
CCTTCGTCGT
TTTGTGGCCA
ACTGTGCGCC
GCCTGATCCT
ATGATCAATC
GTCCGATACA
ACGAGATCAG
GTGACAATCC
CACCTGCGCC
TCTTCCTGTA
GTGGCCAGCG
TTACTCCCTG
GGACTAAGGT
GCCTGAGCGG
Pkotein
1 MGTLSDGNHSG AVFTLLGFSD YPELTIPLFL IFLTIYSITV VGNIGMIVII
51 RINPKLHIPM YFFLSHLSFV DFCYSSIVAP KMLVNLVTMN RGISFVGCLV
1Ol QFFFFCTFVV TESFLLGVMA YDRFVAIRNP LLYTVAMSQR LCAMLVLGSY
151 AWGVVCSLIL TCSALNLSFY GFNMINHFFC EFSSLLSLSR SDTSVSQLLL
201 FVFATFNEIS TLLIILLSYV LIVVTILKMK SASGRRKAFS TCASHLTAIT
251 IFHGTILFLY CVPNSKNSRH TVKVASVFYT VVIPMLNPLI YSLRNKDVKD
301 TVKKIIGTKV YSS-GGTETSQVAPA
162
CCTGAATTCG
GGCAGTGTTC
CCCTGTTCCT
ATCGGAATGA
GTACTTTTTC
TCGTCGCCCC
AGCTTTGTGG
GACCGAGTCC
TCCGGAATCC
ATGCTGGTGC
GACCTGCAGC
ACTTCTTCTG
AGCGTGTCCC
CACTCTCCTC
TCAAGATGAA
TCTCATCTGA
CTGCGTGCCC
TGTTCTATAC
CGCAATAAGG
GTACAGCTCT
CCGCGAGAAG
9OR-OR73 (mOR-EG, mOR174-9)
DNA
1 CCTGAATTCG
51 AGGCGATTAC
101 GCCCCAACTT
151 ATGACCCTGA
201 GTTCAGCGAC
251 CTATCTACAG
301 AGGATTAACC
351 GAGCTTCGTG
401 TCAACCTGGT
451 CAGTTCTTTT
501 AGTCATGGCA
551 CCGTGGCTAT
601 GCATGGGGCG
651 CTCCTTTTAC
701 GCCTGCTCTC
751 TTTGTCTTCG
801 GTCCTACGTG
851 GCAGGAGGAA
901 ATCTTCCACG
951 TAGCAGGCAT
1001 CTATGCTCAA
1051 ACCGTCAAGA
1101 GAGAAG
Protein
1 MRGSHHHHHH
51 GNHSGAVFTL
101 LHIPMYFFLS
151 CTFVVTESFL
201 CSLILTCSAL
251 FNEISTLLII
301 ILFLYCVPNS
351 IGTKVYSS
CCGCCACCAT
AAGGACGACG
CTACGTCCCC
GCGACGGGAA
TACCCCGAAC
CATCACCGTC
CCAAGCTCCA
GACTTCTGCT
GACCATGAAC
TCTTTTGCAC
TACGACAGGT
GAGCCAGAGA
TGGTCTGCAG
GGCTTCAACA
CCTGTCCAGG
CCACTTTCAA
CTCATTGTGG
AGCCTTCAGC
GCACCATCCT
ACTGTGAAGG
CCCCCTGATT
AGATTATCGG
GGDYKDDDDK
LGFSDYPELT
HLSFVDFCYS
LGVMAYDRFV
NLSFYGFNMI
LLSYVLIVVT
KNSRHTVKVA
GCGCGGCAGC
ATGACAAGGG
TTTAGCAACA
CCACTCTGGG
TGACCATCCC
GTCGGCAACA
CATCCCCATG
ACTCTTCTAT
CGCGGCATCA
CTTCGTCGTG
TTGTGGCCAT
CTGTGCGCCA
CCTGATCCTG
TGATCAATCA
TCCGATACAA
CGAGATCAGC
TGACAATCCT
ACCTGCGCCT
CTTCCTGTAC
TGGCCAGCGT
TACTCCCTGC
GACTAAGGTG
GGMNGTEGPN
IPLFLIFLTI
SIVAPKMLVN
AIRNPLLYTV
NHFFCEFSSL
ILKMKSASGR
SVFYTVVIPM
CATCACCACC
AGGCATGAAT
AGACCGGCGT
GCAGTGTTCA
CCTGTTCCTG
TCGGAATGAT
TACTTTTTCC
CGTCGCCCCC
GCTTTGTGGG
ACCGAGTCCT
CCGGAATCCC
TGCTGGTGCT
ACCTGCAGCG
CTTCTTCTGC
GCGTGTCCCA
ACTCTCCTCA
CAAGATGAAG
CTCATCTGAC
TGCGTGCCCA
GTTCTATACT
GCAATAAGGA
TACAGCTCTT
FYVPFSNKTG
YSITVVGNIG
LVTMNRGISF
AMSQRLCAML
LSLSRSDTSV
RKAFSTCASH
LNPLIYSLRN
ATCATCACGG
GGCACCGAAG
CGTGGGGGGC
CCCTGCTCGG
ATCTTTCTGA
CGTGATCATC
TCAGCCACCT
AAGATGCTCG
GTGCCTGGTG
TTCTGCTGGG
CTCCTCTACA
CGGAAGCTAT
CCCTGAACCT
GAATTTTCCA
ACTGCTGCTC
TTATCCTGCT
TCCGCCAGCG
CGCTATCACC
ACAGCAAGAA
GTCGTCATCC
TGTCAAAGAC
GAGCGGCCGC
VVGG-MTLSD
MIVIIRINPK
VGCLVQFFFF
VLGSYAWGVV
SQLLLFVFAT
LTAITIFHGT
KDVKDTVKKI
163
TC6-rho (mORll8-1)
*already contains an NcoI site (no modification necessary)
DI4A
1 CCTGAATTCG
51 CCTCCTCGGG
101 GATTCCTCCT
151 TTCATCACAC
201 GAGGAACTTC
251 AGATGCTCAC
301 TGCTTCCTCC
351 tCTCCTCGCA
401 TGCGGTACGC
451 TGCAGCTGGA
501 GTtcCAACAG
551 ACAACTTTCC
601 TTTCTGGGCT
651 GACCGCCACT
701 GCGCCAAGGA
751 GTCGTGAGCC
801 CAAGAACGGA
851 CAGTGGTGAC
901 CAGGTGAAGC
951 CCAGACCGGA
1001 CGAGAAG
Protein
1 MANSTTVTEF
51 RRLYTPMYYF
101 LYFFLGTTEF
151 LLLIIVPSSI
201 ANFSLLGTLA
251- GSCIFMYVRS
301 REHVSKFQKF
CCGCCACCAT
CTGAGCGACG
GACCTACTTC
TGGCTGACCG
GCCATGCTCG
CAACATCATT
AGGCCTTCCT
GTCATGAGCT
CACAATCATG
TGTCCGGCCT
CCCTTTTGCG
CCTGATGGAG
TCGTGATCGC
TGCTACGGAC
GCGGAAGAAA
TGTTCTACGG
CAGGGGGAGG
CCCCACCCTG
AGGTGTTTAG
GGCACCGAGA
ILLGLSDACE
LRNFAMLEIW
FLLAVMSFDR
VFQQPFCGPN
VTATCYGHIL
GKNGQGEDHN
GGCAAACTCT
CCTGTGAGCT
CTCATCCTGC
CAGGCTGTAC
AGATCTGGTT
ACTGGCCACA
GTACTTCTTC
TCGACAGGTA
TCCAAGAGGG
CCTGCTCATC
GCCCAAACAT
CTGATCTGTG
CAACTTTTCC
ACATCCTGTA
GCATTTAGCA
CTCCTGCATT
ACCACAACAA
AACCCCTTCA
GGAGCACGTG
CCAGCCAGGT
LQVLIFLGFL
FTSVIFPKML
YVAICNPLRY
IINHFFCDNF
YTILHIPSAK
KVVALLNTVV
ACCACCGTGA
GCAAGTCCTC
TGGGAAACTT
ACCCCCATGT
CACCAGCGTG
AAACCATTAG
CTGGGCACCA
CGTGGCCATC
TGTGCGTGCA
ATTGTGCCCT
TATCAACCAC
CCGACACCAG
CTCCTGGGAA
TACCATTCTC
CATGCTCCAG
TtcATGTACG
GGTGGTCGCC
TCTACACACT
TCTAAGTTCC
GGCCCCCGCC
LTYFLILLGN
TNIITGHKTI
ATIMSKRVCV
PLMELICADT
ERKKAFSTCS
TPTLNPFIYT
CCGAGTTTAT
ATTTTCCTCG
CCTGATTATC
ACTACTTTCT
ATCTTCCCAA
CCTGCTCGGC
CAGAGTTTTt
TGCAATCCAC
ACTCGTCTTC
CCAGCATTGT
TTTTTCTGCG
CCTGGTGGAG
CCCTGGCTGT
CACATCCCCA
CCATATCATC
TCAGGTCCGG
CTGCTGAACA
CAGGAACAAA
AGAAATTCTC
TGAGCGGCCG
FLIIFITLAD
SLLGCFLQAF
QLVFCSWMSG
SLVEFLGFVI
SHIIVVSLFY
LRNKQVKQVF
SQT-GGTETSQVAPA
164
MFR-IC6 (mOR118-1)
DNA
1 CCTGAATTCG
51 CGGAGACTAC
101 GCCCCAATTT
151 ATGGCAAACT
201 CGCCTGTGAG
251 TCCTCATCCT
301 CGCAGGCTGT
351 CGAGATCTGG
401 TTACTGGCCA
451 CTGTACTTCT
501 CTTCGACAGG
551 TGTCCAAGAG
601 CTCCTGCTCA
651 CGGCCCAAAC
701 AGCTGATCTG
751 GCCAACTTTT
901 ACACATCCTG
851 AAGCATTTAG
901 GGCTCCTGCA
951 GGACCACAAC
1001 TGAACCCCTT
1051 AGGGAGCACG
1101 GAGAAG
Protein
1 MRGSHHHHHH
51 TVTEFILLGL
101 PMYYFLRNFA
151 GTTEFFLLAV
201 VPSSIVFQQP
251 LGTLAVTATC
301 MYVRSGKNGQ
351 KFQKFSQT
CCGCCACCAT
AAGGATGATG
CTACGTGCCC
CTACCACCGT
CTGCAAGTCC
GCTGGGAAAC
ACACCCCCAT
TTCACCAGCG
CAAAACCATT
TCCTGGGCAC
TACGTGGCCA
GGTGTGCGTG
TCATTGTGCC
ATTATCAACC
TGCCGACACC
CCCTCCTGGG
TATACCATTC
CACATGCTCC
TTTtcATGTA
AAGGTGGTCG
CATCTACACA
TGTCTAAGTT
GGDYKDDDDK
SDACELQVLI
MLEIWFTSVI
MSFDRYVAIC
FCGPNIINHF
YGHILYTILH
GEDHNKVVAL
GAGGGGCTCC
ACGACAAAGG
TTCAGCAACA
GACCGAGTTT
TCATTTTCCT
TTCCTGATTA
GTACTACTTT
TGATCTTCCC
AGCCTGCTCG
CACAGAGTTT
TCTGCAATCC
CAACTCGTCT
CTCCAGCATT
ACTTTTTCTG
AGCCTGGTGG
AACCCTGGCT
TCCACATCCC
AGCCATATCA
CGTCAGGTCC
CCCTGCTGAA
CTCAGGAACA
CCAGAAATTC
GGMNGTEGPN
FLGFLLTYFL
FPKMLTNIIT
NPLRYATIMS
FCDNFPLMEL
IPSAKERKKA
LNTVVTPTLN
CACCATCATC
CGGAATGAAC
AGACCGGCGT
ATCCTCCTCG
CGGATTCCTC
TCTTCATCAC
CTGAGGAACT
AAAGATGCTC
GCTGCTTCCT
TttCTCCTCG
ACTGCGGTAC
TCTGCAGCTG
GTGTtcCAAC
CGACAACTTT
AGTTTCTGGG
GTGACCGCCA
CAGCGCCAAG
TCGTCGTGAG
GGCAAGAACG
CACAGTGGTG
AACAGGTGAA
TCCCAGACCT
FYVPFSNKTG
ILLGNFLIIF
GHKTISLLGC
KRVCVQLVFC
ICADTSLVEF
FSTCSSHIIV
PFIYTLRNKQ
ACCACCACGG
GGCACTGAGG
CGTGGGCGGC
GGCTGAGCGA
CTGACCTACT
ACTGGCTGAC
TCGCCATGCT
ACCAACATCA
CCAGGCCTTC
CAGTCATGAG
GCCACAATCA
GATGTCCGGC
AGCCCTTTTG
CCCCTGATGG
CTTCGTGATC
CTTGCTACGG
GAGCGGAAGA
CCTGTTCTAC
GACAGGGGGA
ACCCCCACCC
GCAGGTGTTT
AAGCGGCCGC
VVGG-MANST
ITLADRRLYT
FLQAFLYFFL
SWMSGLLLII
LGFVIANFSL
VSLFYGSCIF
VKQVFREHVS
165
